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Chapter 1
In this dissertation, neuropsychological assessment and cognitive rehabilitation were 
investigated in patients with low-grade glioma and meningioma after neurosurgery, with 
the overarching goal to improve surgical aftercare for these patients.
CENTRAL NERVOUS SYSTEM TUMORS
Primary central nervous system (CNS) tumors are a heterogeneous group of tumors that 
arise from cells and structures belonging to the CNS. Meningioma are the most common 
type and account for approximately 37% of all primary CNS tumors.1 Meningioma originate 
from the arachnoidal cells of the meninges of the brain, and not from brain tissue itself 
(Figure 1a). They occur twice as often in women than in men and are most likely to be 
diagnosed in adults older than 60 years of age.1,2 In the Netherlands, approximately 450 
to 500 people are diagnosed with a symptomatic intracranial meningioma each year.3 The 
far majority of meningioma are benign tumors (>90% WHO-grade I). These tumors are 
slow-growing, and patients generally have a favorable long-time prognosis. A distinct worse 
prognosis is observed in patients with atypical (WHO-grade II) or anaplastic (WHO-grade 
III) meningiomas, which account for approximately 5-7% and 1-2% of all meningiomas, 
respectively.3 These tumors grow faster, more often invade the brain and are more likely to 
recur after treatment.2 Observation (wait-and-scan), neurosurgical resection, radiosurgery 
and/or radiotherapy are the most common approaches in the management of meningioma.2,3
Figure 1. Patient with a a) Meningioma; b) Low-grade glioma; c) High-grade glioma
Glioma are tumors that grow from glial cells.1 In the Netherlands, 1100 patients are 
diagnosed with a glioma every year4, mostly between the age of 45 and 65. Different types 
of gliomas can be distinguished, based on the type of glia cell from which they originate, 
for example astrocytoma and oligodendroglioma. Glioma can be classified according to 
histological and molecular features, as described in the classification system of the World 
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Health Organization.5 Low-grade glioma are slow-growing tumors with more favorable 
characteristics, compared to high-grade glioma, which are more rapidly growing tumors 
(Figure 1b, c). Prognosis ranges widely, depending on tumor classification and the effects 
of treatment. The median survival of patients suffering from glioma ranges from 15 months 
for glioblastoma (the most frequent and malignant glioma) to 15 years for low-grade 
glioma with favorable molecular markers.6-8 Multiple clinical and biological parameters 
(e.g., tumor location, tumor type, tumor size, WHO-grade, molecular markers, age of the 
patient, neurological functioning, general health status) determine the line of treatment. 
Generally, neurosurgery is the first choice of treatment, followed by radiotherapy and/or 
chemotherapy.
COGNITIVE FUNCTIONING IN PATIENTS WITH BRAIN TUMORS
There is a large body of evidence indicating that a significant proportion of patients with 
brain tumors experience cognitive deficits, with prevalence estimates varying between 19% 
and 90%.9-11 Cognitive deficits are often mild to moderate and most commonly observed in 
processing speed, attention, memory and executive functioning.9,11,12 Cognitive functioning 
can be influenced by tumor characteristics (e.g., localization, type, or recurrence), and its 
treatment (neurosurgery, radiotherapy and/or chemotherapy).13 Furthermore, epilepsy, 
symptoms of (mental) fatigue, sleep-wake disturbances and psychological distress are also 
present in a large number of patients with brain tumors and may affect cognitive functioning 
as well.14,15 Cognitive problems, even if they are mild, can lead to problems in patients’ daily 
life, including restrictions in social participation and work ability.16,17 Moreover, they can 
lead to reductions in quality of life of patients with brain tumors.18,19
ASSESSMENT OF COGNITIVE FUNCTION
Previously, most outcome measures in neuro-oncological studies, especially in the older 
studies, have been related to overall survival and progression-free survival. However, 
nowadays there has been consensus among the majority of researchers and clinicians that, 
in addition to medical outcome measures, neuropsychological outcome measures are also 
important to monitor during the disease process. Routine assessment of cognitive function 
may facilitate medical decision-making and can help to guide referral to appropriate care.20 
In line with this, the current national guidelines also stress the importance of routine 
monitoring of cognitive and psychological status.4 Yet, routine assessment is not always 
embedded in standard clinical care in neurosurgical/neuro-oncological centers. Potential 
barriers to the implementation of routine assessment exist, including limited recourses in 
time, personnel and money.14,21
1
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Computerized test batteries may facilitate the implementation of routine neuropsychological 
assessment into clinical practice and are increasingly being explored in the field of neuro-
oncology.22-25 At the department of neurosurgery of the Elisabeth-TweeSteden Hospital 
(ETZ), computerized neuropsychological assessments have, in collaboration with the 
department of Cognitive Neuropsychology of Tilburg University (TiU), been embedded 
in standard clinical care for patients who undergo a craniotomy since November 2010. 
Neuropsychological assessments are administered one day before surgery and three months 
after surgery and information from these assessments is also used in the multidisciplinary 
consultation that takes place every month. For research purposes, follow-up assessments 
one year and two years after surgery were added to the existing protocol in 2015, to allow 
evaluation of cognitive outcome on the longer-term. Although computerized tests cannot 
fully replace the diagnostic work of a clinical neuropsychologist, they have some important 
advantages including standardized test administration, and accurate as well as less time-
consuming scoring procedures. Furthermore, our group has also demonstrated sufficient 
sensitivity of the computerized test battery CNS VS in the detection of (mild) cognitive 
deficits and change in cognitive function in patients with brain tumors.25-27
In parallel with our patient studies, we further investigated (within a collaboration between 
TiU and ETZ) normative values and psychometric properties of the CNS VS in a sample 
of Dutch healthy controls28,29, in order to be able to draw accurate conclusions on both 
individual performances of patients and change in cognitive functioning over time. First, 
we compared the existing norms of the American population (n = 1069) to performance 
of Dutch healthy controls (n = 158). Also, the effects of sex, age and education on test 
performance were evaluated. Since significant differences were observed between the 
American norms and Dutch healthy controls, as well as significant influences of sex, age 
and education, we developed regression-based norms based on our Dutch healthy sample. 
Subsequently, we evaluated change in test performance over time in this sample. Test-retest 
reliability and practice effects of the CNS VS were evaluated, and formulae were established 
for the determination of individual reliable change in cognitive performance over time, 
taking into account imperfect test-retest reliability and practice effects.
PATIENT REPORTED OUTCOME MEASURES
In addition to the measurement of performance-based outcomes of cognitive functioning, 
assessment of patients’ own experience is equally important in the light of patient-centered 
care, in order to get a complete picture of patients’ everyday functioning. Patient reported 
outcome measures (PROMs) are defined as outcomes directly reported by patients (using 
self-report or interviews), which reflect the patient’s perception of a disease and treatment.30 
Binnenwerk Sophie - Final na proefdruk.indd   10 11-11-19   15:43
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PROMs are useful to quantify symptoms, functioning, health-related quality of life or 
treatment satisfaction.30 A distinction can be made between generic or condition-specific 
instruments.31 The Cognitive Failures Questionnaire (CFQ32) is an example of a generic 
instrument, whereas the MD Anderson Symptom Inventory Brain Tumor Module (MDASI-
BT33) and the EORTC brain cancer-specific Quality of Life Questionnaire34 are condition-
specific instruments for patients with brain tumors. Several validated questionnaires can be 
used to assess the wide variety of possible complaints brain tumor patients can experience, 
including cognitive symptoms, psychological distress and fatigue. To be able to provide 
appropriate care, proper assessment of these symptoms is an important first step. However, 
filling out multiple lengthy questionnaires can be burdensome for neuro-oncological 
patients. Thus, the inclusion of PROMs is important in both research and clinical settings, 
but patient burden should be taken into account, by assessing as efficiently as possible.
In this thesis, particular attention is paid to the assessment of fatigue. Fatigue can be 
described as a subjective feeling of tiredness and a lack of energy, and therefore self-
report questionnaires are probably the most suitable method to measure levels of 
fatigue. In oncological and neurological patients, fatigue is a very common symptom, but 
unfortunately often underdiagnosed and undertreated.35,36 Research showed that fatigue 
in brain tumor patients is associated with cognitive complaints, depressive symptoms and 
sleep-wake disturbances, and moreover, that it affects patients’ daily activities and quality 
of life.14,37,38 More research is necessary to increase knowledge on the prevalence, severity 
and multifactorial determinants of fatigue in patients with meningioma and glioma.
COGNITIVE REHABILITATION IN PATIENTS WITH BRAIN TUMORS
Although cognitive functioning of brain tumor patients is extensively investigated over the 
past decades, research on treatment options for cognitive deficits in this patient group is 
lagging behind. This is in contrast with research in other neurological patient populations, 
for example mild cognitive impairment and multiple sclerosis39-41, where much more 
research is being done on treatment of cognitive deficits, possibly because these disorders 
are more common or because brain tumor patients are not seen as potential candidates 
because of their generally poorer prognosis. However, we feel that more attention should 
be paid to the treatment of cognitive deficits. First and foremost, because cognitive deficits 
often disrupt the normal life of patients and lead to lowered quality of life.18,19 Furthermore, 
due to improvements in medical treatment followed by increased life expectancy6,42, brain 
tumor patients live longer with various possible complaints, including cognitive deficits. 
Therefore, treatment of cognitive deficits, and also management of symptoms of fatigue 
and psychological distress, has become increasingly important in the management of the 
1
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disease.43 Also, from research we know that patients and partners are in need of more 
support for these complaints, but that these needs are regularly unmet.44
Cognitive rehabilitation is one of the main treatment options for cognitive deficits. The 
goal of cognitive rehabilitation is helping patients to improve cognitive functioning or to 
compensate for their cognitive deficits. In cognitive rehabilitation, two methods can be 
distinguished, namely cognitive retraining and compensation training. Cognitive retraining 
aims to ameliorate affected cognitive functions by extensive practice over time. Over the 
past few years, meta-analyses demonstrated that patients can improve on the trained 
task, but evidence for long-lasting effects is often lacking and moreover, that effects in 
near to far transfer to other tasks appear to be small to non-existent.45 Compensatory 
methods include strategy training, that help patients better cope with cognitive problems. 
Examples of strategy training are Goal Management Training46,47 or learning to use external 
memory aids (including assistive devices).48 A large body of evidence on the effectiveness 
of compensation training exists in different patient populations.48-50
A few studies have been conducted on the effects of cognitive rehabilitation in brain tumor 
patients, of which most studies demonstrated positive effects.47,51-55 In the majority of 
studies, use was made of compensation methods, in some cases combined with retraining 
elements. However, there are still many questions left in this field. There is an ongoing 
debate about what timing would be most appropriate for cognitive rehabilitation, and what 
the target group should be. Early intervention ensures that patients and partners are well-
informed and that they know how to handle cognitive problems timely. When cognitive 
function deteriorates, due to for example adjuvant treatment or disease progression, 
patients and their partners are better prepared and potentially, more resilient. On the other 
hand, early interventions can be burdensome and may not have high enough priority for 
patients immediately after surgery or adjuvant treatment. However, studies indicate that the 
need for supportive care is very high, especially in the early stage of the disease.44 Regarding 
the target population for cognitive rehabilitation, patients can be preselected based on 
cognitive complaints (using questionnaires) or cognitive deficits (using neuropsychological 
tests). Another option is rehabilitation to optimize functioning in an early phase regardless 
of disorders or complaints, to potentially minimalize impairments in functioning at a later 
stage, making use of the capabilities that are still intact. It seems a plausible option, given 
that a very large proportion of brain tumor patients experience cognitive deficits at a certain 
point during the disease trajectory. This more proactive approach, as an alternative to an 
impairment-driven approach, is also known as ‘prehabilitation’. Prehabilitation has received 
increased attention over the last years, in other patient populations, particularly regarding 
Binnenwerk Sophie - Final na proefdruk.indd   12 11-11-19   15:43
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exercise before surgery.56,57 Besides timing and target population, the ideal duration, 
intensity and follow-up of cognitive rehabilitation programs also remains largely unknown.
Recapitulating, there are still many uncertainties whether and how cognitive rehabilitation 
can have beneficial effects for patients with brain tumors. For this project, we emphasized 
the importance of proper clinical embedding of the program, in order to minimize patient 
burden. Amongst others, the intervention starts three months after surgery, after 
completion of adjuvant radiotherapy, and appointments are linked to existing appointments 
within the surgical aftercare in the hospital. Also, we chose to adopt a preventive and 
inclusive approach, intervening early in disease process, while not preselecting patients 
based on cognitive complaints or disorders.
THE OPPORTUNITIES OF EHEALTH: DEVELOPMENT OF THE IPAD INTER-
VENTION REMIND
Although face-to-face cognitive rehabilitation programs have proven to be effective in 
patients with brain tumors51,52, they are accompanied by significant limitations. Multiple 
face-to-face sessions with a professional are necessary, which are time-consuming, costly, 
and require frequent hospital visits from patients. These multiple visits can be burdensome 
and are associated with indirect costs (e.g. time of work or travel costs58). Also, multiple 
hospital visits are not always feasible for individual patients, due to, for example, inability 
to drive. To overcome some of the limitations of conventional cognitive rehabilitation 
programs, use can be made of eHealth. Efficient use of eHealth saves time and costs, and 
also, increases the accessibility of interventions to patients.
In 2009, the large randomized controlled trial of Gehring and colleagues demonstrated 
positive effects of a face-to-face cognitive rehabilitation program, which was specifically 
developed for brain tumor patients, on cognitive functioning and mental fatigue in 140 
glioma patients. Delivery of the program was highly intensive, as with other face-to-face 
programs, and after completion of the study, the program was no longer available for 
patients. In a joint patient-researcher initiative, the face-to-face program was converted 
into an iPad-based program (both in Dutch and English) (Figure 2), with the aim of improving 
availability and dissemination of the program. During the development of the ReMind-app, 
optimum use was made of the technical possibilities the new environment offered. Similar to 
the original program59, ReMind consists of compensation training, including psychoeducation 
and teaching of compensatory skills, and attention retraining. The iPad-based program 
allows patients to follow in-home cognitive rehabilitation at their own pace.
1
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Figure 2. Homepage of ReMind
INVOLVEMENT OF INFORMAL CAREGIVERS
As described before, brain tumor patients often suffer from cognitive deficits, mood 
disorders, severe fatigue or personality changes.14 These symptoms, together with physical 
limitations, cause patients to depend increasingly on people in their environment for help 
and support.60 At the same time, informal caregivers have to deal with these cognitive, 
emotional and behavioral symptoms, which leads to increased caregiver burden.61 In the 
field of neuro-oncology, increased attention has been paid to experiences of informal 
caregivers over the last years, regarding functioning of the patient (e.g., symptom monitoring 
during different stages of the disease) and functioning of the caregivers themselves (e.g., 
caregiver burden62). Ultimately, involvement of informal caregivers may contribute to 
improved information exchange, better decision-making and treatment adherence, lower 
caregiver burden and higher self-efficacy of patients and caregivers. Thus, it is important 
to involve informal caregivers closely in the treatment of the patient and also, to provide 
informal caregiver support according to their needs.63,64 In the research described in this 
thesis, informal caregivers were invited to participate in both symptom monitoring (i.e. 
executive functioning) and in the eHealth intervention.
Binnenwerk Sophie - Final na proefdruk.indd   14 11-11-19   15:43
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AIMS AND OUTLINE OF THIS DISSERTATION
In this thesis, we investigated assessment and rehabilitation of cognitive functioning and 
fatigue in patients with low-grade glioma and meningioma after neurosurgery, with the 
ultimate aim to improve the follow-up care for these patients. We have conducted different 
experimental studies, and in this thesis, data were used from a healthy control study, a 
cognitive rehabilitation study and a prospective longitudinal study on the prevalence, 
severity and prediction of cognitive outcome in brain tumor patients (the PREDICT-study).
In part I of the dissertation, neuropsychological assessment in patients with brain tumors 
receives attention. First, in a group of Dutch healthy controls, we investigated psychometric 
properties of the neuropsychological test battery CNS VS (chapter 2), which we used 
throughout all studies in this thesis. Test-retest reliability and practice effects of the CNS 
VS were evaluated, and formulae were proposed for the determination of individual reliable 
change in cognitive performance over time. In chapter 3, we focused on the assessment 
of executive functioning in patients with primary brain tumors, since deficits in executive 
functioning are among the most pronounced cognitive deficits in this patient group and 
have major impact on patients’ daily functioning. Self-report of patients was compared with 
report of their informal caregivers (i.e. proxy-report or observer-report) on patients’ EF and 
with performance-based measures of executive functioning. In chapter 4, we systematically 
examined the prevalence, severity and correlates of fatigue in patients with WHO-grade 
I meningioma. Fatigue is commonly reported by patients with meningioma in clinical care 
but has been scarcely studied in this patient group. Since patients with WHO-grade I 
meningioma have a relatively good long-term prognosis, follow-up care is quite limited and 
problems as cognitive deficits, fatigue and reduced quality of life can be overlooked in these 
patients with benign tumors.
In part II, we focus on post-surgical cognitive rehabilitation in brain tumor patients, 
evaluating the eHealth intervention ReMind. First, the results of a feasibility study on ReMind 
are presented in terms of accrual, attrition, adherence and patient satisfaction (chapter 
5). After successful completion of the pilot study, we started a randomized controlled trial 
(RCT). The study protocol of the RCT on the efficacy of ReMind is described in detail in 
chapter 6. Subsequently, in chapter 7, we present the results of our RCT on the effects of 
ReMind on cognitive performance and PROs in patients with meningioma and low-grade 
glioma after neurosurgery. Finally, in chapter 8, the main findings of the dissertation are 
summarized, methodological considerations are discussed and implications for research 
and clinical practice are provided.
1
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This study examined test-retest reliabilities and (predictors of) practice effects of the widely 
used computerized neuropsychological battery CNS Vital Signs. The sample consisted of 158 
Dutch healthy adults. At 3- and 12-months follow-up, 131 and 77 participants were retested. 
Results revealed low to high test-retest reliability coefficients for CNS VS’ test and domain 
scores. Participants scored significantly higher on the domains of Cognitive Flexibility, 
Processing Speed, and Reaction Time at the 3-month retest. No significant differences 
in performance were found over the second interval. Age, education, and retest-interval 
were not significantly associated with practice effects. These results highlight the need for 
methods that evaluate performance over time while accounting for imperfect test-retest 
reliabilities and practice effects. We provided RCI-formulae for determining reliable change, 
which may be a possible solution for future work facing the methodological issues of retesting. 
PUBLIC SIGNIFICANCE STATEMENT
Imperfect test-retest reliability and practice effects must be taken into account when 
interpreting change in neuropsychological test scores over time, for example by applying 
RCI-formulae for the determination of reliable change.
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INTRODUCTION
The use of repeated neuropsychological assessment, with the purpose of determining 
changes in cognitive functioning over time, is widespread in both clinical and research 
realms. A computerized neuropsychological test battery that is frequently used in serial 
assessment is Central Nervous System Vital Signs (CNS VS1). It has for example been used to 
evaluate the course of a disease (e.g. 2-4), and to evaluate the effects of interventions (e.g., 5-7).
Important considerations when interpreting performance on repeated 
neuropsychological assessments include imperfect test-retest reliabilities; that is random 
variability in scores which were gathered using the same instrument, in the same person, 
and under the same conditions8, and practice effects on follow-up testing performance (i.e., 
performance gain at retest due to familiarity with, and recognition of, test materials and 
procedures9,10). When the influence of these factors is ignored, erroneous conclusions can be 
drawn about the course of a disorder, for example by underestimating cognitive decline, or 
overestimating the effectiveness of a treatment. In general, changes in neuropsychological 
performance can be described in terms of raw change scores, reflecting the difference 
between a test and retest score without taking into account factors such as the test-retest 
reliability of an instrument or effects of practice. However, more suitable methods for 
determining whether observed changes within an individual represent real changes are 
available, such as reliable change indices (RCI).11,12 Although many types of RCIs exist, all 
reflect a ratio of an estimate on an observed change score, as compared to change in a 
control group, and a corresponding standard error of measurement in the denominator.
CNS VS is suggested to be suitable for serial administration due to the generation of 
alternate forms through its random presentation of stimuli.1 A few studies investigated the 
effects of retesting on CNS VS performance in the American population.1,13,14 As CNS VS 
consists of seven tests that generate up to 11 cognitive domain scores, most studies use 
a selection of these domains. The test-retest reliability of CNS VS domain scores varied 
considerably per cognitive domain, where correlations ranged from .11 to .87, reflecting 
low to high test-retest reliability. Across the studies, results were largely consistent: low 
test-retest correlations were found for the domains of memory and adequate to high test-
retest reliability was demonstrated for scores on measures of executive functioning, speed 
and reaction time.1,13,14 Furthermore, Littleton, Register-Mihalik and Guskiewicz described 
that participants (N=40) performed better on 6 out of 9 cognitive domains on the second 
assessment compared to the first.14 Consequently, it was concluded that practice effects 
do occur across serial testing sessions. No further changes were found between a second 
and third assessment.14
Although the former studies sought to determine CNS VS’ psychometric properties in 
relation to repeated assessment, no firm conclusions can be drawn. Included sample sizes 
were small, rendering imprecise estimates of the test-retest correlations. Furthermore, the 
2
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literature describes several factors that are associated with differences in practice effects, 
such as age, education and test-retest interval.10 However, the influence of education on 
practice effects of CNS VS has not yet been studied. Also, translated versions of CNS 
VS might be affected by cultural influences. Therefore, results from previous studies 
in American samples do not necessarily generalize to non-American samples.15 More 
importantly, methods to deal with the previously demonstrated imperfect test-retest 
reliabilities and practice effects for use of CNS VS in daily (clinical) practice have not been 
provided.
The present study examines test-retest reliabilities and practice effects for the 
computerized neuropsychological battery CNS VS in a healthy Dutch sample, as well as 
factors that are known to be associated with practice effects (i.e., age, education, and time 
interval between assessments). Results will be placed into a solution-oriented perspective 
by the use of RCIs.
METHODS
Participants and Procedure
Participants were healthy Dutch adults recruited by convenience (i.e., from the broad 
network of the research group). They were considered healthy if 1) they had no major 
illnesses in the past year (e.g., cancer, myocardial infarction); 2) there was no past or present 
psychiatric or neurologic disorder; 3) they were free of any centrally acting psychotropic 
medication; and 4) did not have a history of drug abuse. All participants provided written 
informed consent and filled out a screening questionnaire querying their health status. 
Information regarding age, sex, educational level, and familiarity with computers was 
obtained by means of a checklist.
The CNS VS battery was administered at three times: at ‘baseline’ (T0), at 3-months 
(T3) and 12-months (T12). Participants were assessed individually following a standardized 
protocol at the university, hospital, or at the participant’s home. All testing was done using 
the CNS VSX local software application, on the same type of laptop computers running 
Windows 7 Professional on 64-bit operating systems with background programs shut down 
and disconnected from Internet resources. Well-trained test technicians remained present 
during the entire assessment and ensured appropriate conditions. At retest, technicians 
checked for health issues or major life events since the previous assessment.
Baseline CNS VS performance of this study sample, including the effects of 
sociodemographic variables, was described in a previous publication.16 The study was 
approved by the Medical Ethics Committee (file number NL41351.008.12).
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CNS Vital Signs
Cognitive functioning was assessed using the formal Dutch translation of the commercially 
available computerized neuropsychological test battery CNS VS (http://www.cnsvs.com). Its 
seven individual tests yield measures of performance in eleven cognitive domains. Stimuli 
are randomly presented over sessions. However, since 4 domains (i.e., composite memory, 
executive functioning, simple attention, and motor speed) generated by CNS VS show 
considerable overlap with other domains of the battery, only seven cognitive domains will be 
considered in this study, as well as 16 test scores (see Table 1). It takes approximately 30-40 
minutes to complete the battery, after which automatic scoring facilitates the immediate 
availability of test results. Results are presented as raw scores, comprising of the number 
of correct and incorrect responses as well as mean reaction times in milliseconds.1
2
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Statistical analysis
Participants’ Characteristics. Descriptive analyses of characteristics (i.e., age, sex, years 
of education, frequency of computer use, and baseline cognitive performance) of the 
participants who completed all three assessments, versus participants who dropped out 
after T0 or T3, were performed.
Test-retest Reliability. To examine the strength of the relationship between the test 
and retest scores, a series of Pearson product-moment correlations, or Spearman rho 
correlations in case of non-normally distributed data, were calculated for CNS VS’ raw 
domain and test scores of T0 with those of T3, and for CNS VS’ raw domain and test scores of 
T3 with those of T12. However, as Pearson’s correlations only capture the linear association 
between scores, high values do not imply that the scores on pretest and posttest are 
identical. This means that Pearson’s correlations are able to show to what extent the rank 
ordering of participants on the construct is stable over assessments, but they fail to show 
to what extent the same scores are obtained. Therefore, intra-class correlation coeffi cients 
(ICCs; see Schuck, 200417) were calculated, which use a more stringent defi nition of 
reproducibility of scores. In particular, a distinction is made between ICCs for consistency 
(ICC
con
) and ICCs for agreement (ICC
agr
). ICCs for consistency evaluate to what extent 
scores at posttest differ from pretest by a constant. High ICCs for consistency are obtained 
when test scores are reliable, but all scores are elevated by the same amount (e.g., due to a 
constant practice effect). ICCs for agreement evaluate to what extent participants obtain 
exactly the same scores at the test and retest. High ICCs for agreement indicate that scores 
are stable and reproducible over time and rule out practice effects and instability of the 
construct envisaged. For the computations of the ICCs, a two-way mixed model was used 
and both ICCs of consistency and absolute agreement were evaluated at the level of single 
measures. Test-retest reliability coeffi cients of ≥.70 were acceptable.18,19 Additionally, the 
following categories were distinguished for further interpretation of reliability coeffi cients: 
coeffi cients <.60 are considered low, .60-69 are marginal, .70-.79 are adequate, .80-.89 
were considered high, and coeffi cients ≥ .90 are very high.19,20
Practice Effects. Paired-sample t -tests were performed to evaluate potential changes 
in participants’ CNS VS’ raw domain and test scores from T0 to T3, and from T3 to T12. 
To assess the magnitude of change, effect sizes (ES) were determined with Cohen’s d.1 ES 
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Potential Predictors of Practice Effects. If practice effects depend on background 
characteristics, the change in neuropsychological performance of participants is different 
across different levels of the background variables (e.g., change scores may be larger in 
younger participants compared to older participants). Therefore, to identify potential 
predictors of the magnitude of practice effects, a series of multiple linear regression 
analyses was conducted using raw CNS VS change scores as the outcome variables and 
a predetermined list of sociodemographic predictors. Age (in years), education (classified 
according to the Dutch Verhage scale22) ranging from unfinished primary school (1) to 
university level (7). Its seven categories were merged into three ordinal categories; low 
(Verhage 1 to 4), middle (Verhage 5), and high educational level (Verhage 6 and 7), which 
were dummy coded with middle education as reference category), and test interval (in 
weeks) were predictor variables which were entered as a single block (‘enter’ method). 
Assumptions were evaluated as follows: independence of observations was evaluated 
by Durbin-Watson tests (its values should be approximately 223), and linearity and 
homoscedasticity were examined using scatter plots of residuals. Indications of potential 
multicollinearity between predictors was examined by inspecting Pearson’s correlation 
coefficients and variance inflation indices, which should respectively not exceed 0.80 and 
10.24 By computing Cook’s distances, which should be ≤1, univariate influential cases were 
identified.5 Normality of residuals was investigated by visual inspection of histograms.
Reliable Change Indices. In order to determine whether observed changes reliably reflect 
true changes in cognitive performance, whilst considering amongst others test-retest 
reliabilities and practice effects, the adjusted regression-based RCI (adjRCI
srb
) presented 








The numerator in Equation 1 represents the estimated true change, and the denominator 
the corresponding standard error. Furthermore, variables Di and Dc denote to the observed 
difference between the raw test score and retest score for the individual i and the average 
difference score in a control group (our sample of healthy participants) c, respectively. Sx 
and Sy denote the standard deviation of the raw test scores x and retest scores y in the 
control group. Variable Xi represents the raw test score for the individual, and Xc is the 
average raw score in the control group. Coefficient rxy is the test-retest correlation, which 
here represents the test-retest reliability. For further details about this method, see formula 
(10) in Maassen, Bossema, and Brand.26
RCI formulae were established for each cognitive domain. Positive RCI values indicate 
that performance has improved at the retest assessment as compared to the preceding 
assessment, and vice versa for negative RCIs representing decline. RCIs are assumed to be 
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standard normally distributed under the null model of no change. This property allows to 
test whether change is statistically significant at the desired alpha level. In particular, for the 
alpha level of 0.10 (corresponding to a confidence interval of 90%), a statistically significant 
improvement or decline is observed when an RCI-value exceeds ±1.645. In those cases, one 
speaks of reliable change.
Data were analyzed using SPSS (Version 23.0; IBM SPSS Inc.). To reduce false discovery 
rate due to multiple testing, resulting p-values (i.e., from the descriptive analyses of 
characteristics, and analyses with regard to (predictors of) practice effects) were set against 
a corrected alpha, using the Benjamini-Hochberg (BH) procedure.27
RESULTS
Participants’ Characteristics
Table 2 presents the sociodemographic characteristics of the participants. A total of 
158 Dutch healthy participants were enrolled in the study and completed T0, of whom 
131 participants also completed T3. As part of an earlier project, T0 and T3 assessments 
were already completed in 33 participants. No T12 assessment was performed in these 
participants. Nevertheless, the previously collected data were included in the database 
of the current study. Of the resulting 98 participants, 77 participants completed all 
three assessments. To sum up, 81 participants did not complete all assessments. Besides 
the expired follow-up time for 33 participants who were assessed as part of an earlier 
project, the most important reasons for discontinuation were difficulties in contacting 
the participants for follow-up assessment and that participants had busy schedules and 
other priorities. Nevertheless, between group comparisons revealed no significant baseline 
differences between participants who dropped out the study and those who did not, on 
age, years of education, sex, and baseline cognitive performance (p-values > BH-corrected 
alpha .004).
Mean age of the participants was 45.9 (±14.4) years at the time of baseline assessment. 
Fifty-seven percent of the sample was female; participants completed 16.9 (± 3.3) years of 
education on average. The median time interval between T0 and the 3-month assessment 
T3 was 3.5 months (mean 4.2±1.7 months), with a range of 2.0 – 9.2 months. Median time 
interval between the 3-month and 12-month interval (T3 and T12) was 8.3 months (mean 
7.6±2.0 months), with a range of 3.7 – 11.0 months.
2
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Table 2. Characteristics of dropouts and groups who underwent baseline, 3- and 12-month follow-up 
assessment with CNS VS
T0 (n = 158) T3 (n = 131) T12 (n = 77)
Drop-outs
(n = 81)












Sex; male (n;%) 68; 43.0% 51; 38.9% 28; 36.4% 40; 45.3%











Level of educationa (n; %b)
Low 19; 12.0% 15; 11.5% 12; 15.6% 7; 8.6%
Middle 57; 36.1% 46; 35.1% 27; 35.1% 30; 37.0%
High 82; 51.9% 70; 53.4% 38; 49.4% 44; 54.3%
Computer usec (n,%b)
Never 1; 0.6% 1; 0.8% 1; 1.3% -
Some 4; 2.5% 4; 3.1% 4; 5.2% -
Frequent 153; 96.8% 126; 96.2% 72; 93.5% 81; 100%
a Education is classified according to the Dutch coding system of Verhage22 and categorized as 
follows: low educational level (Verhage 1 to 4), middle educational level (Verhage 5), and high 
educational level (Verhage 6 and 7). 
b Percentages do not always sum up to 100 due to rounding 
c Computer use was rated on a three-point scale with categories ‘never’, ‘some’, or ‘frequent’.
Test-retest Reliability
Table 3 lists detailed results of the test-retest reliability analyses, including Pearson/
Spearman correlations and ICCs for consistency and agreement. ICCs for consistency of 
CNS VS’ domain scores ranged from .40 to .89. For the individual tests scores, ICCs between 
.17 and .88 were found. Test-retest correlation coefficients of the second interval (T3-T12) 
generally appeared to be higher than the coefficients of the first interval (T0-T3). Overall, 
minor differences between Pearson/Spearman correlation coefficients and both ICCs for 
consistency and ICCs for agreement were observed.
Adequate to high reliability correlation coefficients were observed on the domains of 
Reaction Time, Cognitive Flexibility, Psychomotor Speed and Processing Speed as well 
as on the tests of Finger Tapping, Symbol Digit Coding and Shifting Attention. Reliability 
correlation coefficients of domains and tests of memory were low, suggesting poor reliability 
of test scores on these measures. Scores on the domain of Complex Attention showed poor 
test-retest reliability over the first interval (T0-T3), and turned out to be marginal, but still 
inadequate, over the second interval (T3-T12). Reliability correlation coefficients on the 
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Stroop Test were poor over the first interval (T0-T3). Over the second interval (T3-T12), 
ICCs of part II and III were adequate and high, but reliability correlation coefficients on part 
I remained inadequate. Due to minimal variance of (in-) correct responses on the Continuous 
Performance Test, the calculation of valid test-retest reliability correlation coefficients was 
not possible.
Practice Effects
As shown in Table 4, a series of two-tailed paired-sample t-tests demonstrated statistically 
significant (given a BH-corrected alpha of .009) changes between mean group performances 
at T0 and T3 on 3 out of 7 raw cognitive domain scores: performance was improved on 
Reaction Time (t(127) = 3.84, p = <.001, Cognitive Flexibility (t(127) = -4.81, p <.001), and 
Processing Speed (t(130) = -2.67, p = .0085) at T3. No significant changes in mean scores 
were found for Verbal Memory, Visual Memory, Psychomotor Speed, and Complex 
Attention. Effect sizes were small, with Cohen’s ds ranging from 0.15 to 0.32. There were 
no statistically significant changes in mean domain scores between T3 and T12 for any of 
the domains.
Inspection of the mean differences for the individual tests showed significantly higher 
raw scores on six out of seventeen measures at T3 compared to T0. Participants showed 
more correct responses in the direct recognition part of the Verbal Memory Test, and more 
correct answers on both the Symbol Digit Coding Test as well as the Shifting Attention 
Test at T3. Furthermore, faster responses were found for condition II and III of the Stroop 
Test, and the Shifting Attention Test. All effect sizes were small, with Cohen’s ds ranging 
from 0.09 to 0.33. Again, no statistically significant changes were found on any of the tests 
between scores obtained between T3 and T12.
Potential Predictors of Change
None of the assumptions regarding the regression analyses were violated. No significant 
effects (given a BH-corrected alpha of .004) of age, education, and duration of T0-T3 test 
interval were found on change in performance on any of the CNS VS’ raw domain scores: 
Verbal Memory (F(4, 118) = 1.68, p = .159, R2 = .054), Visual Memory (F(4, 120) = 1.28, 
p = .282, R2 = .041), Psychomotor Speed (F(4, 125) = 1.21, p = .310, R2 = .037), Reaction 
Time(F(4,123) = 0.75, p =  .560, R2 =  .024), Complex Attention (F(4, 121) =  .79, p =  .537, 
R2 = .025), Cognitive Flexibility (F(4, 123) = 1.31, p = .268, R2 = .041), Processing Speed (F(4, 
126) = 0.94, p = .445, R2 = .029). Along the same lines, no significant effects of the predictors 
were found on change in CNS VS domain scores for the T3-T12 test interval: Verbal Memory 
(F(4, 69) = 1.68, p = .164, R2 = .089), Visual Memory (F(4, 69) = 2.69, p = .038, R2 = .135), 
Psychomotor Speed (F(4, 71) = 0.64, p = .635, R2 = .035), Reaction Time (F(4, 72) = 0.69, 
p =  .599, R2 =  .037), Complex Attention (F(4, 71) = 1.08, p =  .374, R2 =  .057), Cognitive 
2
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Flexibility (F (4, 71) = 1.59, p = .187, R2 = .082), and Processing Speed (F(4, 72) = 0.35, p = .847, 
R2 = .019).
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Repeated assessment using CNS VS
Table 4. Continued
* Statistical significance was considered as p < .009. Alpha was adjusted using the Benjamini-
Hochberg procedure.27 
a
 positive mean differences represent improvements 
b
 Cohen’s d effect sizes: ≤ 0.20 – 0.49: small, 0.50 – 0.79: medium, ≥ 0.80: large.21 
c
 higher scores indicate lower performance
Reliable Change Indices
Table 5 shows RCI formulae for the determination of reliable change in CNS VS’ domain 
scores over repeated assessments of the T0-T3 interval. Since practice effects were only 
observed between the first and second assessment, RCI-formulae for the determination 
of change over the second time interval are not described but available upon request. An 
example of the use of RCI formulae is presented in Box 1.
Table 5. RCI formulae for determining individual change on CNS VS’ domain scores between T0 – T3





Verbal Memory AdjRCI'()𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉	𝑚𝑚𝑉𝑉𝑚𝑚𝑚𝑚𝑉𝑉𝑚𝑚 =
D6 − 0.82 + [1 − (4.55/4.37)](X6 − 52.04)
H(4.37I + 4.55I)(1 − 0.43)
 
Visual Memory AdjRCI'()𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉	𝑚𝑚𝑉𝑉𝑚𝑚𝑚𝑚𝑉𝑉𝑚𝑚 =
D6 − −0.21 + [1 − (4.81/4.34)](X6 − 46.27)
H(4.34I + 4.81I)(1 − 0.41)
 
Psychomotor Speed AdjRCI'()	𝑃𝑃𝑉𝑉𝑚𝑚𝑃𝑃ℎ𝑚𝑚𝑚𝑚𝑚𝑚𝑜𝑜𝑚𝑚𝑉𝑉	𝑉𝑉𝑠𝑠𝑉𝑉𝑉𝑉𝑠𝑠 =
D6 − 0.99 + [1 − (23.50/20.42)](X6 − 179.05)
H(20.42I + 23.50I)(1 − 0.88)
 
Reaction Timea AdjRCI'()	𝑅𝑅𝑉𝑉𝑉𝑉𝑃𝑃𝑜𝑜𝑉𝑉𝑚𝑚𝑅𝑅	𝑜𝑜𝑉𝑉𝑚𝑚𝑉𝑉 =
D6 − −16.77 + [1 − (67.86/68.24)](X6 − 632.06)
H(68.24I + 67.86I)(1 − 0.78)
∗ −1 
Complex Attentiona AdjRCI'()𝐶𝐶𝑚𝑚𝑚𝑚𝑠𝑠𝑉𝑉𝑉𝑉𝐶𝐶	𝑉𝑉𝑜𝑜𝑜𝑜𝑉𝑉𝑅𝑅𝑜𝑜𝑉𝑉𝑚𝑚𝑅𝑅 =
D6 − −0.76 + [1 − (4.07/4.30)](X6 − 6.44)
H(4.30I + 4.07I)(1 − 0.55)
∗	−1 
Cognitive Flexibility AdjRCI'()𝐶𝐶𝑚𝑚𝐶𝐶𝑅𝑅𝑉𝑉𝑜𝑜𝑉𝑉𝐶𝐶𝑉𝑉	𝑓𝑓𝑉𝑉𝑉𝑉𝐶𝐶𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑜𝑜𝑚𝑚 =
D6 − 3.77 + [1 − (12.14/11.37)](X6 − 46.90)
H(11.37I + 12.14I)(1 − 0.74)
 
Processing Speed AdjRCI'()𝑃𝑃𝑉𝑉𝑚𝑚𝑃𝑃𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑅𝑅𝐶𝐶	𝑉𝑉𝑠𝑠𝑉𝑉𝑉𝑉𝑠𝑠 =
D6 − 1.81 + [1 − (13.09/11.47)](X6 − 57.66)






r l ry j I'()𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉	𝑚𝑚𝑉𝑉𝑚𝑚𝑚𝑚𝑉𝑉𝑚𝑚
6 . [ ( . . )]( 6 . )
( . I . I)( . )
 
is l ry j I'()𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉	𝑚𝑚𝑉𝑉𝑚𝑚𝑚𝑚𝑉𝑉𝑚𝑚
6 . [ ( . . )]( 6 . )
( . I . I)( . )
 
syc t r S  j I'()	𝑃𝑃𝑉𝑉𝑚𝑚𝑃𝑃 𝑚𝑚𝑚𝑚𝑚𝑚𝑜𝑜𝑚𝑚𝑉𝑉	𝑉𝑉𝑠𝑠𝑉𝑉𝑉𝑉𝑠𝑠
6 . [ ( . . )]( 6 . )
( . I . I)( . )
 
cti  i a j I'()	𝑅𝑅𝑉𝑉𝑉𝑉𝑃𝑃𝑜𝑜𝑉𝑉𝑚𝑚𝑅𝑅	𝑜𝑜𝑉𝑉𝑚𝑚𝑉𝑉
6 . [ ( . . )]( 6 . )
( . I . I)( . )
 
l x tt ti a j I'()𝐶𝐶𝑚𝑚𝑚𝑚𝑠𝑠𝑉𝑉𝑉𝑉𝐶𝐶	𝑉𝑉𝑜𝑜𝑜𝑜𝑉𝑉𝑅𝑅𝑜𝑜𝑉𝑉𝑚𝑚𝑅𝑅
6 . [ ( . . )]( 6 . )
( . I . I)( . )
	  
itiv  Fl xi ility j I'()𝐶𝐶𝑚𝑚𝐶𝐶𝑅𝑅𝑉𝑉𝑜𝑜𝑉𝑉𝐶𝐶𝑉𝑉	𝑓𝑓𝑉𝑉𝑉𝑉𝐶𝐶𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑜𝑜𝑚𝑚
6 . [ ( . . )]( 6 . )
( . I . I)( . )
 
r c ssi  S  j I'()𝑃𝑃𝑉𝑉𝑚𝑚𝑃𝑃𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑅𝑅𝐶𝐶	𝑉𝑉𝑠𝑠𝑉𝑉𝑉𝑉𝑠𝑠
6 . [ ( . . )]( 6 . )







Verbal Memory AdjRCI'()𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉	𝑚𝑚𝑉𝑉𝑚𝑚𝑚𝑚𝑉𝑉𝑚𝑚 =
D6 − 0.82 + [1 − (4.55/4.37)](X6 − 52.04)
H(4.37I + 4.55I)(1 − 0.43)
 
Visual Memory AdjRCI'()𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉	𝑚𝑚𝑉𝑉𝑚𝑚𝑚𝑚𝑉𝑉𝑚𝑚 =
D6 − −0.21 + [1 − (4.81/4.34)](X6 − 46.27)
H(4.34I + 4.81I)(1 − 0.41)
 
Psychomotor Speed AdjRCI'()	𝑃𝑃𝑉𝑉𝑚𝑚𝑃𝑃ℎ𝑚𝑚𝑚𝑚𝑚𝑚𝑜𝑜𝑚𝑚𝑉𝑉	𝑉𝑉𝑠𝑠𝑉𝑉𝑉𝑉𝑠𝑠 =
D6 − 0.99 + [1 − (23.50/20.42)](X6 − 179.05)
H(20.42I + 23.50I)(1 − 0.88)
 
Reaction Timea AdjRCI'()	𝑅𝑅𝑉𝑉𝑉𝑉𝑃𝑃𝑜𝑜𝑉𝑉𝑚𝑚𝑅𝑅	𝑜𝑜𝑉𝑉𝑚𝑚𝑉𝑉 =
D6 − −16.77 + [1 − (67.86/68.24)](X6 − 632.06)
H(68.24I + 67.86I)(1 − 0.78)
∗ −1 
Complex Attentiona AdjRCI'()𝐶𝐶𝑚𝑚𝑚𝑚𝑠𝑠𝑉𝑉𝑉𝑉𝐶𝐶	𝑉𝑉𝑜𝑜𝑜𝑜𝑉𝑉𝑅𝑅𝑜𝑜𝑉𝑉𝑚𝑚𝑅𝑅 =
D6 − −0.76 + [1 − (4.07/4.30)](X6 − 6.44)
H(4.30I + 4.07I)(1 − 0.55)
∗	−1 
Cognitive Flexibility AdjRCI'()𝐶𝐶𝑚𝑚𝐶𝐶𝑅𝑅𝑉𝑉𝑜𝑜𝑉𝑉𝐶𝐶𝑉𝑉	𝑓𝑓𝑉𝑉𝑉𝑉𝐶𝐶𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑜𝑜𝑚𝑚 =
D6 − 3.77 + [1 − (12.14/11.37)](X6 − 46.90)
H(11.37I + 12.14I)(1 − 0.74)
 
Processing Speed AdjRCI'()𝑃𝑃𝑉𝑉𝑚𝑚𝑃𝑃𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑅𝑅𝐶𝐶	𝑉𝑉𝑠𝑠𝑉𝑉𝑉𝑉𝑠𝑠 =
D6 − 1.81 + [1 − (13.09/11.47)](X6 − 57.66)







l  j I ( 𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉	𝑚𝑚𝑉𝑉𝑚𝑚𝑚𝑚𝑉𝑉𝑚𝑚
6 . . . 6 .
. . .
 
i l  j I ( 𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉	𝑚𝑚𝑉𝑉𝑚𝑚𝑚𝑚𝑉𝑉𝑚𝑚
6 . . . 6 .
. . .
 
t   j I ( 	𝑃𝑃𝑉𝑉𝑚𝑚𝑃𝑃 𝑚𝑚𝑚𝑚𝑚𝑚𝑜𝑜𝑚𝑚𝑉𝑉	𝑉𝑉𝑠𝑠𝑉𝑉𝑉𝑉𝑠𝑠
6 . . . 6 .
. . .
 
ti  i a j I ( 	𝑅𝑅𝑉𝑉𝑉𝑉𝑃𝑃𝑜𝑜𝑉𝑉𝑚𝑚𝑅𝑅	𝑜𝑜𝑉𝑉𝑚𝑚𝑉𝑉
6 . . . 6 .
. . .
 
l  tt ti a j I ( 𝐶𝐶𝑚𝑚𝑚𝑚𝑠𝑠𝑉𝑉𝑉𝑉𝐶𝐶	𝑉𝑉𝑜𝑜𝑜𝑜𝑉𝑉𝑅𝑅𝑜𝑜𝑉𝑉𝑚𝑚𝑅𝑅
6 . . . 6 .
. . .
	  
iti  l i ilit  j I ( 𝐶𝐶𝑚𝑚𝐶𝐶𝑅𝑅𝑉𝑉𝑜𝑜𝑉𝑉𝐶𝐶𝑉𝑉	𝑓𝑓𝑉𝑉𝑉𝑉𝐶𝐶𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑜𝑜𝑚𝑚
6 . . . 6 .
. . .
 
i   j I ( 𝑃𝑃𝑉𝑉𝑚𝑚𝑃𝑃𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑅𝑅𝐶𝐶	𝑉𝑉𝑠𝑠𝑉𝑉𝑉𝑉𝑠𝑠









Verbal Memory AdjRCI'()𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉	𝑚𝑚𝑉𝑉𝑚𝑚𝑚𝑚𝑉𝑉𝑚𝑚 =
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H(20.42I + 23.50I)(1 − 0.88)
 
Reaction Timea AdjRCI'()	𝑅𝑅𝑉𝑉𝑉𝑉𝑃𝑃𝑜𝑜𝑉𝑉𝑚𝑚𝑅𝑅	𝑜𝑜𝑉𝑉𝑚𝑚𝑉𝑉 =
D6 − −16.77 + [1 − (67.86/68.24)](X6 − 632.06)
H(68.24I + 67.86I)(1 − 0.78)
∗ −1 
Complex Attentiona AdjRCI'()𝐶𝐶𝑚𝑚𝑚𝑚𝑠𝑠𝑉𝑉𝑉𝑉𝐶𝐶	𝑉𝑉𝑜𝑜𝑜𝑜𝑉𝑉𝑅𝑅𝑜𝑜𝑉𝑉𝑚𝑚𝑅𝑅 =
D6 − −0.76 + [1 − (4.07/4.30)](X6 − 6.44)
H(4.30I + 4.07I)(1 − 0.55)
∗	−1 
Cognitive Flexibility AdjRCI'()𝐶𝐶𝑚𝑚𝐶𝐶𝑅𝑅𝑉𝑉𝑜𝑜𝑉𝑉𝐶𝐶𝑉𝑉	𝑓𝑓𝑉𝑉𝑉𝑉𝐶𝐶𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑜𝑜𝑚𝑚 =
D6 − 3.77 + [1 − (12.14/11.37)](X6 − 46.90)
H(11.37I + 12.14I)(1 − 0.74)
 
Processing Speed AdjRCI'()𝑃𝑃𝑉𝑉𝑚𝑚𝑃𝑃𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑅𝑅𝐶𝐶	𝑉𝑉𝑠𝑠𝑉𝑉𝑉𝑉𝑠𝑠 =
D6 − 1.81 + [1 − (13.09/11.47)](X6 − 57.66)







l  j I ( 𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉	𝑚𝑚𝑉𝑉𝑚𝑚𝑚𝑚𝑉𝑉𝑚𝑚
6 . . . 6 .
. . .
 
i l  j I ( 𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉	𝑚𝑚𝑉𝑉𝑚𝑚𝑚𝑚𝑉𝑉𝑚𝑚
6 . . . 6 .
. . .
 
t   j I ( 	𝑃𝑃𝑉𝑉𝑚𝑚𝑃𝑃 𝑚𝑚𝑚𝑚𝑚𝑚𝑜𝑜𝑚𝑚𝑉𝑉	𝑉𝑉𝑠𝑠𝑉𝑉𝑉𝑉𝑠𝑠
6 . . . 6 .
. . .
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6 . . . 6 .
. . .
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6 . . . 6 .
. . .
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D6 − −16.77 + [1 − (67.86/68.24)](X6 − 632.06)
H(68.24I + 67.86I)(1 − 0.78)
∗ −1 
Complex Attentiona AdjRCI'()𝐶𝐶𝑚𝑚𝑚𝑚𝑠𝑠𝑉𝑉𝑉𝑉𝐶𝐶	𝑉𝑉𝑜𝑜𝑜𝑜𝑉𝑉𝑅𝑅𝑜𝑜𝑉𝑉𝑚𝑚𝑅𝑅 =
D6 − −0.76 + [1 − (4.07/4.30)](X6 − 6.44)
H(4.30I + 4.07I)(1 − 0.55)
∗	−1 
Cognitive Flexibility AdjRCI'()𝐶𝐶𝑚𝑚𝐶𝐶𝑅𝑅𝑉𝑉𝑜𝑜𝑉𝑉𝐶𝐶𝑉𝑉	𝑓𝑓𝑉𝑉𝑉𝑉𝐶𝐶𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑜𝑜𝑚𝑚 =
D6 − 3.77 + [1 − (12.14/11.37)](X6 − 46.90)
H(11.37I + 12.14I)(1 − 0.74)
 
rocessing Speed AdjRCI'()𝑃𝑃𝑉𝑉𝑚𝑚𝑃𝑃𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑅𝑅𝐶𝐶	𝑉𝑉𝑠𝑠𝑉𝑉𝑉𝑉𝑠𝑠 =
D6 − 1.81 + [1 − (13.09/11.47)](X6 − 57.66)




Higher raw scores on Reaction Time and Complex Attention indicate lower performance, 
for all other domains, higher raw scores represent higher performance. Therefore, RCI values 
for Reaction time and Complex Attention must be multiplied by -1 to facilitate consistent 
interpretation of change on each cognitive domain
2
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Box 1. Application of RCI formulae and a real-life example
1. Subtract the assessed person’s 
raw baseline test-score (X
i
) from the 
raw retest-score (Y
i
): this will result 
in a difference score (D
i
).
Consider a person with a baseline score of 57 (X
i
) and 
a retest score of 73 (Y
i
) on Cognitive Flexibility. The 
calculated difference score (D
i
) is 16.
2. Complement the RCI formula 
with the person’s difference score, 




𝐃𝐃𝐢𝐢 − D0 + [1 − (S6/S8)](𝐗𝐗𝐢𝐢 − X0)






𝐃𝐃𝐢𝐢 − 3.77 + [1 − (12.14/11.37)](𝐗𝐗𝐢𝐢 − 46.90)






𝟏𝟏𝟏𝟏 − 3.77 + [1 − (12.14/11.37)](𝟓𝟓𝟓𝟓 − 46.90)




 = Difference score: posttest score 
– pretest score of an individual
D
c
 = Difference score of the control 






 = SD of the pretest (x) and 




 = Pretest score of an individual
X
c





coefficient of pre- and posttest
We complement the RCI formula with the person’s 




𝐃𝐃𝐢𝐢 − D0 + [1 − (S6/S8)](𝐗𝐗𝐢𝐢 − X0)





𝐃𝐃𝐢𝐢 − 3.77 + [1 − (12.14/11.37)](𝐗𝐗𝐢𝐢 − 46.90)






𝟏𝟏𝟏𝟏 − 3.77 + [1 − (12.14/11.37)](𝟓𝟓𝟓𝟓 − 46.90)
W(11.37? + 12.14?)(1 − 0.74)
		 
 = 1.36
3. Interpret the person’s RCI, for 
example by applying the 90% 
confidence interval (CI): RCI values 
that fall within the 90% CI can be 
classified as ‘stable’ on this cognitive 
domain, whereas values outside the 
CI (i.e., ±1.645) can be denoted as 
having significantly ‘improved’ or 
‘declined’.
An RCI value of 1.36 falls within the 90% CI and the 
person’s performance over time (despite the apparent 
improvement from 57 to 73) is therefore interpreted as 
‘stable’.
DISCUSSION
Various clinical and research settings require repeated neuropsychological assessment, 
for example to evaluate the course of a disorder or the effects of an intervention on 
cognitive functioning. In the current study, test-retest reliabilities and practice effects for 
the frequently used computerized neuropsychological battery CNS VS were examined in 
sample of healthy Dutch participants.
The results demonstrated heterogeneous test-retest reliability coefficients for 
cognitive domains as well as test scores, thereby only partly supporting their stability in 
follow-up assessments over time. Test-retest reliability coefficients in the current study 
were generally consistent with those documented by prior studies on CNS VS’ test-retest 
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reliability1,13,14, and with other studies that examined other computerized neuropsychological 
assessment tools.28 In accordance with paper-and-pencil neuropsychological tests and the 
abovementioned studies, the lowest test-retest reliabilities were observed on measures 
of memory, as opposed to domains reflecting speed and reaction time, where test-retest 
reliabilities were high.29,30 This common finding of relatively poor reliability for scores on 
memory tests has been attributed to the increased variability of memory as a construct in 
comparison with other cognitive functions29,30, rather than to unreliable test instruments. 
Nevertheless, one should put additional effort in the interpretation of changes in 
performance on the memory domain, for example by examining aspects of memory with 
more than one test or by incorporating measures of reliability in the determination of 
changes in performance.
Practice effects were demonstrated on three out of seven cognitive domains: higher 
performance on Cognitive Flexibility, Processing Speed, and Reaction Time was found 
at the three-month retest compared to the first assessment. No significant changes in 
performance were demonstrated between the second and third assessment. Previous 
research also demonstrated that practice effects predominantly occur between the first 
and second assessment, but diminish after the second assessment.10,14 Practice effects 
may result from several factors, for example due to setting familiarity, task familiarity 
(e.g., including gaining comprehension of directions and knowledge of the sequence of a 
task), and familiarity with specific items (e.g., memorization of words on a list). Although 
CNS VS employs random presentation of stimuli from a reservoir of words and figures, the 
literature reports limited support for the effectiveness of precluding practice effects by 
using alternate forms of tests (e.g.,31). Indeed, our results suggest that practice effects were 
not fully precluded by the alternate forms of CNS VS. Future studies might for example 
consider the use of a multiple baseline design to control for effects of practice (e.g., 32,33). 
Results of the current study are also in line with previous findings on types of tests that 
suffer from practice effects, namely novel challenging cognitive tasks (e.g., Stroop Test and 
Symbol Digit Coding Test).30,34
Although in the literature several participant characteristics have been associated with 
variability in the magnitude of practice effects (i.e., practice effects becoming smaller with 
increased age (e.g., 35), or becoming larger with higher education (e.g., 10,36), we found no 
evidence that either age, education, or test interval is associated with variability in effects 
of practice regarding performance on CNS VS.
Use of raw difference scores for interpretation of change in individuals may not provide 
a reliable and unbiased picture, because of the imperfect test-retest correlations as well 
as the practice effects that we found with regard to repeated assessment using CNS VS 
that confound interpretation of these change scores. With the presented RCI-formulae 
specifically related to performance on the computerized battery CNS VS in a Dutch sample, 
2
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we provide a standardized method for addressing cognitive change over time whilst taking 
methodological issues such as practice effects into account. By presenting RCI formulae 
we do not only aim to provide a solution for interpreting performance in Dutch participants 
when CNS VS is used repeatedly over time, but we also hope for employment of this 
approach into clinical practice and in future studies examining other neuropsychological 
measures over time. Although our results may not be generalizable to other countries 
or populations who speak other languages, they demonstrate that CNS VS users should 
be cautious when interpreting performance on repeated assessments using the original 
American norms. As for our own research and clinical practice, we will from now on 
incorporate the RCI into our ongoing patient studies, in which we evaluate the course and 
effects of surgery in patients with brain tumors.
A few limitations to the interpretation and application of the presented results should 
be discussed. First, CNS VS may be self-limiting in its ability to show practice effects over 
time. Ceiling effects of the test may limit improvements in performance – for example, a 
potential ceiling effect was reached for the Continuous Performance Test from upon the 
first test administration (i.e., raw mean score was 39.94 at T0 whereas the highest achievable 
score for this particular test is 40). However, since we did not observe clear ceiling effects 
on other tests, this factor is unlikely to explain findings with regard to (the absence of) 
practice effects for some domains in the current study. Second, the findings presented in 
this study are based on performance in healthy Dutch participants recruited on availability 
(i.e., convenience sampling). Preventing participants from dropping out of the study before 
completion of all follow-up assessments proved to be challenging, which might partly be 
explained by the fact that participants did not receive a compensation for participation 
in the study. These factors may have caused selection and retention biases, although 
no significant differences between the sociodemographic characteristics and baseline 
cognitive performance of participants who completed all assessments and of participants 
who dropped out were demonstrated. Thirdly, a relatively small number of low educated 
participants (i.e., 12% compared to approximately 35% in the general Dutch population37) 
was included in the present sample. Yet, no significant importance with regard to the effects 
of educational level on change scores between the first and second, and second and third 
assessment was found. One should be aware that results might not be generalizable to 
(clinical) populations with much lower levels of education. However, one should always be 
careful when interpreting (changes in) individual test performance of people who are in the 
extreme ends of education or other predictor variables. Fourth, the test-retest intervals in 
our study varied considerably amongst subjects and were also relatively long compared to 
other studies involving repeated assessments using CNS VS (e.g.,13,14). Within this longer 
timeframe, systematic error, random error and real changes in cognitive function are more 
likely to have occurred. To control for the impact of these systematic and random errors, we 
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computed ICCs for agreement and established RCI-formulae. Since the test-retest interval 
used in this study closely approximated the design of our ongoing patient studies (e.g.,7), 
this relatively long interval was still preferred.
Although repeated neuropsychological assessment is of great value both in clinical 
and research settings, the interpretation of change in performance at retesting can be 
challenging. With regard to repeated assessment using CNS VS, we found imperfect 
test-retest reliabilities and practice effects for some of its domains in a Dutch sample. As 
previous research shows, these issues also impact the interpretation of performance on 
other computerized, as well as conventional paper-and-pencil, neuropsychological tests, we 
expect that many clinicians and researchers face these difficulties. This clearly highlights 
the need for methods that evaluate individual change in performance over multiple 
assessments whilst accounting for imperfect test-retest reliabilities and practice effects. 
Establishing RCI-formulae for specific populations and tests may be a practical method for 
determining individual reliable change in future longitudinal scientific or clinical work facing 
the methodological issues of repeated testing.
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CHAPTER 3
Assessment of executive functioning 
in patients with meningioma and 
low-grade glioma: A comparison of 
self-report, proxy-report and test 
performance




Objective: This study aimed to examine 1) patient-proxy agreement on executive 
functioning (EF) of patients with primary brain tumors, 2) the relationships between patient- 
and proxy-report with performance-based measures of EF and 3) the potential influence 
of performance-based measures on the level of agreement.
Method: Meningioma and low-grade glioma patients and their informal caregivers 
completed the Behavior Rating Inventory of Executive Function (BRIEF-A) three 
months after surgery. The two index scores of the BRIEF-A, Behavioral Regulation and 
Metacognition, were evaluated. Mean scores of patients and proxies were compared 
with normative values and with each other. Patient-proxy agreement was evaluated 
with Lin’s concordance correlation coefficients (CCCs) and Bland-Altman plots. Pearson 
correlation coefficients between reported EF and performance-based measures of EF were 
calculated. Multiple regression analysis was used to evaluate the potential influence of test 
performance on differences in dyadic reports.
Results: A total of 47 dyads were included. Patients reported significantly more problems 
on the Metacognition index compared to norms, and also in comparison with their proxies. 
Effect sizes indicated small differences. Moderate to substantial agreement was observed 
between patients and proxies, with CCCs of .57 and .61 for Metacognition and Behavioral 
Regulation respectively. Correlations between reported EF and test performance 
ranged between -.37 and .10. Dyadic agreement was not significantly influenced by test 
performance.
Conclusions: Patient-proxy agreement was found to be moderate. No clear associations 
were found between reported EF and test performance. Future studies should further 
explore existing and new methods to assess everyday EF in brain tumor patients.
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INTRODUCTION
Over the last few decades, patients and their family members are increasingly being 
involved in care decisions.1,2 To be able to make informed decisions, patients need sufficient 
cognitive abilities and self-awareness, but these functions can be disturbed in patients with 
brain disorders (e.g., 3-5). More specifically, evidence emerging from patient studies, imaging 
research and behavioral paradigms suggests that different components of executive 
functioning (EF) play a crucial role in decision making and that impairments in EF seem to 
be associated with risky and ambiguous decision making.6-8 Executive functions include 
several higher-order cognitive processes that enable people to control and regulate their 
own behavior. Key executive functions are inhibition (i.e. deliberate overriding of dominant 
responses), cognitive flexibility (i.e. shifting between different tasks or mental sets) and 
working memory (i.e. constant monitoring and updating of retained information).9-11 With 
respect to decision making, executive functions are necessary for, amongst others, assessing 
probabilities, categorizing options, selecting decision making strategies and using feedback 
to revise strategies if necessary.8
Impairments in EF are amongst the most pronounced cognitive deficits in patients 
with primary brain tumors.12-15 Impairments in EF can have a negative impact on patients’ 
everyday lives, but also on the lives of the people in their environment.16-18 It is important 
to identify problems with EF at an early stage, so we can refer to intervention programs in 
time, including for example Goal Management Training (GMT).19
From research and clinical practice, it is known that patients who experience cognitive 
complaints, do not necessarily show lower scores on neuropsychological tests. And vice 
versa, if patients demonstrate lower test performance, they do not always experience 
cognitive complaints in their daily life.20,21 Therefore, both neuropsychological tests and 
self-report questionnaires on EF are often used to get a full picture of a person’s EF. When 
patients are unable to complete assessments, due to for example language problems or 
paralysis, information from informal caregivers can be of added value. When using proxy-
report as an addition to, or as a substitute for self-report, it is crucial to know how these 
measures are related.
A few studies in brain tumor patients evaluated patient-proxy agreement with respect 
to patients’ quality of life. Overall, moderate to high levels of concordance were observed, 
if patients did not suffer from cognitive dysfunction.22-25 Also, high congruence was found 
in the study of Armstrong et al. on a brain tumor symptom checklist (MDASI) that was 
administered in 115 brain tumor patients and their caregivers.26 Additionally, a study in 
60 brain tumor patients showed high level of agreement between patients and proxies 
on the Dexamethasone Symptom Questionnaire-Chronic.27 By contrast, the study of 
Rooney and colleagues demonstrated substantial disagreement between glioma patients 
and their proxies in the evaluation of depressive symptoms, with proxies reporting more 
3
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depressive symptoms than patients themselves.28 These authors suggested that patients 
and proxies generally seem to agree on objective signs and overt behavior of patients, but 
that agreement is limited on subjective, internal symptoms, such as mood and emotional 
functioning.28
It is important to know how brain tumor patients perceive their EF, and how this relates 
to the experience of their informal caregivers and to performance-based measures of EF. 
In the current study, the main objective was to evaluate the level of agreement between 
patient-report and proxy-report of patients’ EF. Second, associations of reported measures 
of EF with performance-based measures of EF (i.e., neuropsychological tests) were 
examined, as well as the influence of these performance-based measures on the level of 
patient-proxy agreement. Since from previous studies it is known that brain tumor patients 
suffer from executive deficits, we hypothesized that this may also influence their self-
assessment, potentially resulting in disagreement among patients and proxies. We also 
expected that lower patients’ scores on performance-based measures would be associated 
with greater patient-proxy discrepancies.
METHOD
Design & procedure
Data of this study were gathered at pre-intervention assessments in a feasibility study29 
and a randomized controlled trial30 on cognitive rehabilitation in brain tumor patients, 
initiated at the Elisabeth-TweeSteden Hospital Tilburg, The Netherlands. This research 
was conducted in accordance with the Declaration of Helsinki.31 The cognitive rehabilitation 
study (i.e., feasibility study and RCT) was approved by the local ethical review board (METC 
Brabant: NL 51152.028.14) and registered with clinicaltrials.gov (NTC03373487) and the 
Dutch Trial Register (NTR5392).
Before and three months after surgery, patients underwent neuropsychological 
assessment (NPA) as part of usual clinical care in the hospital. Directly after the 3-month 
NPA, patients who participated in the randomized controlled trial were randomized to an 
intervention or control condition. During an appointment with the researcher three months 
after surgery, participants and proxies completed the adult version of the Behavior Rating 
Inventory of Executive Function (BRIEF-A).32
Participants
Adult patients who were scheduled for resective surgery for a meningioma or low-grade 
glioma, were invited to participate in one of the cognitive rehabilitation studies. Patients 
undergoing only biopsy were not eligible. Exclusion criteria were tumor resection in the last 
year; chemotherapy or radiotherapy in the last two years; presence/history of progressive 
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neurological disease; severe psychiatric disorder or substance abuse; diagnosis of acute 
neurological or mild psychiatric disorders in the last two years (e.g., CVA); multiple (>1) 
tumors; lack of basis proficiency in Dutch; Karnofsky Performance Score below 70; IQ below 
85 or (very) low cognitive skills; and insufficient reading skills, visual impairment, or motor 
impairment. Patients were also excluded if they had severe surgery-related complications 
or if they were referred to formal cognitive rehabilitation.
Study participants were invited to involve an informal caregiver (e.g., spouse, family 
member or close friend) to the study. No exclusion criteria were applied to the proxies. If 
patients agreed, informed consent was obtained from the proxies. Only participants who 
involved an informal caregiver were included in the present analyses.
Measures
The BRIEF-A assesses problems in an adult’s EF as experienced in his or her daily life.32 A 
self-report and informant-report version are available and both questionnaires consist of 
75 items. Patients and proxies were asked to assess the extent to which certain behavior 
of the patient occurred during the past month. The informant version of the BRIEF-A 
uses a proxy-proxy perspective: proxies need to report on how they think the patient 
is functioning. Answers are given on a three-point scale (i.e., never = 1, sometimes = 2, 
often = 3). Two index scores, Behavioral Regulation and Metacognition, can be calculated 
based on 30 and 40 items respectively. Behavioral Regulation contains four subscales (i.e. 
Inhibit, Shift, Emotional Control and Self-monitor), and Metacognition has five subscales 
(i.e. Initiate, Working Memory, Plan/Organize, Task-monitor, and Organization of Materials). 
Three validity scales (i.e., Negativity, Infrequency and Inconsistency) were checked, and in 
case of invalid responses, patients were excluded from analyses. Cases were also excluded 
if there were ≥ 5 missing answers. Missing values were handled in accordance with the 
manual33 and scores of “1” were imputed in case of missing values. Raw scores on the indices 
were converted into T scores, using representative norms of the Dutch/Flemish population 
(self-report: n = 1600, informant-report: n = 1082).33 These standardized T scores were 
converted into Z scores and also reversed, to coincide with performance-based scores, so 
that lower Z scores indicate lower subjective EF. Z scores ≤ -1.5 were considered as low.33 
Psychometric properties of the Dutch version of the self-report and informant-report are 
good, with Cronbach’s alphas above 0.90 and intra-class correlation coefficients between 
0.73 and 0.81, for the two indices.33
Three neuropsychological tests from the 3-month assessment were included to measure 
different aspects of performance-based EF. Response inhibition and cognitive flexibility 
were measured, respectively, with the Stroop Test and the Shifting Attention Test (SAT) 
of the computerized test battery Central Nervous System Vital Signs (CNS VS, LCC, 
Morrisville, North Carolina). Regarding validity and reliability, Gualtieri and Johnson (2006) 
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concluded that psychometric characteristics of the CNS VS’ tests were comparable with the 
conventional tests on which they were based.34 Additionally, previous studies demonstrated 
sufficient sensitivity of the CNS VS in the detection of (mild) cognitive deficits and change in 
cognitive function in patients with brain tumors.35-37 Furthermore, the Digit Span Backward 
of the Wechsler Adult Intelligence Scale (WAIS-III)38 was used to assess working memory. 
Patients’ scores on the neuropsychological tests were compared to representative, recently 
collected Dutch norms.39-41 Patient test scores were corrected for sex, age, educational 
level and practice effects, and converted into Z scores, with lower scores indicating worse 
EF performance. Again, Z scores ≤ -1.5 were considered as low.
Data analysis
Descriptive statistics of the sample were calculated and compared with patients who were 
not included in the current study (i.e. patients who did not include a proxy in the cognitive 
rehabilitation study) using independent-samples t-tests and Chi-square tests.
Mean scores of patients and proxies were compared with normative values (M=0, SD=1) 
using two-tailed one-sample z-tests. The standardized mean differences between patients 
and the normative values, and those between proxies and normative values, are interpreted 
as Glass’ delta effect sizes, with 0.20-0.49 indicating small effects, 0.50-0.79 medium 
effects, and ≥0.80 reflecting large effects.42 Subsequently, means of the patients were 
compared with means of the proxies using two-tailed paired-sample t-tests, to investigate 
potential systematic differences, and effect sizes (Cohen’s d43) were calculated.
To examine the level of concordance between patient- and proxy-reports, Lin’s 
concordance correlation coefficients (CCCs)44,45 were calculated for the two indices of the 
BRIEF-A. CCCs were interpreted as follows: 0.21–0.40 fair, 0.41–0.60 moderate, 0.61–
0.80 substantial, 0.81–1.00 almost perfect to perfect agreement.46 As described in the 
manual of the BRIEF-A33, in order to be able to consider patient-report and proxy-report 
as interchangeable, ICC’s of at least 0.60 are required. Bland-Altman plots were generated, 
plotting the difference between measurements (i.e. patient score - proxy score) against 
the mean of the two measurements (i.e., (mean patient score + mean proxy score)/2).47 
By visualizing these differences, patterns of agreement, types of bias and outliers can be 
further identified. We computed 95% confidence envelopes around the mean difference 
(i.e., mean ± 1.96 × SD of difference scores), which shows the range of difference scores that 
covers 95% of the observations. Patient and proxy scores can be used interchangeably if 
the range is small given the application envisaged. Furthermore, patient and proxy scores 
on the two indices were dichotomized denoting low (Z score ≤-1.5) or normal (Z score >-1.5) 
EF. Percentages of cases below the cut-off were calculated and percentages of dyadic 
agreement about the presence or absence of reported EF impairment were determined.
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Furthermore, performance-based measures of EF were examined, with standardized 
mean scores of the patients being compared to normative values (M = 0, SD = 1) with 
z-tests. The relationship between performance-based measures of EF and reported EF 
was explored by calculating Pearson’s product moment correlation coefficients between 
standardized performance scores and index scores of both patients and proxies. Correlation 
coefficients between 0.10 and 0.29 were considered as small, 0.30-0.49 were considered 
as medium, and 0.50-1.0 reflected large correlation coefficients.43
Finally, the association between objective EF and the level of agreement was examined 
using multiple regression analysis. The observed difference scores (patient self-report - 
proxy-report score) on the two BRIEF-A indices served as the dependent variables. All 
independent variables (standardized scores on the Stroop Test, Shifting Attention Test 
and Digit Span Backward of the 3-month NPA) were entered at the same time for each of 
the two analyses. Assumptions were evaluated using Durbin-Watson tests48, scatterplots 
and histograms of residuals, variance inflation indices (not exceeding 0.80 and 10)49 and 
Cook’s distances (≤ 1)50.
Statistical analyses were conducted using SPSS Statistics (version 24.0). All statistical 
tests were performed at an alpha level of .05.
RESULTS
Participants’ characteristics
Three months after surgery, 47 out of 75 participants (63%) of the cognitive rehabilitation 
studies chose to involve a proxy. Regarding age, years of education, sex, tumor histology 
and patient-reported EF, no significant differences were observed between patients who 
did included a proxy and those who did not (p-values > .05). Included patients (n = 47) had a 
mean age of 51 years and 26 patients (55%) were female. Twenty-eight patients (60%) were 
diagnosed with a meningioma and 19 (40%) with a low-grade glioma. In 26 patients (55%), 
the tumor was located in the frontal lobe. In the large majority (94%), the relationship of the 
proxy to the patient was partner. Three patients involved their mother, sister or brother.
All BRIEF-A questionnaires met the validity criteria. There were no questionnaires with 
≥ 5 missing values. In this study, Cronbach’s alphas of the indices ranged between .90 and 
.96 in patients and proxies, indicating good internal consistency.51
Patient-report and proxy-report of patients’ EF
Patients scored on average significantly lower on the Metacognition index in comparison 
with normative values (M = -0.47, SD = 1.04, z = -3.25, p = .001). Glass’ delta effect size of 
0.47 suggested a small effect. On the Behavioral Regulation Index, the average patient 
score did not significantly differ from normative values (M = 0.02, SD = 1.01, z = 0.13, 
3
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p = .896). There were no significant differences between proxy evaluations of patients’ EF 
and normative values for both indices (Table 1).
When comparing mean patient scores with mean proxy scores using paired-sample 
t-tests (Table 1), a significant mean difference was observed on the Metacognition Index. 
Patients reported significantly lower EF (i.e. more concerns) than their proxies (t(46) = -2.40, 
p = .021, Cohen’s d = -0.35), with Cohen’s d indicating a small effect. On the Behavioral 
Regulation index, no significant mean difference was observed between patients and 
proxies (t(46) = -0.83, p = .703, Cohen’s d = -0.06).
On the Metacognition and Behavioral Regulation index, 23% and 9% of the patients 
scored below the cut-off (Z score ≤-1.5), respectively. According to the report of the proxies, 
13% and 6% of the patients would score below the cut-off of the Metacognition index and 
Behavioral Regulation index respectively.
Level of agreement between patients and proxies
Lin’s CCCs, listed in Table 2, indicated moderate to substantial agreement among patients 
and proxies (CCCs of 0.57 for Metacognition and 0.61 for Behavioral Regulation). Figure 
1 shows the Bland-Altman plots. The lower and upper limits were -2.11 and 1.47 for 
Metacognition and -1.76 and 1.67 for Behavioral Regulation. The Bland-Altman plots 
showed that 93.6% of the data points (i.e. 44/47) lied within these limits of agreement. 
Inspection of the plots revealed no particular trends in agreement with respect to the 
level of reported EF. When the cutoff for reported EF impairment (i.e. Z score ≤-1.5) was 
applied, congruence was observed in 94% (44/47) dyads on Behavioral Regulation and 
in 77% (36/47) dyads on Metacognition (Table 3). Based on the dichotomized data of the 
Metacognition index, 8 proxies of the 11 non-agreeing dyads did not rate the patient’s EF 
as impaired, whereas the patient did (Table 3).
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Table 3. Dyadic agreement on the presence or absence of reported EF impairment
Behavioral Regulation
Patient Score
Non-impaired Lower reported EF Total
Proxy Score
Non-impaired 42 2 44
Lower reported EF 1 2 3
Total 43 4 47
Metacognition
Patient Score
Non-impaired Lower reported EF Total
Proxy Score
Non-impaired 33 8 41
Lower reported EF 3 3 6
Total 36 11 47
Note: Z scores ≤ -1.5 were considered as low.33
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Figure 1: Bland-Altman plot for agreement on the a) Behavioral Regulation index, and b) 
Metacognition index
Note: Dashed lines represent the upper and lower limit of the 95% confidence intervals
3
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Performance-based versus reported EF
Compared to normative values of the general population, patients scored significantly lower 
on the Stroop Test (M = -0.91, SD = 1.71, z = -6.25, p < .001), the Shifting Attention Test 
(M = -1.09, SD = 1.34, z = -7.26, p < .001) and Digit Span Backward (M = -0.84, SD = 0.96, 
z = -75, p <.001) three months after surgery (Table 3).
Using a cut-off of Z ≤ -1.5, 15 patients (32%) had low scores on the Stroop Test, 14 (30%) 
on the Shifting Attention Test and 12 (26%) patients scored low on Digit Span Backward. 
In total, 31 patients (66%) had Z scores ≤ -1.5 on one or more tests.
Correlation coefficients of neuropsychological tests scores with patient-report and 
proxy-report are listed in Table 4. Overall, non-significant very small correlations were 
observed, with r’s ranging from -0.29 to 0.10, except for Digit Span Backward, were 
significant negative correlations were observed with patient-report of EF (r’s of -0.33 and 
-0.37 for Behavioral Regulation and Metacognition respectively).
Association between EF test performance and patient-proxy differences
Multiple regression analyses indicated that scores on performance-based measures of EF 
(Stroop Test, Shifting Attention Test and Digit Span Backward) had no significant influence 
on the patient-proxy difference scores of Behavioral Regulation (F (3,47) = 0.109, p = .954, 
R2 = .008) and Metacognition (F (3,47) = 0.924, p = .412, R2 = .065).
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The present study was performed to evaluate patient-proxy agreement with respect to 
report of executive functioning (EF) in patients with meningioma and low-grade glioma. 
In addition, the relationship between reported EF with performance-based measures of 
EF was investigated, as was the effect of EF test performance on the level of agreement. 
Since patients are increasingly involved in health-care decisions, it is important to gain more 
insight in their metacognitive abilities, and, how their experiences relate to experiences of 
their informal caregivers and to performance-based measures of EF.
Firstly, compared to normative data, lowered patient scores were observed on reported 
EF (Metacognition index) and on EF test performance (Stroop Test, Shifting Attention 
Test and Digit Span Backward). These findings contribute to the large body of evidence 
showing that patients with primary brain tumors experience complaints and deficits in 
EF after neurosurgery. Moreover, it stresses the importance of careful assessment of EF. 
Since problems in EF can have major impact on everyday life of patients and health care 
decisions, attention should be paid to EF of patients throughout their disease trajectory, in 
both clinical care and research settings.
In this study, patients reported significantly more problems than their proxies on the 
Metacognition index. A similar mismatch between patients and partners has been reported 
in patients with dementia. It has been suggested that in the early stages of the disease, 
patients experience subtle cognitive complaints, that are not always noticed by their 
partners (e.g., 52,53). However, when the disease progresses, diminished disease awareness 
often arises5, leading to the reversed pattern: partners often report more problems than 
patients.52 Our sample consists of brain tumor patients who have slow-growing tumors and 
a relatively favorable prognosis. It is possible that self-reported EF problems may decrease 
as the disease progresses and that studies in patients with high-grade glioma or metastases 
with less favorable prognosis would render different results. However, more research is 
needed to further explore this hypothesis. Furthermore, no systematic differences between 
patients and proxies were observed in group means of the Behavioral Regulation index. 
Possibly, this is due to the fact that this index generally contains more items that are aimed 
at the report of concrete, overt behavior (e.g., “I drum my fingers or wiggle my legs”; “I 
start things on the last moment”), which makes it easier for proxies to assess patients’ 
functioning.28
Regarding the degree of concordance as measured with Lin’s CCCs, findings indicate 
moderate to substantial agreement among dyads on patients’ EF, with CCCs of .61 and 
.57 for the Behavioral Regulation index and Metacognition index. Based on these CCCs, 
we can conclude that proxy-reports are a reasonable estimate of patient-reported EF. 
The additional information from the Bland-Altman plots and cross tables, suggests less 
agreement between patients and proxies on the Metacognition index compared to 
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the Behavioral Regulation index. This can also be explained by the more concrete and 
observable symptoms assessed by the Behavioral Regulation index, as described above.
Although patients showed lower EF test scores, no clear associations were observed 
between patients’ self-reports and proxy reports with performance-based measures of EF. 
Overall, (very) small correlations were observed in this study, which is in line with previous 
research in brain tumor patients and other neurologic populations.54-57 Based solely on 
the absence of associations of patients’ self-report and performance-based results, one 
might conclude that patients are not able to estimate the objective level of their EF, possibly 
due to a lack of insight or reduced cognitive capabilities. However, the current findings 
render this explanation more unlikely, since we found that there was concordance between 
patient and proxies, and proxy-report was also not significantly correlated with patients’ 
test performance. Thus, there is a mismatch between reported EF and test performance, 
but we do not know which of the measures is the most accurate.
There are many difficulties involved in measuring EF, and an objective gold standard is 
missing. Based on the finding that reported EF was not correlated with EF test performance 
in both clinical and non-clinical samples, Toplak and colleagues concluded in their review that 
rating measures of EF and performance-based measures of EF appear to capture different 
underlying mental constructs and therefore, they cannot be interpreted as equivalent nor be 
used interchangeably.58 Tests often focus on a particular domain of EF and are administered 
in a quiet and controlled environment on a certain moment in time, while EF in everyday life 
requires complex, integrated and dynamic skills. Ecological validity of performance-based 
measures of EF is limited, and thus will not fully capture experienced problems in patients’ 
day-to-day functioning. On the other hand, several studies demonstrated that self-reported 
EF is associated with psychological variables, such as personality and mood56,59,60 and that 
self-report response biases can affect validity and reliability.61
In addition to neuropsychological tests, Noll and colleagues made use of measures of 
functional independence (i.e. the Functional Independence Measure and the Karnofsky 
Performance Status) and found significant correlations between functional independence 
and performance-based measures of EF (r’s between .28 and .42).62 A potential promising 
alternative is using an Experience Sampling Method (ESM) to measure self-reported EF, 
at multiple times throughout the day, actually integrated in the daily lives of patients.63,64 
By gathering real-time data, some biases that occur through reporting in retrospect on 
conventional self-report questionnaires can be avoided. Furthermore, virtual environments 
(VE) are increasingly being used to enhance neuropsychological testing, so that they better 
reflect situations patients face in the outside world.65,66 These relatively new assessment 
techniques, with potentially improved validity and reliability, could also be explored in future 
studies in patients with primary brain tumors.
3
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In this study, no effect of executive test performance on dyadic agreement was found, 
which is in contrast with our expectations based on previous research on health-related 
quality of life in brain tumor patients22,24,25 and studies in other populations67,68. It should be 
noted that the instruments used to assess cognitive performance differed across studies 
(e.g. the Mini Mental State Examination or extensive neuropsychological test batteries), as 
well as the statistical procedures used to examine the possible effect of test performance 
on dyadic agreement. Moreover, it is possible that deficits in EF are more likely to relate 
to patient-proxy agreement when patients report less problems than proxies (potentially 
resulting from impaired insight), instead of more problems, as was observed in our sample 
of meningioma and low-grade glioma patients.
Besides EF test performance, other factors may also have modulated the level of 
agreement between patients and proxies, including patient- or disease-related factors, 
proxy-related factors or factors related to the assessment of EF. The small sample size of 
this study limited our possibilities to explore the potential influence of, for example tumor 
location or tumor histology, with valid statistical testing. Also, we had little information 
available on the informal caregivers or the quality of the relationship with the patient, 
restricting the possibility to take this into account. Moreover, informal caregivers were 
involved in the cognitive rehabilitation study, only if patients (and proxies) were willing to. 
Possibly, this may have led to a selection bias (i.e. sampling bias), namely the inclusion of 
dyads who are highly motivated and might agree on the patient’s functioning more than 
dyads not included in this study. In addition, all patients in this study were participants in a 
cognitive rehabilitation trial, with strict in- and exclusion criteria, which may also hamper 
generalizability of the findings to the low-grade glioma and meningioma patient population 
as a whole.
In conclusion, patients with primary brain tumors experience executive deficits after 
neurosurgery. Congruence between brain tumor patients and their proxies was observed 
in the evaluation of patients’ EF, but correlations with performance-based measures of EF 
were low. Since problems in EF are commonly observed in brain tumor patients, and can 
lead to lowered quality of life, it is important to assess EF carefully throughout the disease 
trajectory, using both questionnaires and performance-based measures of EF. At the same 
time, research on the use of innovative methods to assess EF in patients with primary brain 
tumors should be expanded.
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CHAPTER 4
Prevalence and correlates of fatigue 
in patients with meningioma before 
and after surgery




Background: Fatigue is a common symptom in patients with brain tumors, but 
comprehensive studies on fatigue in patients with meningioma specifically are lacking. This 
study examined the prevalence and correlates fatigue in meningioma patients.
Methods: Patients with grade I meningioma completed the Multidimensional Fatigue 
Inventory (MFI-20) before and one year after neurosurgery. The MFI consists of five 
subscales: General Fatigue, Physical Fatigue, Mental Fatigue, Reduced Motivation and 
Reduced Activity. Patients’ scores were compared to normative data. Preoperative fatigue 
was compared to postoperative fatigue. Correlations with sex, age, education, tumor 
hemisphere, preoperative tumor volume, antiepileptic drugs (AEDs), symptoms of anxiety/
depression and self-reported cognitive complaints were explored.
Results: Questionnaires were completed by 65 patients preoperatively, and 53 patients 
postoperatively. Of 34 patients, data from both time-points were available. Patients had 
significantly higher fatigue levels on all subscales compared to normative values at both 
time points. Mean scores on General Fatigue, Physical Fatigue and Mental Fatigue remained 
stable over time and improvements were observed on Reduced Motivation and Reduced 
Activity. Preoperatively, the prevalence of high fatigue (Z-score ≥ 1.3) varied between 34% 
for Reduced Motivation and 43% for General Fatigue/Mental Fatigue. The postoperative 
prevalence ranged from 19% for Reduced Activity to 49% on Mental Fatigue. Fatigue was 
associated with cognitive complaints, anxiety and depression, but not with education, tumor 
lateralization, tumor volume or AEDs.
Conclusion: Fatigue is a common and persistent symptom in patients with meningioma 
undergoing neurosurgery. Findings emphasize the need for more research and appropriate 
care targeting fatigue for meningioma patients.
Binnenwerk Sophie - Final na proefdruk.indd   70 11-11-19   15:43
71
Fatigue in meningioma patients
INTRODUCTION
Meningiomas are for the most part slow-growing tumors that compress the surrounding, 
healthy brain and eventually may cause symptoms. They account for approximately one-
third of all diagnosed primary central nervous system tumors.1 Most meningiomas will 
remain asymptomatic and undetected during a person’s lifetime, but a subset receives 
medical attention because of related symptoms (e.g. seizures or neurological deficits) 
or because they are coincidentally detected on a brain scan.2 Observation (wait-and-
scan), neurosurgical resection and (stereotactic) radiation therapy are the most common 
treatment options. The majority of meningiomas are benign (i.e. >90% WHO-grade I) and 
have a favorable long-term prognosis.1,3 A distinct worse prognosis is generally observed in 
patients with atypical (WHO-grade II) or anaplastic (WHO-grade III) meningiomas. These 
tumors grow faster, are more likely to recur and may invade the brain.3 It is a common clinical 
presumption that patients with grade I meningioma have the most favorable recovery in 
terms of quality of life and return to normal socioprofessional life. However, accumulating 
evidence indicates that a significant number of these patients experience cognitive deficits 
and lower quality of life, even long after treatment has ended.4,5
Fatigue is a very common symptom in patients with primary brain tumors, with 
prevalence estimates varying between 39% and 96%.6-8 Fatigue is described as a subjective 
feeling of tiredness and a lack of energy.9 It is a multidimensional construct, wherein a 
distinction can be made between physical and mental fatigue.10-11 In healthy individuals, 
fatigue is a normal and adaptive response to physical or mental activities, which can be 
alleviated by periods of sleep or rest. However, in neurological and oncological patients, 
fatigue can be a persisting and/or relapsing symptom, which is not in proportion to recent 
activities and not adequately alleviated by rest.10-11 Importantly, fatigue can substantially 
interfere with patients’ personal and professional activities, and it can significantly lower 
patients’ quality of life.6,12
Most of the research on fatigue in brain tumor patients has been conducted in 
patients with glioma, often malignant tumors that grow from glial or precursor cells in the 
brain.1 These studies indicate that symptoms of fatigue are quite common already prior 
to treatment, and that they can persist several years thereafter.7,8,13,14 Fatigue in glioma 
patients has been associated with various factors, including higher age, female sex, left-
hemispheric location, radiotherapy, chemotherapy, the use of anti-epileptic drugs (AEDs) 
and opioids, psychological distress, sleep disturbances and cognitive complaints.7,15,16
Little research has been conducted on fatigue in patients with meningioma. Several 
studies on quality of life in patients with meningioma made use of instruments including a 
few items on fatigue (e.g.,17,18). In addition, a handful of studies evaluated the (side-) effects 
of (stereotactic) radiotherapy in which fatigue was one of the outcome measures.19-22 These 
studies suggest that fatigue is present in patients with meningioma, but firm conclusions 
4
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cannot be drawn, because mostly heterogeneous samples or small samples of meningioma 
patients were included. Moreover, fatigue has never been included as a primary outcome 
and consequently, results regarding fatigue have not always fully been described, have 
not been described separately for patients with meningioma or not described at all. Also, a 
comparison with a control group has often been lacking, which may have distorted findings 
in patient samples, since fatigue is also a common complaint in the general population. 
Additionally, all previous studies assessed fatigue with single-item measures (yes/no), or 
with very brief unidimensional questionnaires or subscales whereas it is a multidimensional 
construct. As a consequence, there is insufficient understanding of the severity and type 
of fatigue in patients with meningioma.
This study evaluates fatigue, using a validated multidimensional questionnaire, in a 
select sample of patients with WHO-grade I meningioma, before surgery and one year after 
surgery. Patients’ mean levels of fatigue were compared with normative data from a large 
sample of the general population. Furthermore, proportions of patients with (very) high 
fatigue scores were examined. Additionally, relationships of fatigue with sociodemographic, 
clinical and psychological variables were explored.
METHODS
Participants
Patients with histologically proven intracranial meningioma (WHO grade I), who underwent 
surgery between June 2014 and July 2017 at the Elisabeth-TweeSteden Hospital Tilburg, 
were included in this study. Patients were excluded if they had: multiple meningiomas; a 
history of intracranial neurosurgery or whole-brain radiation therapy; a history of severe 
psychiatric or neurological disease; a Karnofsky Performance Score (KPS) below 70; a lack 
of basic proficiency in Dutch; or severe motor, language or visual problems, limiting the 
ability to complete the assessments. Patients with severe surgery-related complications 
(e.g., stroke or meningitis) were excluded from the 12-month postoperative analyses.
Procedure
Data of this study were prospectively collected as part of a larger follow-up study in patients 
with intracranial tumors who undergo resective surgery at the Elisabeth-TweeSteden 
Hospital, Tilburg, the Netherlands. The study was approved by the Medical Ethics 
Committee Brabant (project number NL41351.008.12). Informed consent was obtained 
from all individual patients included in this study.
Neuropsychological assessments are administered one day before surgery (T0) and 
three months after surgery (T3; not used in the present analyses). These assessments 
have been embedded in standard clinical care for patients with intracranial tumors and 
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information from these assessments is also used in the multidisciplinary consultation 
that takes place every month. Three months after surgery, patients are invited by nurse 
practitioners to participate in a follow-up assessment (T12) for research purposes. 
Neuropsychological assessments consist of a standardized interview, questionnaires on 
anxiety, depression and cognitive complaints, and standardized neuropsychological tests 
(not included in the present analyses). Questionnaires on work, community integration and 
fatigue are administered at T0 and T12, but not at T3. All assessments were conducted in 
the hospital by well-trained test technicians.
This study focused on self-reported fatigue, which was examined one day before surgery 
(T0) and one year after surgery (T12). Because the pre- and postoperative questionnaires on 
fatigue were added to the existing test protocol simultaneously in June 2015, patients who 
participated in the one-year post surgery measurement between June 2015 and June 2016 
(and had their preoperative assessment between June 2014 and June 2015), completed the 
MFI at T12, but did not fill out the preoperative questionnaire on fatigue.
Study measures
Fatigue. Symptoms of fatigue were assessed using the Multidimensional Fatigue Inventory 
(MFI). Participants were asked to report their fatigue experiences over ‘the last few 
days’. This 20-item questionnaire takes about five minutes to administer and covers the 
following five dimensions of fatigue: General Fatigue, Physical Fatigue, Mental Fatigue, 
Reduced Motivation and Reduced Activity. These scales are based on ways in which fatigue 
can be expressed, as indicated in the literature and as resulted from patient interviews.23 
Reliabilities of the five different scales are sufficient, with Cronbach’s a ranging from .72 
to .87.23 Questionnaires were not included if there were > 4 missing answers. In case of 
1-4 missing items in less than 5% of the cases (Missing At Random or Missing Completely 
At Random), use was made of data imputation (using the mean of patient’s filled out items 
on that particular scale). Representative normative data from the general population of 
Germany (n = 2037) were available for comparison.24 We used these norms to convert 
patients’ raw scores into sex- and age-corrected Z-scores per subscale for both time-points. 
Higher Z-scores indicate greater fatigue severity. ‘High’ and ‘very high’ fatigue scores were 
determined by using widely-used cut-offs of, respectively, 1.3 (90th percentile) and 2.0 (97.5th 
percentile).25,26
Anxiety and depressive symptoms. The Hospital Anxiety and Depression Scale (HADS)27, 
originally developed for somatic outpatients, was used to assess symptoms of anxiety 
and depression. This widely-used screening instrument consists of 14 items, referring 
to symptoms within the last week, from which an anxiety scale score (HADS-A) and a 
depression scale score (HADS-D) can be derived. Higher scores indicate more psychological 
4
Binnenwerk Sophie - Final na proefdruk.indd   73 11-11-19   15:43
74
Chapter 4
distress. Reliability of the Dutch version of the HADS is satisfactory to good, with test-retest 
reliability coefficients between .86 and .90 and Cronbach’s alphas ranging from .71 to .90.28
Cognitive complaints. The Cognitive Failures Questionnaire (CFQ)29 was used to measure 
subjective cognitive functioning. Frequency of everyday cognitive failures in motor function, 
perception and memory was assessed with 25 items, with response options from 0 (never) 
to 4 (very often). Psychometric properties of the Dutch version of the CFQ were sufficient, 
with test-retest reliability of .83 and Cronbach’s alphas of .75 and .81.30
Sociodemographic and clinical variables. Number of years of education and completed 
level of education were self-reported by the patients during a standardized interview. 
Education was classified using the Dutch coding system of Verhage31, which ranges from 
1 (only primary school) to 7 (university degree). Its seven categories were subdivided into 
three levels, namely low (Verhage 1 to 4), middle (Verhage 5) and high educational level 
(Verhage 6 and 7). Relevant clinical information was extracted from electronic medical 
charts. The location of the tumor was classified by the neurosurgeon. Tumor volume was 
semi-automatically segmented by trained researchers using the software application ITK-
SNAP.32
Statistical analysis
Data are presented as means ± standard deviations (SD) or frequencies and percentages. 
Preoperative and postoperative fatigue scores of the patient sample were compared to the 
normative sample using two-tailed one-sample z-tests. Two-tailed one-sample z-tests are 
conducted, since the means and SDs of the general population (i.e., normative sample) are 
known (M = 0, SD = 1). The standardized mean differences between patients and controls 
can be interpreted as effect sizes, with 0.20-.49 indicating small effects, 0.50-.79 medium 
effects, and ≥0.80 reflecting large effects.33 Changes from preoperative to postoperative 
mean scores were examined using two-tailed paired-sample t-tests. Effect sizes were 





again with 0.20-0.49 small, 0.50-0.79 medium, and ≥0.80 large effects.34 Automatically, 
correlation coefficients between preoperative and postoperative levels of fatigue were 
calculated. Correlation coefficients of .10 to .29 were considered as small, .30 to .49 were 
considered as medium, and .50 to 1.0 reflected large correlation coefficients.34
The prevalence of high and very high fatigue levels was determined by counting 
individual patients who scored above the cut-offs of Z ≥ 1.3 (90th percentile) and Z ≥ 2.0 
(97.5th percentile) respectively25,26, for each of the MFI subscales at each time-point.
To investigate clinical and demographic factors associated with dimensions of fatigue, 
correlation coefficients were calculated between the subscales of the MFI and sex, age, level 
of education, tumor hemisphere, preoperative tumor volume, use of AEDs, self-reported 
symptoms of anxiety/depression and self-reported cognitive complaints. Selected variables 
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were mainly based on previous studies in neuro-oncological patients7,15. Sex- and age-
corrected fatigue scores were used24, but these variables were included in the correlation 
analysis as well, to check if there was no additional effect of sex and age in this patient 
sample. Pearson’s product-moment correlations (r) were calculated for the continuous 
variables, Spearman’s rank-order correlations (ρ) were applied to the ordinal variable 
(i.e. level of education) and point-biserial correlations (r
pb
) were used for the dichotomous 
variables. Interpretation of the correlation coefficients is described above. Statistical 
analyses were conducted using SPSS Statistics (version 24.0), with an alpha level of .05.
RESULTS
Patient characteristics
Data from preoperative assessments of 65 patients were included in this study (Table 1). 
Their mean age was 56.2 ± 12.1 years and 74% were female. The majority of tumors were 
located in the frontal lobe (63%) and mean tumor volume was 42.7 ± 26.0 cm3. At one-year 
post surgery, data from 53 patients were available of whom 34 also participated in the 
preoperative assessment. Data imputation was used in 4 cases with single missing values. 
Table 1 presents sociodemographic and clinical characteristics of the different groups.
Table 1. Sociodemographic, clinical and psychological characteristics of the different groups




Subgroup with both 
assessments
Sample size (n) 65 53 34
Age at T0 (Mean; SD) 56.2; 12.1 54.8; 11.3 54.2; 11.4
Sex (n female; %) 48; 74% 40; 76% 25; 74%
Years of education (Mean; SD) 14.4; 3.8 14.9; 3.5 14.9; 3.5
Level of education (n; %)a
Low 17; 26% 12; 23% 8; 24%
Middle 24; 37% 10; 38% 15; 44%
High 24; 37% 21; 40% 11; 32%
Tumor hemisphere (n; %)
Right 29; 45% 25; 47% 14; 41%
Left 26; 40% 20; 38% 15; 44%
Bilateral 10; 15% 8; 15% 5; 15%
Tumor location (n; %)
Frontal 41; 63% 28; 53% 19; 56%
Non-frontal 16; 25% 18; 34% 10; 29%
4








Subgroup with both 
assessments
Posterior fossa 8; 12% 7; 13% 5; 15%
Presenting neurological symptom 
(n; %)a
Visual deficit 16; 25% 12; 23% 9; 26%
Headache, dizziness 14; 22% 11; 21% 8; 24%
Cognitive or language deficits 12; 18% 9; 17% 4; 12%
Seizure 11; 17% 9; 17% 6; 18%
Focal weakness 6; 9% 7; 13% 3; 9%
Accidental finding 3; 5% 2; 4% 2; 6%
Other 3; 5% 3; 6% 2; 6%
Preoperative tumor volume (cm3; 
Mean; SD) b
42.7; 26.0 41.7; 27.0 42.4; 25.7
Use of antiepileptic drugs (n; %) 10; 15% 8; 15% 5; 15%
Symptoms of anxiety (Mean; SD) 7.1; 4.5 4.0; 3.2 6.5; 4.0c 3.6; 3.0d
Symptoms of depression (Mean; SD) 6.1; 4.3 3.7; 3.6 5.3; 4.0c 3.4; 3.7d
Cognitive complaints (Mean; SD) 27.7; 13.0 33.3; 16.0 25.3; 12.5c 32.4; 16.4d
a Percentages may not add up, due to rounding. 
b Data was available from 58 patients at T0 and 49 patients at T12. 
c At T0 
d At T12
Mean levels of fatigue in patients with meningioma
Results of the group-level analyses are listed in Table 2. Patients’ mean scores were 
significantly higher on each subscale of the MFI, both pre- and postoperatively, compared 
with norms from the general population (all p-values <.01). The largest effects were 
observed on the subscales of General Fatigue and Mental Fatigue, with effect sizes ranging 
from 0.89 to 1.07.
In the subset of patients who underwent both assessments (n = 34), improvements 
over time were observed for Reduced Activity and Reduced Motivation. No significant 
differences were observed between pre- and postoperative mean levels of General Fatigue, 
Physical Fatigue and Mental Fatigue (Table 3).
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Table 2. Preoperative and postoperative mean patients’ levels of fatigue compared to normative values
MFI Subscale N Meana SD z-value P-value Effect sizeb
Preoperative fatigue (T0)
General Fatigue 65 1.07 1.46 8.59 <.001* 1.07
Physical Fatigue 65 0.76 1.40 6.13 <.001* 0.76
Mental Fatigue 65 1.02 1.46 8.20 <.001* 1.02
Reduced Activity 65 0.88 1.24 7.12 <.001* 0.88
Reduced Motivation 65 0.77 1.40 6.18 <.001* 0.77
Postoperative fatigue (T12)
General Fatigue 53 0.89 1.34 6.47 <.001* 0.89
Physical Fatigue 53 0.44 1.03 3.17 .002* 0.44
Mental Fatigue 53 1.07 1.38 7.82 <.001* 1.07
Reduced Activity 53 0.38 1.11 2.74 .006* 0.38
Reduced Motivation 53 0.36 1.16 2.64 .008* 0.36
a Higher scores indicate higher levels of fatigue. Test values (based on norms of Schwarz et al., 
2003): m = 0; s = 1 
b Standardized mean differences can be interpreted as effect sizes, with .20-.49 indicating small 
effects, .50-.79 medium effects, and ≥.80 reflecting large effects.33 
* p < .05 
Table 3. Preoperative levels of fatigue compared to postoperative levels of fatigue in meningioma
T0-T12 pairs N Mean difference SD
diff
t-value P-value Effect sizea rb
General Fatigue 34 0.09 1.67 0.31 .759 0.05 .37*
Physical Fatigue 34 0.40 1.40 1.68 .102 0.29 .39*
Mental Fatigue 34 0.23 1.44 0.94 .355 0.16 .48*
Reduced Activity 34 0.63 1.43 2.57 .015* 0.44 .25





, with .20-.49 indicating small effects, .50-.79 medium effects, and ≥.80 
reflecting large effects34 
b Coefficients for correlations between pre- and post-surgery fatigue; coefficients of .10 to .29 were 
considered as small, .30 to .49 as medium, and .50 to 1.0 reflected large correlation coefficients34 
* p < .05 
Prevalence and severity of fatigue in patients with meningioma
Figure 1 illustrates the proportions of patients scoring normal, high and very high per 
subscale of the MFI. Preoperatively, the prevalence of high fatigue (Z-score ≥ 1.3) varied 
between 34% for Reduced Motivation and 43% for General Fatigue and Mental Fatigue. 
4
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Postoperative prevalence of high fatigue ranged from 19% for Reduced Activity to 49% 
on Mental Fatigue.
In total, 44/65 patients (68%) scored high (Z-score ≥ 1.3) on one or more subscales of 
the MFI before surgery. Of these 44 patients, 35 scored very high (Z-score ≥ 2.0) on one or 
more subscales. Postoperatively, 30/53 patients (57%) scored high on one or more subscales 
and 21 of these patients scored very high on one or more subscales.
Correlates of fatigue in patients with meningioma
As shown in Table 3, the preoperative fatigue scores were weakly to moderately correlated 
with fatigue scores at T12 (r’s between .25 and .48). Furthermore, correlation analyses 
showed medium to large associations between fatigue and self-reported symptoms of 
depression and cognitive complaints pre- and post-surgery, and with anxiety post-surgery 
(Table 4). We found no clear correlations between standardized scores on the subscales of 
the MFI and sex, age, education, tumor hemisphere, preoperative tumor volume and use 
of AEDs.
Figure 1. Prevalence of fatigue in patients with meningioma at T0 (n = 65) and T12 (n = 53)
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In this study we comprehensively examined pre- and postsurgical prevalence, severity 
and correlates of fatigue in patients with meningioma using a multidimensional fatigue 
instrument. Symptoms of fatigue were assessed in patients with WHO grade I meningioma 
prior to surgery (n = 65) and one year after surgery (n = 53). On all subscales of the MFI, 
patients reported more fatigue compared to norms of the general population, both before 
and one year after surgery. In total, 68% and 57% of the patients scored (very) high on one or 
more subscales of the MFI before and after surgery respectively. In general, proportions of 
patients scoring very high were larger than proportions of patients scoring high, indicating 
that the reported symptoms were rather severe than mild. Furthermore, mean levels of 
General Fatigue, Physical Fatigue and Mental Fatigue did not decrease significantly over 
the one-year follow-up period in a subgroup of patients (n = 34). These findings indicate 
that fatigue is a substantial and persistent clinical problem in meningioma patients up to 
one year after surgery.
The prevalence rates found in this study roughly correspond with those found in 
patients with glioma.7,8,14 This may seem remarkable given the differences in etiology and 
oncological prognosis between meningioma and glioma. Glioma infiltrate the brain and 
are the leading cause of death in patients due to disease progression. Meningioma, on the 
other hand, grow extra-axially and are mostly benign.1 However, previous studies have also 
demonstrated long-term impairments in cognitive functioning and quality of life in patients 
with meningioma.4,5 Although it is often assumed that meningioma patients recover well 
after surgery, this research contributes to the finding that a substantial number of patients 
are left with various problems, even long after medical treatment has ended.
Our results indicate that patients’ motivation and activity were significantly increased 
one year after surgery, but serious fatigue remained present in their daily functioning. 
Persistent symptoms of fatigue can lead to several problems, including difficulties in social 
participation, mental health issues or inability to return to (previous) work.35 Fatigue may not 
only affect patients’ lives, but also the lives of their families.35 However, results of the within-
group analyses must be interpreted with some caution, since only a part of the participants 
completed both the preoperative and postoperative questionnaires (n = 34). Furthermore, 
although stability is observed at group level on three subscales of the MFI, it is possible that 
different patterns of change occur on the individual level.36 An interesting next step would 
be to look at individual-level change in fatigue scores (compared to change scores of an 
appropriate control group) and predictors of improvement or decline using a longitudinal 
study design with more patients.
In the present sample, fatigue was associated with self-reported symptoms of depression, 
anxiety and cognitive complaints. These findings correspond with previous observations 
in patients with glioma7,8,17,37, as well as with findings in other patient populations.38-40 Due 
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to interconnectedness and overlap of symptoms, it is difficult to distinguish between, for 
example, a major depressive disorder and serious fatigue. Depression can cause fatigue and 
vice versa, and a third factor can cause both depression and fatigue. It is possible that these 
symptoms are an expression of shared neurobiological mechanisms (e.g., inflammation or 
brain abnormalities), but these mechanisms have not been extensively studied in patients 
with meningioma yet. Furthermore, sleep-wake disturbances are common in brain tumor 
patients41,42, and often co-occur with symptoms of fatigue, depression and anxiety, but for 
this study, we did not collect data on sleep quality. More extensive research is necessary to 
gain insight into causal relationships between fatigue and its multifactorial determinants 
in patients with meningioma.
In this study, the highest prevalence rates were found for Mental Fatigue. Short 
unidimensional questionnaires or subscales used in previous research often contain 
floor and ceiling effects due to the narrow range of possible scores and moreover, tend to 
measure mainly symptoms of physical fatigue.43 To prevent problems with (mental) fatigue 
being under-diagnosed and thus under-treated, we recommend the use of a short validated 
multidimensional screening tool, such as the MFI, for patients with surgically treated 
meningioma during aftercare. Ideally, for each patient with increased scores, contributing 
and perpetuating factors should be identified using a comprehensive examination. By 
addressing these specific factors, treatment can be better tailored to the individual patient.44 
Although only a few intervention studies have been done on fatigue in patients with brain 
tumors, there is some evidence that patients who experience fatigue may benefit from 
exercise interventions or psychological interventions (e.g., cognitive behavioral therapy or 
educational programs) to help patients manage symptoms of fatigue.41,45-48 Treatment with 
psychostimulants have been shown to have insufficient effect on symptoms of fatigue in 
patients with brain tumors.49,50
This study has some limitations that should be attended to in further studies. The sample 
sizes were relatively small, and only a subset of patients completed both the preoperative 
questionnaire and the one-year follow-up assessment. There are other factors that may 
have affected generalizability. For example, we included participants who underwent 
surgery and who had relatively favorable clinical characteristics (e.g., patients without a 
history of neurological/psychiatric disorders, with a KPS above 70 and without surgery-
related complications). This could have resulted in an underestimation of fatigue in patients 
with meningioma in general. It is also possible that the timing of the first assessment (i.e., one 
day before surgery) may have influenced the results, since psychological distress appeared 
to be related to self-reported fatigue.
The current study is a necessary first step in investigating fatigue in patients with 
meningioma, but clearly more work has to be done in this area. The relationship between 
fatigue, sleep quality, medication use, and objective measures of cognitive functioning 
4
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should be further clarified. At the same time, research on treatment options for fatigue in 
patients with brain tumors should be expanded.45
The findings of the current study indicate that fatigue is a serious, common and 
persistent symptom in patients with meningioma undergoing neurosurgery. Health care 
providers and researchers should be aware of this, pay attention to this debilitating 
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CHAPTER 5 
Feasibility of the evidence-based 
cognitive telerehabilitation program 
ReMind for patients with primary 
brain tumors




Many patients with primary brain tumors experience cognitive deficits. Cognitive 
rehabilitation programs focus on alleviating these deficits, but availability of such programs 
is limited. Our large randomized controlled trial (RCT) demonstrated positive effects of 
the cognitive rehabilitation program developed by our group. We converted the program 
into the iPad-based cognitive rehabilitation program ReMind, to increase its accessibility. 
The app incorporates psychoeducation, strategy training and retraining. This pilot study 
in patients with primary brain tumors evaluates the feasibility of the use of the ReMind-
app in a clinical (research) setting in terms of accrual, attrition, adherence and patient 
satisfaction. The intervention commenced 3 months after resective surgery and patients 
were advised to spend 3 h per week on the program for 10 weeks. Of 28 eligible patients, 15 
patients with presumed low-grade glioma or meningioma provided informed consent. Most 
important reason for decline was that patients (7) experienced no cognitive complaints. 
Participants completed on average 71% of the strategy training and 76% of the retraining. 
Some patients evaluated the retraining as too easy. Overall, 85% of the patients evaluated 
the intervention as “good” or “excellent”. All patients indicated that they would recommend 
the program to other patients with brain tumors. The ReMind-app is the first evidence-
based cognitive telerehabilitation program for adult patients with brain tumors and this pilot 
study suggests that postoperative cognitive rehabilitation via this app is feasible. Based on 
patients’ feedback, we have expanded the retraining with more difficult exercises. We will 
evaluate the efficacy of ReMind in an RCT.
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INTRODUCTION
Many patients with primary brain tumors suffer from cognitive deficits.1,2 These deficits 
can cause difficulties in patients’ everyday lives and affect their quality of life.3,4 Reported 
prevalence rates of cognitive deficits vary widely, which is partly due to the differences in 
used methods, but range between 19% and 90%.2,5,6 Since survival rates are increasing7,8 and 
patients are living longer with possible cognitive deficits, management of cognitive deficits 
becomes an increasingly important part of total care in patients with primary brain tumors.
Unfortunately, treatment options for these cognitive deficits are scarce. Over the last 
years, a few intervention studies have been conducted in brain tumor patients, which 
demonstrated positive effects of cognitive rehabilitation.9-11 Our randomized controlled 
trial (RCT) in 140 glioma patients with stable disease demonstrated positive effects of a 6 
weeks’ face-to-face cognitive rehabilitation program that consisted of psychoeducation, 
teaching of use of compensatory skills and retraining.9,12 Despite the positive findings of 
previous studies and patients’ needs for rehabilitation services, cognitive rehabilitation 
is not always accessible for every patient in clinical practice.13,14 Conventional in-person 
cognitive rehabilitation can be demanding and costly, due to, amongst others, multiple 
hospital visits and lengthy face-to-face sessions with professionals.
To overcome some of the limitations of conventional cognitive rehabilitation, a number 
of studies explored the possibilities of cognitive telerehabilitation programs in other 
neurological and oncological patient populations.15-18 Cognitive telerehabilitation is a form 
of eHealth, and it is defined as “the use of information and communication technologies to 
provide rehabilitation services to people remotely in their homes or other environments”.19 
To our knowledge, no studies on cognitive telerehabilitation have been conducted in adult 
patients with brain tumors.
Based on the positive findings of our previous RCT, and ongoing requests of doctors and 
patients to utilize the cognitive rehabilitation program, we converted our program into an 
iPad-based cognitive rehabilitation application, named ReMind. The goal of the development 
of the ReMind-app was to increase the accessibility of the program to brain tumor patients 
in a cost-efficient mode of delivery, while maintaining the contents of the original program. 
Before we initiated an RCT to evaluate the efficacy of ReMind, we conducted a small-scale 
study to investigate the feasibility of, and potential barriers to, the use of the program in the 
clinical (research) setting in terms of accrual, attrition, adherence and patient satisfaction. 
Since cognitive telerehabilitation has not yet been investigated in adult patients with 
primary brain tumors (i.e. vulnerable patients with higher levels of fatigue, psychological 
distress and concentration problems), this feasibility study is an important first step.
5





Patients with a radiologically suspected supratentorial low-grade glioma or meningioma, 
who were scheduled for resective surgery in the Elisabeth-TweeSteden Hospital Tilburg, 
were invited to participate. Patients who met any of the following criteria were excluded: 
history of intracranial neurosurgery, history of severe psychiatric or neurological disorder, 
diagnosis of multiple meningioma, complete unfamiliarity with the use of computers, 
lack of basic proficiency in Dutch, inability to undergo neuropsychological assessment 
due to motor/language/visual problems, Karnofsky Performance Score (KPS) below 70 
or a premorbid IQ below 85. Patients who were referred to in- or outpatient cognitive 
rehabilitation were excluded as well. The projected sample size was 15. Informed consent 
was obtained from all individual participants included in the study.
Design and procedure
This single-arm pilot study was approved by the local medical ethical review board (METC 
Brabant: NL51152.028.14), registered in The Netherlands National Trial Register (NTR 
5392).
Two weeks before surgery, patients were informed about the study by a nurse 
practitioner. Interested patients received an information letter. One day before surgery, 
patients were hospitalized and neuropsychological assessment (T0) was carried out as 
part of usual clinical care. At the beginning of the assessment, patients who were willing 
to participate in the study provided written informed consent. If patients chose to make 
use of the possibility to involve a significant other in the cognitive rehabilitation trajectory 
(see below), the significant other had to give informed consent as well. Three months 
after surgery, a second usual care neuropsychological assessment (T3) was conducted. 
Immediately afterwards, the cognitive telerehabilitation program ReMind commenced. 
Three months later (i.e. six months after surgery), after completing ReMind, the final 
neuropsychological assessment took place (T6) for the purpose of this study. Additionally, 
study-specific evaluation questionnaires were completed. The current study was embedded 
in standard clinical care provided by the hospital.
Intervention
The program. The cognitive telerehabilitation program Remind was developed in a joint 
patient/researcher initiative and is based on our previously evaluated face-to-face cognitive 
rehabilitation program.9,12,20 The ReMind-app is provided via an iPad (Figure 1(a)) and is 
available in both Dutch and English. In the current study, the Dutch version was used.
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Similar to the original program12, ReMind consists of compensation training, including 
psychoeducation and teaching of compensatory skills, and attention retraining (see 
Figure 1(b) and 1(c)). In the compensation training, psychoeducation about cognitive 
functions is provided in six modules, namely on 1) Cognitive functions, 2) Influences, 3) 
Compensation, 4) Attention, 5) Planning & control, and 6) Memory. Additionally, in each 
module, compensatory strategies are taught and many exercises are included to learn to 
apply these strategies in everyday life. Patients learn, for example, to minimize distraction 
and deal with time pressure, and to optimally use external devices for support. Due to the 
strong interdependence of all cognitive functions, the strategy training was designed so 
that patients should go through all the 6 modules one by one, to benefit the most from the 
strategy training. Progression through each module is visualized, with checkmarks at the 
bottom of the screen (Figure 1(b)).
In the retraining part, named C-Car, four different modes of attention are trained, 
namely sustained, selective, alternating and divided attention. It includes visual and 
auditory exercises, wherein both verbal and numeric stimuli are presented. All patients 
started with the same version of this training, independently of their pre-intervention 
neuropsychological scores. Series of hierarchically graded tasks were used, so that higher 
levels are reached, if previous levels are mastered. In this manner, the retraining is tailored to 
the level of the patient. After each exercise, patients receive feedback on their performance.
During the development of the app, optimum use was made of the additional (technical) 
possibilities the new environment offered. The instructional texts of the strategy training 
are provided in videos, audio clips and read-only formats and patients can look back as 
often as they feel necessary. ReMind incorporates several other functions to make it as 
user-friendly as possible, such as help-overlay screens and links to explanations of important 
definitions. The program also offers the possibility to involve a significant other, which can 
be a spouse, family member, friend or professional: the ReMinder. Patients can send this 
ReMinder an email from anywhere in the program, for example to ask for advice when they 
get stuck in a text or an exercise.
Guidance. Three months after surgery, immediately after the second neuropsychological 
assessment (T3), a face-to-face appointment was planned, to hand over the iPad on 
which the ReMind-app was installed together with an explanation of the app. During the 
intervention period, the researcher contacted the patients by telephone every two weeks, 
to check on their progress, plan the course of their training and to address questions. It was 
advised and expected that patients spent 3 hours per week on the program, to complete 
the program within 10 weeks. A second face-to-face appointment took place at the end of 
the program, to retrieve the iPad and to collect the completed questionnaires.
5
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Figure 1. Screenshots of different parts of ReMind: a homepage, b strategy training, and c 
retraining
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Measures
Accrual and attrition. Accrual was defined as the total number of included patients as 
compared to the number of invited patients. The number of patients who declined 
participation and reasons for decline were carefully recorded. The same was done for the 
number of patients who dropped out of the study and reason(s) for this attrition.
Adherence. Adherence to the program was indicated by both the number of completed 
module sections in the strategy training and the number of exercises performed in the 
retraining, each expressed in percentages of total available sections and exercises, 
respectively. If patients completed ≥ 80% of both the strategy training and the retraining, 
adherence was considered acceptable. To calculate mean percentages for the group, a 
maximum of 100% per individual was used, even if patients worked through the program 
more than once. Reasons for non-adherence as reported in the telephone calls during the 
intervention and in the face-to-face appointment at the end of the program were recorded.
Patient experience. After completing the program, patients were requested to fill out a 
study-specific questionnaire, evaluating their experiences with ReMind (e.g., satisfaction, 
enjoyment, usefulness and burden), whether they would recommend any changes in 
(elements of) the program, and if they would recommend it to other patients.
Feasibility of neuropsychological assessments. Neuropsychological tests and patient-
reported outcome measures (PROMs) were administered to describe baseline functioning 
of the patients and to test the feasibility of procedures for later use on a larger scale. 
Objective cognitive functioning was assessed by the computerized neuropsychological test 
battery CNS Vital Signs21,22 and three paper-and-pencil tests, namely Letter Fluency, Digit 
Span (WAIS), and Paired Associates (WMS).23-25 Z-scores were calculated using normative 
data and Z-scores ≤ -1.5 were considered as low. Subjective cognitive functioning was 
assessed with the Cognitive Failures Questionnaire (CFQ).26 Based on Dutch representative 
normative data27, a total score of ≥ 42 was considered as clinically high. Symptoms of anxiety 
and depression were assessed with the Hospital Anxiety and Depression Scale (HADS)28,29, 
with a cut-off for both scales of ≥ 8.
Data analysis
Percentages of eligible, included, excluded and dropped-out patients were calculated. 
Descriptive statistics of participants are presented. This feasibility study (n = 15) was not 
designed, and therefore not powered, to evaluate the efficacy of ReMind.
5





Data on accrual and attrition are presented in a flow diagram (Figure 2). Out of 65 
consecutive patients who were scheduled to undergo surgery for presumed low-grade 
glioma/meningioma, 37 patients (57%) were excluded. Of the 28 eligible patients who were 
invited to participate, 15 patients provided informed consent (54%) and 13 patients (46%) 
declined. The most important reason for decline was that patients (n = 7) did not experience 
cognitive deficits and felt no need to follow a cognitive rehabilitation program at this stage.
In the 3 months prior to the start of the intervention, one patient withdrew from the study 
because of lack of cognitive complaints. An additional patient was excluded after informed 
consent, since she was referred to cognitive rehabilitation elsewhere. No dropout occurred 
during the intervention phase. Nine participants (69%) chose to involve a significant other 
(in all cases, a spouse).
 
Figure 2. Flowchart of enrolment and attrition.
NPA neuropsychological assessment, LGG low-grade glioma, MEN meningioma, KPS Karnofsky 
performance score
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a Education is classified according to the Dutch coding system of Verhage ranging from 1 (less than 
primary education) to 7 (university degree) (Verhage, 1964) 
b Number of impaired outcomes of objective cognitive functioning (Z-score of ≤-1.5; 11 scores were 
considered) 
c PROMs included the CFQ and HADS, with cut-offs of ≥ 42 and ≥ 8 respectively, ‘No’ indicated no 
scores above the cut-offs 
d Adherence rates ≥ 80% were considered as acceptable. To calculate mean percentages, a 
maximum of 100% per individual was used 
e A: illness of spouse, B: technical problems, C: return to full-time work, D: rehousing, E: severe 
fatigue due to adjuvant treatment 
f Awake craniotomy 
g Received temozolomide after T6
Demographic, clinical and neuropsychological characteristics
Table 1 shows the demographic, clinical and neuropsychological characteristics of the 
sample. Thirteen patients (38% female), with a mean age of 52 years (range 40 – 68), 
followed the cognitive rehabilitation program and completed all assessments. Six patients 
were diagnosed with a grade I meningioma, one patient with a WHO grade II meningioma 
and four patients with a WHO grade II glioma. For two other patients, the radiologically 
suspected diagnosis of low-grade glioma was not confirmed after surgery (Table 1). After 
surgery, five patients (38%) were treated with radiotherapy and three of these patients also 
received chemotherapy at T3. The majority (69%) of the patients were highly educated. 
Before the start of the intervention, seven patients demonstrated low Z-scores (≤ -1.5) 
on one or more measures of objective cognitive functioning. Based on the scores of the 
HADS, three of the patients possibly suffered from depression, and one of them possibly 
from anxiety as well (Table 1).
Adherence
Adherence per participant is presented in Table 1. On average, participants completed 
71% of the strategy training 76% of the retraining. According to our definition of adherence 
(completion of ≥ 80% of both the strategy training and the retraining), seven out of 13 
patients (54%) adhered to the program. Six patients (46%) completed the entire strategy 
training and seven patients (54%) completed the entire retraining. Four patients (31%) 
fully completed both the strategy- and retraining. Three participants reported specific 
circumstances that explained non-adherence: one was confronted with serious illness of 
her spouse, one experienced technical problems with the retraining part of the program 
(which were solved afterwards) and one moved to a new house during the intervention. Two 
participants who had a (very) low adherence to the program reported that they were too 
busy with other activities and had other priorities. On the other hand, other patients also 
experienced interfering circumstances, but were still able to adhere to the intervention. 
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One low-grade glioma patient reported that following the program was burdensome in 
combination with adjuvant tumor treatment.
Patient experience
Results of the study-specific evaluation questionnaire are listed in Table 2. The majority 
evaluated the difficulty and the quantity of psychoeducation, fill-in exercises (to practice 
with learned strategies) and retraining tasks as sufficient. However, four participants 
reported that there were too many fill-in exercises included in the strategy training, whereas 
four other participants rated the retraining as (a bit too) easy and found there were (too) 
few retraining exercises included in the program. Furthermore, eight patients enjoyed 
working with ReMind. Using an iPad-app for cognitive rehabilitation was appreciated. 
Overall, 11 patients (85%) evaluated the cognitive rehabilitation program ReMind as “good” 
or “excellent”. All participants indicated that they would recommend the program to other 
brain tumor patients.
Feasibility of neuropsychological assessments
Three patients were excluded from the study beforehand, because they did not undergo 
the first neuropsychological assessment (T0) due to (logistical) problems with planning. All 
13 participants fully completed neuropsychological assessments, one questionnaire of a 
participant was not returned.
Table 2. Post-intervention ratings of different aspects of ReMind (n = 13)
Difficulty of (too) easy just right (too) difficult
Information in strategy training 3 10 -
Fill-in exercises in strategy training 1 10 2
Retraining (C-Car game) 4 9 -
Amount/number of (too) little/few about right (too) much/many
Information in strategy training 1 12 -
Fill-in exercises in strategy training - 9 4
Retraining exercises (C-Car game) 4 8 1
Supervision of the researcher/trainer - 13 -
Usefulness of (very) useful neutral not (very) useful
Information in strategy training 7 6 -
Fill-in exercises in strategy training 3 9 1
Retraining exercises (C-Car game) 11 2 -








Content addressed daily problems fully/largely partly not
8 4 1
Application of learnt (strategies) in daily life often/regularly sometimes seldom/never
3 5 5
Impact of cognitive problems has changed yes, positively noa yes, negatively
6 7 -










Using an iPad-app for cognitive 
rehabilitation
11 1 1
Capability of the researcher/trainer 13 - -
Contact with the researcher/trainer 12 1 -
Overall rating of the program 11 1 1
yes no
Recommendation to other brain tumor 
patients
13 0
a No change, there was no impact on daily life (5) or no change, impact remained the same (2) 
b Coping is still good (8), or coping is still not good (0)
DISCUSSION
ReMind is the first cognitive telerehabilitation program specifically developed for adult 
patients with primary brain tumors. The current pilot study was designed to test the 
feasibility of an evidence-based telerehabilitation program in the clinical (research) setting 
in preparation for a larger RCT. The results suggest that, for the subset of interested patients 
who were included in the study based on specific criteria, cognitive rehabilitation by using 
the ReMind-app was feasible. Overall, participants were satisfied with the program and 
dropout was low.
The recruitment of participants to the study was the most challenging aspect of this 
feasibility study. A substantial part (57%) of the patients who were undergoing surgery 
for low-grade glioma or meningioma were not eligible based on the exclusion criteria. In 
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hindsight, the exclusion criteria appeared to be overly strict, which, in an attempt to reduce 
bias through controlling patients’ characteristics and potential confounders, potentially 
compromised the generalizability of the results to the target patient population of patients 
with presumed low-grade glioma and meningioma.30,31 In particular, a large proportion of 
patients with a history of neurological/psychiatric disorders or previous intracranial surgery 
were excluded, although cognitive rehabilitation may be relevant for them as well. Based 
on these experiences, we adapted the inclusion criteria of the RCT. Furthermore, 46% of 
eligible patients declined participation, half of them reporting to feel no need to undergo 
cognitive rehabilitation at this stage (n = 7). Two patients specifically declined participation 
since an iPad-based intervention was not appealing to them.
With respect to adherence, 54% of the participants met the criterion for sufficient 
(completion of ≥ 80% of both the strategy training and the retraining) adherence, which 
was comparable with other studies that investigated psychological eHealth interventions 
in other patient populations32, but not as high as the adherence to the face-to-face program 
in our previous RCT.9,12 Whereas our previous study included a sample of patients with 
clinically stable lower-grade gliomas with a disease duration of several years, the patients 
in the present study participated only shortly after, or even during, the tumor treatment 
phase of their disease. For example, five patients received adjuvant treatment during 
the intervention. The patients in our pilot study lived through a turbulent period, in 
which psychosocial developments, in addition to medical treatment and recovery, are 
predominating. Some of them resume their work and/or family care during this period. 
It may be that, for some patients, undergoing cognitive rehabilitation in this phase is (too) 
burdensome. Furthermore, in contrast to our previous study, experiencing subjective 
cognitive (or objective) dysfunction was not an inclusion criterion. Consequently, not all 
patients in our sample experienced cognitive dysfunction (yet), which may have led to a lack 
of motivation to fully adhere to the program for some. Along this line, all three participants 
who reported psychological complaints showed (more than) sufficient adherence rates.
In order to reduce the well-known problems with adherence in remote interventions 
and, in particular, to find substitutes for the low amount of (face-to-face) supervision, before 
the start of the pilot study, we incorporated several features into the program that are 
known to enhance adherence.32-34 For example, we provided regular guidance during the 
intervention, through telephone counseling and by provision of feedback from the program 
itself. Additionally, the program offers the possibility to patients to involve a significant 
other in the process, an option that nine patients chose. Seven of these patients showed 
sufficient adherence rates. Despite the efforts made, adherence rates were suboptimal.
Overall, participants who followed the program reported that an iPad-app was an 
appropriate mode of delivery of cognitive rehabilitation. In fact, this mode enables many 
patients with brain tumors to follow a cognitive rehabilitation program at their own homes, 
5
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which is a great advantage since many patients are not allowed to drive due to epileptic 
seizures. Another important advantage is that patients can follow the program at their 
own pace and can spread the material over as many sessions as they want, which could be 
helpful for (vulnerable and/or) older patients in particular.20 All patients indicated that they 
would recommend the program to other brain tumor patients. However, some participants 
indicated that the retraining was too easy for them. Therefore, we decided to expand the 
retraining with nine more difficult exercises for use in the RCT and beyond, ensuring that 
the retraining remains challenging for each individual.
In intervention studies, the timing of the intervention is an important, but difficult 
issue, wherein a balance is sought between intervening not too early, but also not too 
late. Research in patients with brain tumors demonstrated that the need for supportive 
care is very high, especially in the early stage of the disease.14 We hypothesized that early 
cognitive rehabilitation may enhance the recovery process and may prevent/minimize the 
negative impact of cognitive side effects of adjuvant treatment, and we decided to start 
the intervention soon after physical recovery from the surgery and after completion of 
radiotherapy. At three months after surgery, the intervention could be easily embedded in 
the existing logistics of our clinical aftercare, thereby minimizing patient burden. Because 
of the hypothesized preventative effects at this stage, both patients with and without 
cognitive complaints/deficits were eligible. We assume that several aspects of our cognitive 
rehabilitation program, for example psychoeducation about cognitive (dys)functioning in 
patients with brain tumors, could be helpful for a broad group of patients at an early stage.
We have started a larger trial to evaluate the efficacy of ReMind with respect to cognitive 
functioning and patient-reported outcomes, in which patients are consecutively randomized 
to an intervention group or waiting-list control group by minimization35 after the 3 months’ 
assessment. Based on the experiences in the pilot study, exclusion criteria were revised to 
include a broader group of patients and two participating medical centers were added. A 
6-months follow-up assessment was added to the design and participants are requested to 
keep records of their time spent on the program using registration forms. In addition, a pilot 
study in 20 glioma patients with stable disease and cognitive complaints is currently being 
conducted, using the English version of the ReMind-app, at the University of California, San 
Francisco (UCSF) (clinicaltrials.gov NCT02783495). Ultimately, if the results of the RCT 
demonstrate beneficial effects of ReMind at the postoperative stage, this telerehabilitation 
program may enable many patients with brain tumors to follow a cognitive rehabilitation 
program at their own pace in their own environment early in the course of the disease.
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CHAPTER 6
Study protocol for a randomized 
controlled trial evaluating the 
efficacy of an evidence-based app 
for cognitive rehabilitation in patients 
with primary brain tumours




Background: Many patients with primary brain tumors suffer from cognitive deficits, which 
negatively impact their quality of life. However, cognitive rehabilitation programs for these 
patients are scarce. We developed an iPad-based cognitive rehabilitation program for brain 
tumor patients, which was based on our effective face-to-face cognitive rehabilitation 
program. After successful completion of a feasibility study, a randomized controlled trial 
(RCT) has been started.
Objective: The aim of the RCT is to evaluate the immediate and longer-term effects of the 
iPad-based program on cognitive performance and patient-reported outcome measures 
(PROMs) in patients with primary brain tumors in an early stage of the disease.
Methods: Prior to surgery, patients with presumed low-grade glioma and meningioma are 
included. Before surgery and three months after surgery, neuropsychological assessments 
are conducted. After the second neuropsychological assessment, patients are assigned 
to the intervention group or waiting-list control group. The intervention consists of 
psychoeducation, compensation training and retraining. Patients are advised to spend 3 
h per week on the program for 10 wk. Immediately after completion of the program and a 
half-year thereafter, post-intervention assessments take place. Patients in the control group 
are offered the opportunity to follow the program after all study assessments.
Expected outcomes: We expect that early cognitive rehabilitation has beneficial effects 
on cognitive performance and PROMs in brain tumor patients.
Discussion: The iPad-based program allows brain tumor patients to follow a cognitive 
rehabilitation program from their homes. Forthcoming results may contribute to further 
improvement of supportive care for brain tumor patients.
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GENERAL INFORMATION
Protocol Title
Cognitive rehabilitation in brain tumor patients after neurosurgery.
Trial Registration
The study has been registered in The Netherlands National Trial Register (NTR 5392) and 
on ClinicalTrials.gov (NTC03373487).
Funding
This research (project number: 842003009) is supported by the Dutch organization for 
health research and innovation, ZonMw (Laan van Nieuw Oost-Indie 334, 2593 CE, The 
Hague, The Netherlands). The development of the iPad-app ReMind was funded by Health 
Insurers Innovation Foundation, CbusineZ and ‘t Hoofdgerecht without commercial interest.
Investigators and Research Sites
An overview of the participating institutions and researchers involved is provided in Table 1.
Table 1. Investigators and research sites of the study
Project member Role Research site
GJM Rutten, MD, PhD Principal investigator, 
neurosurgeon
Elisabeth-TweeSteden Hospital
SD van der Linden, MSc PhD student, coordinating 
investigator
5022 GC Tilburg, The Netherlands
K Gehring, PhD Project leader, coordinating 
investigator
Tilburg University
MM Sitskoorn, PhD Project leader 5000 LE, Tilburg, the Netherlands
CMF Dirven, MD, PhD Associate investigator Erasmus Medical Center
DD Satoer, PhD Associate investigator, contact 
person EMC
3015 CE Rotterdam, The 
Netherlands
MJB Taphoorn, MD, PhD Associate investigator Haaglanden Medical Center
L Dirven, PhD Associate investigator, contact 
person HMC
2501 CK The Hague, The 
Netherlands
RATIONALE AND BACKGROUND INFORMATION
Patients with primary brain tumors experience various symptoms, including cognitive 
deficits. Many factors can cause or aggravate cognitive deficits, for example, the tumor 
itself, tumor treatment, tumor-related epilepsy or psychological distress.1,2 Cognitive 
rehabilitation programs are aimed at alleviating (the impact of) these cognitive deficits. 
6
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A few methodologically well-designed studies demonstrated positive effects of cognitive 
rehabilitation in brain tumor patients.3,4 However, despite the high need for rehabilitation 
services and supportive care in brain tumor patients, cognitive rehabilitation programs 
are not always available or accessible for patients with primary brain tumors in clinical 
practice.5-7
Several years ago, our group conducted a randomized controlled trial (RCT) in 140 
patients with glioma on the effects of a face-to-face cognitive rehabilitation program and 
demonstrated beneficial effects of the program.3 In a joint patient-researcher initiative, the 
program was converted into an iPad-based cognitive rehabilitation program, both in Dutch 
and English, to make the program widely available for patients with primary brain tumors. 
The content of the program has largely remained the same. We successfully completed a 
small-scale study to evaluate the feasibility of the use of the renewed program in a clinical 
(research) setting.8 Although recruitment of patients appeared to be challenging, patients 
were satisfied with the program and dropout rate was low. Based on the findings in the 
feasibility study, adjustments were made to improve the study protocol and the program, 
before the initiation of a larger RCT. In the RCT, the efficacy of the iPad-based cognitive 
rehabilitation program will be evaluated. In this manuscript, a detailed description of the 
study protocol is presented.
STUDY GOALS AND OBJECTIVES
The purpose of this study is to evaluate the immediate and longer-term effects of early 
cognitive rehabilitation in patients with primary brain tumors. Effects on cognitive 
performance as determined by neuropsychological testing, as well as effects on patient-
reported outcome measures (PROMs) will be evaluated, both on a group level and on an 
individual level. We hypothesize that early cognitive rehabilitation has beneficial effects 
on cognitive test performance and PROMs in brain tumor patients recovering from 
neurosurgery.
The specific objectives are:
1. To investigate the immediate and longer-term effects of early cognitive rehabilitation 
via the ReMind-app on group and individual cognitive performance (i.e., tests of attention, 
memory and executive functioning).
2. To investigate the immediate and longer-term effects of early cognitive rehabilitation 
via the ReMind-app on group and individual self-reported cognitive functioning, fatigue, 
psychological distress, community integration and professional functioning.
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STUDY DESIGN
Figure 1 illustrates the design of the study. This prospective, controlled study compares 
outcomes of two parallel groups, namely an intervention group and a waiting-list control-
group, to evaluate the efficacy of an early cognitive rehabilitation program. Adult patients 
with presumed low-grade glioma and meningioma who will undergo resective surgery 
are screened for eligibility. Inclusion and exclusion criteria are described in Table 2. 
Neuropsychological assessments are carried out one day before surgery (T0), three months 
after surgery (T3; pre-intervention), six months after surgery (T6; post intervention) and 
twelve months after surgery (T12; half-year follow-up). With the use of this dual baseline 
design, practice effects can be minimized. In the coordinating center of the study, T0 and T3 
assessments are embedded in standard clinical care in the hospital. Immediately after T3, the 
pre-intervention assessment, patients are allocated in a 1:1 ratio to the intervention group 
or control group, after which the intervention group follows the cognitive rehabilitation 
program on a borrowed iPad (Apple Inc., Cupertino, California, United States) for about 
10 wk. Immediate effects of the intervention are examined at T6. A half-year later (T12), 
longer-term effects are evaluated. After completion of all study assessments, patients in 
the control group have the opportunity to follow the cognitive rehabilitation program.
Figure 1. Study Design
Note: CRP = Cognitive rehabilitation program 
METHODOLOGY
Participants
Between February 2016 and July 2018, patients are included according to the eligibility 
criteria listed in Table 2. Patients were included in the coordinating center, and two medical 
centers were recently added. We aim to include 150 participants prior to surgery. With a 
maximum attrition rate of 33%, 100 patients will be evaluated (50 per group). Every effort 
will be made to obtain assessments for patients who drop out of the study, to facilitate 
carrying out intention-to-treat analyses. Prior to the first neuropsychological assessment 
(T0), informed consent is obtained. Patients can choose to involve an informal caregiver 
in the study/rehabilitation program. If they choose so, the informal caregiver will have to 
provide informed consent as well.
6
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Table 2. Eligibility Criteria of the Study
Inclusion criteria
· Adult patients (age ≥18)
· A supratentorial or infratentorial brain tumor that is radiologically suspect for either a meningioma 
or low-grade glioma
· Resective surgery for this brain tumor
Exclusion criteria
· Tumor resection in the last year
· Chemotherapy or radiotherapy in the last 2 years
· Presence/history of progressive neurological disease, severe psychiatric disorder or substance 
abuse
· Diagnosis of acute neurological or mild psychiatric disorders in the last 2 years (e.g., CVA)
· Multiple (>1) tumors
· Lack of basic proficiency in Dutch
· Karnofsky Performance Score below 70
· IQ below 85, or (very) low cognitive skills
· Insufficient reading skills, visual impairment or motor impairment limiting the ability to follow the 
cognitive rehabilitation program
Exclusion after informed consent
· Severe surgery-related complication (e.g., meningitis or CVA)
· Referral to formal cognitive rehabilitation
Intervention
The iPad-app ReMind, based on our face-to-face cognitive rehabilitation program3,9,10, is 
used in this study. The program consists of psychoeducation, compensation training and 
retraining. In the compensation training, compensatory strategies are provided, together 
with fill-in exercises to practice with the strategies in daily life. The retraining includes 
game-like exercises aimed at training different forms of attention (i.e., sustained, selective, 
alternating and divided attention). For a detailed description of content of the ReMind-app, 
we refer to our feasibility study.8 In a first face-to-face meeting with the researcher, patients 
receive an iPad (Apple Inc., Cupertino, California, United States) with the app installed, so 
that they can work through the program at home. After this meeting, patients are called 
every two weeks by the researcher to monitor their progress. It is expected that patients 
spend approximately 3 h per week on the program to complete the program within 10 wk. 
Adherence to the program is considered acceptable if patients complete ≥ 80% of both 
the strategy training and the retraining. An English version of the app is currently being 
evaluated in a pilot study in San Francisco (NCT02783495).
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‘Randomization’ by minimization
Group assignment takes place immediately after the three-month assessment (i.e., the pre-
intervention assessment). Patients are consecutively assigned to the cognitive rehabilitation 
group and the waiting-list control group in a 1:1 ratio by means of the minimization method, 
which will balance the groups for age, tumor histology, baseline cognitive performance, 
physical status and participation in other psychosocial interventions. The minimization 
method has been proven to provide more balanced groups in smaller trials, compared 
to restricted (stratified) and unrestricted (simple) randomization.11 Access to an online 
minimization program is provided by the Dutch Cancer Institute.12
Measures
Outcome measures of the study are listed in Table 3. A computerized neuropsychological 
test battery, CNS Vital Signs (CNS VS)13(CNS Vital Signs, LCC, Morrisville, North Carolina, 
United States), is administered to measure different aspects of cognitive functioning, 
including attention, memory and executive functioning. This user-friendly tool can 
be easily embedded in clinical care, due to rapid administration and semi-automatic 
processing of results. The battery consists of seven tests, which are based on conventional 
neuropsychological tests (e.g., Stroop and Symbol Digit Coding). Additionally, three paper-
and-pencil (sub)tests were added to the assessment protocol, to measure verbal memory 
recall14, working memory15 and word fluency16; cognitive functions that are not sufficiently 
covered by the tests of CNS VS (CNS Vital Signs, LCC, Morrisville, North Carolina, United 
States).
Self-reported cognitive functioning, fatigue and psychological distress are evaluated 
at all time-points using different questionnaires.17-19 At T0 and T12, questionnaires 
on community integration and professional functioning are administered as well.20-22 
Additionally, self-report and proxy-report questionnaires on executive functioning are 
filled out before (T3) and immediately after (T6) the intervention23, and a study specific 
evaluation questionnaire is administered at T6. This distribution of questionnaires was 
chosen to minimize patient burden per time point (see Table 3).
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DISCUSSION
Many patients with primary brain tumors suffer from cognitive deficits, but evidence-based 
interventions targeting these problems are scarce.2,24,25 A few studies have been conducted 
on the effectiveness of cognitive rehabilitation in brain tumor patients, but studies are often 
hampered by methodological limitations. For example, the majority of previous studies 
included (very) small sample sizes and/or did not include a control group.26-30 A decade ago, 
our RCT demonstrated positive results of our face-to-face cognitive rehabilitation program 
in 140 glioma patients with stable disease.3 Shortly thereafter, the RCT of Zucchella and 
colleagues in 53 brain tumor patients indicated that early cognitive rehabilitation had 
beneficial effects on cognitive function.4 Unfortunately, in the last couple of years, very 
little additional research has been carried out on this topic. More research with larger 
patient samples and comparison of an intervention group to a control condition is needed, 
to rule out effects of practice and natural recovery. Also, attention should be paid to the 
dissemination of the program and the implementation in clinical care.
Therefore, we initiated an RCT on the effects of the iPad-based cognitive rehabilitation 
program ReMind, which was based on our effective face-to-face program and specifically 
developed for brain tumor patients in a joint patient-researcher initiative. One of the 
strengths of the study is that both objective cognitive performance as well as patient-
reported outcome measures are included. Using relevant questionnaires, insight is gained 
into patients’ daily functioning, which we aim to improve with cognitive rehabilitation. Also, 
a unique aspect of the study is that informal caregivers are involved. This is important, since 
brain tumor diagnosis does not only affect the patient, but also the people in his or her 
environment. Informal caregivers are invited to assist the patient during the intervention 
and complete a few questionnaires. Besides an extra source of information, involvement 
of informal caregivers may also be associated with better treatment adherence and less 
caregiver burden. In addition, patient-proxy agreement on patient’s executive functioning 
can be studied using the completed questionnaires from this study.
Based on previous research and patients’ needs, some authors have suggested that 
cognitive rehabilitation should preferably start as early as possible.4,7,27 Potentially, this has 
the advantage that cognitive dysfunction, for example due to adjuvant treatment, can be 
minimized or prevented. By including a half-year follow-up assessment (T12) in our study, 
such potential preventive effects can be evaluated.
A weakness of the study may be that patients are not selected based on presence of 
cognitive deficits/complaints at T0. However, as we expect preventative effects of early 
cognitive rehabilitation, potential stable good performance in the intervention group versus 
a decline in the control group may be observed over time. Also, based on our feasibility 
study8 and patient recruitment up to now, we expect that accrual of sufficient participants 
in the RCT will be challenging. This is not only a problem in our study, but a common 
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phenomenon in studies in cancer patients.31,32 To increase patient accrual, two additional 
participating centers are recruiting patients now.
Our study will include a mix of patients with glioma and meningioma. Different types 
and grades of brain tumors may affect reorganizational processes in the brain in different 
ways. In addition, varying treatment regimens (radiotherapy and/or chemotherapy or none) 
that our patients undergo may further impact cognitive functioning. Subgroup analyses 
in patients with glioma and meningioma separately may help to determine potentially 
distinctive gains, and maintenance thereof, after cognitive rehabilitation.
To conclude, the effects of an iPad-based cognitive rehabilitation program on cognitive 
performance and PROMs will be examined in patients with primary brain tumors early in 
the course of the disease. If this program proves to be effective, we may be able to improve 
supportive care for brain tumor patients, by implementing this easily accessible cognitive 
rehabilitation program in clinical practice early after surgery.
TRIAL STATUS
The trial status at the time of submission of this manuscript is recruiting.
SAFETY CONSIDERATIONS
For patients in this study, there are no risks of participation, which is also confirmed by 
the local medical ethical review board. All Serious Adverse Events (SAEs) are immediately 
recorded in the Investigator Site File and reported to the local medical ethical review board 
on a yearly basis.
FOLLOW-UP
Neuropsychological assessments are conducted prior to surgery and 3, 6 and 12 months 
after surgery. SAEs are reported until the end of the study.
DATA MANAGEMENT AND STATISTICAL ANALYSIS
Data is handled confidentially. A patient identification code list, which is only accessible 
by direct members of the research team, is used to link the data obtained from 
neuropsychological testing, questionnaires and medical charts to the participant. Collected 
data (i.e., pseudonymized paper/digital files) are stored at the coordinating medical center 
and are only accessible by direct members of the research team. The ReMind-app saves data 
locally on the PIN code protected iPad (Apple Inc., Cupertino, California, United States).
All statistical analyses will be conducted using SPSS version 24, with an alpha set at 
.05. First, descriptive statistics will be calculated. Subsequently, it will be checked whether 
the randomization via the minimization method has been successful in balancing the 
intervention and control group. Then, group analyses on the efficacy of the program will 
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be conducted on an intention-to-treat basis. Analysis of (co)variance will be conducted to 
compare mean post intervention scores of the intervention group with mean scores of 
the control group. Alternatively, we may use linear mixed models that implicitly deal with 
missing data under the assumption of missing at random.
Since group results may mask the variability in individual responses to the intervention, 
we also plan to study change at the individual patient level. Reliable Change Indices (RCIs) 
will be calculated, reflecting change at the individual level in the context of observed 
changes for the control group of this study.33 Using this method, possible practice effects, 
natural recovery and measurement errors are taken into account. Numbers of patients 
who have improved versus the number of patients who remained stable, or declined, will 
be compared between groups.
QUALITY ASSURENCE
Annual monitoring is performed by an independent clinical monitor within the hospital. 
Interim progress reports are sent to the local medical ethical review board and to the 
funding agency. The principal investigator and coordinating investigator have successfully 
completed the course on Good Clinical Practice and the study is carried out in accordance 
with these guidelines.
EXPECTED OUTCOMES OF THE STUDY
After the feasibility study8, this randomized controlled trial is the next necessary step 
towards broader dissemination of the cognitive rehabilitation program. There is a high 
need for management of cognitive problems and patients do not always find their way to 
cognitive rehabilitation.34 As previously described, cognitive rehabilitation programs for 
brain tumor patients are scarce and research on cognitive rehabilitation in brain tumor 
patients is lagging. If we are able to demonstrate that cognitive rehabilitation via this eHealth 
intervention is effective in our sample of meningioma and low-grade glioma patients, the 
next step will be to make the app widely-available for patients in both Dutch and English.
DURATION OF THE PROJECT
Patient recruitment runs from February 2016 to June 2018. The study ends after the last 
follow-up assessment one year later, in June 2019.
PROJECT MANAGEMENT
The study is designed and led by the principal investigator dr. Rutten, and project leaders 
dr. Gehring and prof. dr. Sitskoorn. The treating neurosurgeon/physician assistant identifies 
eligible patients and provide information about the study. Neuropsychological assessments 
are carried out by well-trained research assistants. Prior to the first neuropsychological 
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assessment, informed consent is obtained by the research assistants or the study 
investigator. The study investigator, Ms. Van der Linden, coordinates the logistics, supervises 
all patients and manages the data. The investigators will present the findings in manuscripts 
and on the registered platforms. App maintenance is managed by dr. Gehring.
ETHICS
The study is approved by the local medical ethical review board (METC Brabant/CCMO: 
P1449, NL51152.028.14) and the study protocol is approved by the institutional review 
board of each participating center. All substantial changes to the protocol will be re-
submitted to the relevant review boards. The study will be conducted in accordance with 
the Declaration of Helsinki35 and in accordance with the Dutch Medical Research Involving 
Human Subjects Act (WMO). Prior to the first neuropsychological assessment (T0), written 
informed consent will be obtained from all participants. For ethical reasons, patients in the 
waiting list control group may borrow an iPad (Apple Inc., Cupertino, California, United 
States) and follow the cognitive rehabilitation program after completion of all study 
assessments (Figure 1).
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Results of a randomized controlled 
trial evaluating an iPad-based 
cognitive rehabilitation program for 
brain tumor patients




Background: Evidence-based cognitive rehabilitation programs for brain tumor patients 
are not always available for patients, despite the high needs.
Objective: We aimed to evaluate immediate and longer-term effects of an iPad-based 
cognitive rehabilitation program on cognitive performance and patient-reported outcomes 
(PROs) in brain tumor patients following neurosurgery.
Methods: Patients with presumed low-grade glioma and meningioma were recruited before 
surgery. Three months after surgery, patients were randomized to the intervention group 
or waiting-list control group. The 10-week eHealth intervention, based on our effective 
face-to-face intervention, consisted of psychoeducation, strategy training and attention-
retraining. Neuropsychological tests and questionnaires (on cognitive functioning, fatigue 
and psychological distress) were administered before surgery and 3, 6 and 12 months 
thereafter. Mean scores over time, percentages of cognitively impaired patients (Z scores 
≤1.5 on ³1 test) and reliable change indices (RCIs) were compared between groups.
Results: Sixty-two out of 330 screened patients were randomized. After randomization, 
13 patients dropped out. Patients completed 86% of the strategy training and 91% of the 
retraining. No significant differences were observed between the intervention group (n=23) 
and controls (n=26) over time on group means and RCIs of cognitive performance and PROs. 
Percentages of cognitively impaired patients were comparable between groups at 3- and 
6-months post-surgery (±70% of the patients), but 12 months after surgery, there was a 
significant difference between the intervention group (35%) and control group (68%).
Conclusion: Recruitment difficulties were present, resulting in limited power for the 
analyses. No statistically significant effects of the eHealth intervention on mean scores 
and RCIs of cognitive performance and PROs were found. For future research on cognitive 
rehabilitation, intervening at a later stage can be considered.
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INTRODUCTION
Cognitive deficits are common in patients with primary brain tumors.1-3 Despite the fact 
that these cognitive deficits are often mild and diffuse in nature, they can lead to problems 
in social and professional functioning.4,5 In addition, brain tumor patients often face severe 
fatigue, psychological distress or language problems6,7, which may all contribute to lower 
quality of life. Particularly, patients with meningioma and glioma patients with favorable 
prognosis8,9 live longer with a variety of symptoms, including cognitive deficits. Therefore, 
treatment of cognitive deficits has become increasingly important in the management of 
the disease.10
The few studies that have been conducted on cognitive rehabilitation in brain tumor 
patients demonstrated positive effects of cognitive rehabilitation on cognitive outcomes 
in patients in different stages of the disease, e.g.,11-15 In a previous randomized controlled 
trial (RCT) of our group12, glioma patients who followed cognitive rehabilitation, consisting 
of psychoeducation, strategy training and attention retraining, performed better on tests 
of memory and attention, and reported less cognitive complaints and mental fatigue 
afterwards. To increase the accessibility of this cognitive rehabilitation program16 in a cost-
efficient and patient-friendly way, we developed an iPad-based version of the program. An 
initial pilot study demonstrated that post-surgical cognitive rehabilitation via this iPad-app 
was feasible in patients with meningioma and low-grade glioma.17
In this small RCT we investigated the efficacy of the iPad-based program, with respect 
to cognitive performance and self-reported cognitive functioning, fatigue and psychological 
distress, in patients with meningioma and low-grade glioma.18
METHODS
The study was conducted in accordance with the Declaration of Helsinki19 and was approved 
by the local medical ethical review board (METC Brabant: NL51152.028.14). All participants 
included in this study provided written informed consent. Greater details regarding the 
methods, materials and intervention used in this study were described in a previously 
published study protocol.18
Participants
Prior to surgery, adult patients with presumed low-grade glioma or meningioma were 
included at the Elisabeth-TweeSteden Hospital Tilburg, Haaglanden Medical Center 
the Hague and Erasmus Medical Center Rotterdam. Based on power analyses, it was 
projected to include 150 patients before surgery. With a maximum attrition rate of 33%, 
we aimed to evaluate data from 100 patients (50 per group). Patients were not eligible 
if: they had multiple brain tumors; had undergone brain tumor resection in the last year; 
7
Binnenwerk Sophie - Final na proefdruk.indd   125 11-11-19   15:44
126
Chapter 7
had had chemotherapy or radiotherapy in the last two years; had a history of progressive 
neurological disease/severe psychiatric disorders or substance abuse; had been diagnosed 
with acute neurological/psychiatric disorders in the last two years; lacked a basic proficiency 
in Dutch; had an IQ below 85; had a KPS below 70; or had visual, language or motor 
impairments limiting participation in the study (the ability to complete neuropsychological 
assessment and/or to follow the iPad-based program). After surgery patients were also 
excluded if they suffered from surgery-related complications or if they were referred to 
cognitive rehabilitation elsewhere.
Design and procedure
Patients in this multicenter prospective RCT were invited to participate prior to surgery. 
After patients’ approval, informal caregivers were also invited to participate. Patients 
underwent neuropsychological assessments before surgery (T0) and three months after 
surgery (T3). At T3, patients were assigned to the intervention group or to the waiting-
list control group. The minimization method20 was used to balance groups for age, 
tumor histology, baseline cognitive test performance, physical health status (ASA score) 
and participation in other psychosocial interventions. Software was provided by the 
Netherlands Cancer Institute Amsterdam.21 Neuropsychological follow-up assessments 
were conducted immediately after the intervention (six months after surgery; T6) and 
one year after surgery (T12). Caregivers were asked to complete a questionnaire on the 
patient’s executive functioning and a study-specific evaluation questionnaire. Patients in the 
waiting-list control group were offered the opportunity to follow the cognitive rehabilitation 
program after the last assessment.
Intervention
The iPad-based cognitive rehabilitation program ReMind includes psychoeducation, strategy 
training and an attention retraining game. The psychoeducational information and strategy 
training are spread over six modules, namely (1) Cognitive functions, (2) Influences, (3) 
Compensation, (4) Attention, (5) Planning & Control, and (6) Memory. The program includes 
several technical features to provide support, for example the possibility of using videos/
audio clips in addition to written information, and help-overlay screens. The retraining 
exercises are aimed at sustained, selective, alternating and divided attention. After the 
feasibility study17, we made a few adjustments to the iPad-based rehabilitation program, 
based on the feedback of the pilot participants, for example the addition of more (complex) 
retraining exercises. For more details on the content of ReMind, we refer to the publication 
on our feasibility study.17
Binnenwerk Sophie - Final na proefdruk.indd   126 11-11-19   15:44
127
eHealth cognitive rehabilitation in brain tumor patients: RCT
The advice to patients was to spend 3 hours a week on the program, to complete the 
program in 10 weeks. During the intervention, assistance was provided by the researcher 
through telephone assistance every two weeks, and if desired by their informal caregiver.
Outcome measures
Enrollment and attrition. The number of patients invited to participate was recorded, as were 
the numbers of patients who agreed or declined. Reasons for decline, and later, reasons for 
dropout, were recorded as well.
Adherence and patient satisfaction. The number of completed modules in the strategy 
training and the number of completed exercises in the retraining, each expressed in 
percentages, were used to measure adherence to the program. Adherence was considered 
sufficient if patients completed ≥ 80% of both the strategy training and the retraining. 
A maximum of 100% per individual was used to calculate mean adherence rates, even 
if patients worked through the program more than once. Experiences of patients, and 
of informal caregivers if involved, with the iPad-based program were evaluated post-
intervention, with a study-specific evaluation questionnaire.17
Performance-based cognitive outcomes. Cognitive functioning was measured with the 
computerized neuropsychological test battery Central Nervous System Vital Signs (CNS 
VS, LCC, Morrisville, North Carolina).22 CNS VS consists of seven tests, assessing the 
following domains: verbal memory, visual memory, processing speed, psychomotor speed, 
reaction time, complex attention and cognitive flexibility. Additionally, working memory was 
assessed with the Digit Span Test of the Wechsler Adult Intelligence Scale (WAIS-III), and 
verbal fluency was measured with a Letter Fluency test.23 Patient scores were converted 
to Z scores (correcting for age, sex and/or education) using Dutch norms.23-25 Z scores ≤ -1.5 
indicated impaired cognitive functioning.
Patient reported outcomes (PROs). The Cognitive Failures Questionnaire (CFQ) was used 
to measure self-reported cognitive failures. Additionally, two index scores of the Behaviour 
Rating Inventory of Executive Function (BRIEF-A) were evaluated, namely Behavioral 
regulation and Metacognition. Two subscales of the Multidimensional Fatigue Inventory 
(MFI-20) were also included, to measure the level of physical fatigue and mental fatigue. 
Symptoms of anxiety and depression were examined using the Hospital Anxiety and 
Depression Scale (HADS). Scores were converted to Z scores based on published norms26-
29 and again, Z scores ≤ -1.5 were considered as low.
Statistical analysis
Statistical analyses were conducted using SPSS version 24 (IBM Inc, Armonk, New York), 
with alpha set at .05. Preintervention (T3) sociodemographic and clinical characteristics 
were compared between the intervention and control group using independent sample 
7
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t-tests, Chi-square tests and Fisher’s exact tests, depending on the distribution of the tested 
variable. Preintervention neuropsychological scores were also compared between groups.
To evaluate potential differences in outcome with respect to cognitive performance 
tests and PROs over time between the intervention group and control group, repeated 
measures ANOVAs were used. Standardized scores of cognitive performance-based 
outcomes and PROs on T3, T6 and T12 were each included as dependent variables in the 
series of analyses, with ‘group’ (intervention versus controls) as between-subject factor. 
Additionally, mean within-group changes were presented in bar charts. Chi-square tests 
were conducted to evaluate frequencies of patients with impairment (Z scores ≤ -1.5) at 
each time-point.
Reliable change indices (RCIs) were calculated for the performance-based outcomes 
and PROs. RCIs reflect change in individual patient scores relative to observed changes 
in the control group, thus taking into account practice effects, natural recovery and 
measurement errors.30 Reliable improvement was defined as RCI values above +1.645 and 
decline below -1.645 (based on an alpha of .10, corresponding to a 90% confidence interval). 
RCIs were calculated over the first time-interval (T3-T6) and over the second interval (T3-
T12). Numbers of patients who reliably improved/declined on one or more outcomes were 




Figure 1 presents the flow of patients throughout the trial. Prior to surgery, 330 patients 
with presumed meningioma and low-grade glioma were screened for eligibility. Based on 
the inclusion/exclusion criteria, 183 patients were eligible and were invited to participate 
at T0, of whom 84 declined participation and 99 provided written informed consent. 
Most important reasons for decline were that (patients anticipated that) it would be too 
burdensome and/or too time-consuming (n=47); they had no affinity with iPads/computers 
(n=13); or that they felt no need because of the absence of cognitive complaints (n=7). 
From surgery to T3, i.e. before randomization, 37 patients dropped out of the study. 
Most important reasons were lack of motivation (n = 14; including 8 patients who wanted 
to devote full attention to work resumption) and referral to conventional cognitive 
rehabilitation (n=11).
Three months after surgery, 62 patients were randomized to the intervention or control 
group. Between T3 and T6, 8 patients in the intervention group dropped out the study and 
5 controls. Between T6 and T12, 3 intervention group patients and 1 control dropped out 
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(Figure 1). As a result, T6 data of 23 patients in the intervention group and 26 in the control 
group and T12 data from 20 and 25 patients were analyzed.
Patient characteristics
Sociodemographic and clinical characteristics of the intervention and control group are 
listed in Table 1. Patients in the intervention group were significantly younger than the 
controls (M
diff
=-6.92, p=.03). Also, in the intervention group, the percentage of women was 
significantly higher compared to the control group (74% vs 46%, p<.05). Sixteen patients in 
the intervention group (70%) and 20 patients in the control group (77%) chose to involve 
an informal caregiver (Table 1). Mean pre-intervention scores on the performance-based 
outcomes and PROs did not differ significantly between the intervention group and control 
group (all p-values>.05).
Adherence and patient satisfaction in the intervention group
The twenty-three patients completed on average 86% of the strategy training and 91% of 
the retraining. Sufficient adherence (completion of ≥80% of both the strategy training and 
retraining) was observed in 16 patients (70%). Furthermore, 14 patients completed the 
retraining more than once.
The evaluation questionnaire was fully completed by 21 patients, and partly by one other 
patient (Table 2). Overall, 90% of patients rated to program as “good” or “excellent”, and 95% 
would recommend the program to other brain tumor patients. The difficulty and amount 
of information in the strategy training was perceived as sufficient and patients indicated 
that the information was useful. However, a substantial part of the patients (n=14) indicated 
that there were too many fill-in exercises included in the strategy training. Furthermore, 11 
patients reported that there were (too) few exercises included in the retraining and 13 that 
the retraining was (too) easy, but nevertheless the retraining exercises were perceived as 
(very) useful by 19 patients. Twenty patients indicated to have appreciated the iPad-based 
delivery of the program and 16 patients indicated that the two-weekly telephone assistance 
was (very) useful.
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Figure 1. Flow of participants through the trial
Note: CR = Cognitive Rehabilitation; KPS = Karnofsky Performance Status
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Table 1. Sociodemographic and clinical characteristics of intervention group and control group





Age at T3 (Mean; SD) 45.7 (11.7) 52.6 (10.4) .033*
Sex (n female; %) 17 (74%) 12 (46%) .048*
Years of education (Mean; SD) 15.4 (3.6) 15.1 (3.6) .766
Level of education (n; %) .334
Low 4 (17%) 5 (19%)
Middle 4 (17%) 9 (35%)
High 15 (65%) 12 (46%)
Physical status (n; %)a 1.00
ASA I/II 23 (100%) 25 (96%)
ASA III/IV - 1 (4%)
Tumor histology (n; %)b .821
Meningioma (grade I) 13 (57%) 14 (54%)
Atypical meningioma (grade II) 1 (4%) 1 (4%)
Grade II glioma 9 (39%) 10 (39%)
Grade III glioma - 1 (4%)
Tumor hemispherec (n; %) .681
Left 11 (48%) 11 (42%)
Right 11 (48%) 14 (54%)
Bilateral 1 (4%) 1 (4%)
Radiotherapy after surgerya,d (n; %) 4 (17%) 10 (39%) .103
Chemotherapy after surgeryd (n; %) 3 (13%) 7 (27%) .299
Psychotropic medication at T3 (n; %) 11 (48%) 17 (65%) .215
Cognitive impairmente at T3 (n; %) 16 (70%) 16 (69%) .980
Low PRO scoresf at T3 (n; %) 14 (61%) 18 (69%) .539
Involvement of informal caregiver 16 (70%) 20 (77%) .339
a Fisher’s Exact Test was interpreted, since not all cell counts were greater than five. 
b Proportions of patients with meningioma and glioma were compared between groups (not 
separated by tumor grade). 
c Patients with bilateral tumors were excluded for the statistical comparison. 
d During study participation (i.e. within one-year post-surgery) 
e Z score ≤ -1.5 on one or more performance-based outcomes 
f Z score ≤ -1.5 on one or more PROs
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Table 2. Post-intervention ratings of different aspects of ReMind (n = 22)
Difficulty of (too) easy just right (too) difficult
Information in strategy training 7 13 2
Fill-in exercises in strategy training 9 7 4
Retraining (C-Car game) 13 8 -
Amount/number of (too) little/few about right (too) much/many
Information in strategy training 1 19 2
Fill-in exercises in strategy training - 7 14
Retraining exercises (C-Car game) 11 10 1
Supervision of the researcher/trainer - 22 -
Usefulness of (very) useful neutral not useful
Information in strategy traininga 14 5 2
Fill-in exercises in strategy traininga 5 10 5
Retraining exercises (C-Car game) 19 2 1
(telephone) contact with the researcher/
trainer
16 6 -
Content addressed daily problems fully/largely partly not
10 7 4




Impact of cognitive problems has changed yes, positively nob yes, negatively
10 11 -
Coping with cognitive problems has 
changed
improved coping noc worsened coping
6 16 -
Pleasantness of working on ReMind (very) pleasant neutral (very) unpleasant
7 14 -
excellent/good sufficient insufficient/poor
Using an iPad-app for cognitive 
rehabilitation
20 2 -
Capability of the researcher/trainer 20 2 -
Contact with the researcher/trainer 21 1 -
Overall rating of the program 19 1 1
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Table 2. Continued
yes no
Recommendation to other brain tumor 
patients
21 1
a Missing values for two participants 
b No change, there was no impact on daily life (7) or no change, impact remained the same (4) 
c Coping is still good (14), or coping is still not good (2)
Evaluation of mean scores on cognitive performance and PROs
Mean scores of the groups at the different time points are listed in Table 3 and mean 
changes over time in both groups are presented in Figure 2. Repeated measures ANOVAs 
demonstrated no significant interaction effects of time and group on the outcome variables 
(all p-values >0.05). Regarding cognitive performance, significant positive main effects 
of time (irrespective of group) were observed for processing speed, complex attention, 
cognitive flexibility and working memory. For the PROs, positive main effects of time were 
found, indicating fewer concerns with respect to behavioral regulation, metacognition and 
mental fatigue.
Evaluation of impairment on cognitive performance and PROs
Proportions of patients in the intervention group and control group, who scored below 
the cutoff (Z scores ≤ -1.5) on one or more performance-based outcomes pre- and 
immediately post-intervention (T3 and T6), were not significantly different between the 
groups, with percentages lying around 70% (Table 3). At T12, significantly fewer patients 
in the intervention group showed cognitive impairment, with 35% of the patients in the 
intervention group scoring low on one or more performance-based outcomes vs 68% of the 
control group (p=.027). Regarding PROs, no significant between-group differences were 
observed for any of the time-points.
Individual-level change in cognitive performance and PROs
Over the first interval (T3-T6), 48% of the patients in the intervention group and 23% of the 
patients in the control group showed reliable improvements on one or more performance-
based outcomes, and reliable decline was observed in 30% vs 15% of the patients (Table 4). 
Between T3 and T12, improvement was observed in 35% of the patients in the intervention 
group vs 24% of the controls, and decline in respectively 20% vs 32% (all p’s>.05).
Over the first interval, 83% patients in the intervention group, and 89% of the controls 
improved reliably on one or more PROs. Reliable decline was observed in 30% and 19% of 
the patients in the intervention group and control group respectively. Over the long-term, 
improvements were observed for 85% of the patients in the intervention group vs 72% of 
7
Binnenwerk Sophie - Final na proefdruk.indd   133 11-11-19   15:44
134
Chapter 7
the controls, and decline was observed in 10 vs 20% respectively (Table 4). None of the 
differences in proportions were statistically significant (p>.05).
Table 3. Mean scores of the intervention group and control group on cognitive performance and PROs 
per time-point














Verbal memory -0.41 -0.10 0.09 -0.68 -0.64 -0.68
Visual memory 0.13 0.09 -0.07 -0.37 -0.45 -0.56
Processing Speed -0.36 -0.07 0.09 -0.60 -0.51 0.00
Psychomotor Speed -0.22 -0.28 0.12 -0.36 -0.38 -0.27
Reaction Time -0.55 -0.44 -0.13 -1.36 -1.32 -1.46
Complex Attention -1.54 -0.35 0.00 -1.22 -0.75 -0.51
Cognitive Flexibility -0.98 -0.45 -0.18 -1.19 -0.77 -0.57
Working Memory -0.06 0.09 0.34 -0.05 0.05 0.15
Verbal Fluency -0.34 -0.33 -0.05 -0.60 -0.28 -0.25















Cognitive complaints (CFQ) -0.43 -0.07 0.23 0.12 0.23 0.08
Behavioral Regulation (BRIEF-A) -0.13 0.19 - 0.10 0.26 -
Metacognition (BRIEF-A) -0.66 -0.27 - -0.41 -0.24 -
Physical fatigue (MFI) -0.63 -0.52 -0.29 -0.66 -0.81 -0.46
Mental fatigue (MFI) -0.96 -0.69 -0.42 -1.04 -0.74 -0.63
Anxiety symptoms (HADS) 0.12 0.26 0.19 0.18 0.37 0.38
Depressive symptoms (HADS) -0.02 -0.09 0.26 0.19 0.13 0.11












Note: Higher mean scores indicate better outcomes
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Figure 2. Mean changes in Z scores over the first (T3-T6) and second (T3-T12) interval for 
the intervention group and control group
Note: Positive change scores indicate improvement on the outcome variables, whereas negative 
scores indicate decline.
7































































































































































































































































































































































































































































































































Binnenwerk Sophie - Final na proefdruk.indd   136 11-11-19   15:44
137
eHealth cognitive rehabilitation in brain tumor patients: RCT
DISCUSSION
In this RCT, the effects of the iPad-based cognitive rehabilitation program starting three 
months after surgery were evaluated in 49 patients with low-grade glioma and meningioma. 
Recruitment of patients before surgery was challenging, only 19% of the patients who were 
screened were randomized at T3. A substantial proportion of included patients (37%) 
dropped out in the first three months after surgery and before randomization. Adherence 
rates of the patients who followed the intervention were sufficient, with patients completing 
on average 86% of the strategy training and 91% of the retraining. Moreover, patients 
evaluated the program positively.
Although mean changes over time for cognitive performance and PROs were generally 
larger in the intervention group than in the control group, no significant effects were found 
at group level. Also, in the evaluation of individual reliable change in cognitive performance 
and PROs, we found no significant differences in proportions between the intervention 
group and controls. Percentages of patients with cognitive impairment were comparable 
between groups at T3 and T6 (±70%), but at T12, a significant difference in proportions was 
found between the intervention group (35%) and controls (68%). This, however, may be 
partly explained by the fact that pre-intervention scores of the patients in the intervention 
group were already (not statistically, but still a little) higher. Post-surgical cognitive 
improvements over time in both groups, due to amongst other natural recovery, may have 
led to a higher percentage of patients in the intervention group scoring within normal (non-
impaired) ranges at T12. On the other hand, one may argue that in the control group with 
observed lower scores there was more room for improvement, which was not seen.
Our previous RCT, evaluating the face-to-face version of the cognitive rehabilitation 
program in lower-grade glioma patients with cognitive complaints and disorders, 
demonstrated small to medium positive effects on self-reported mental fatigue and 
performance on memory and attention tests.12. In contrast, we found no beneficial effects 
of the iPad-based cognitive rehabilitation program in the current RCT. Several differences 
may explain null findings of the current trial, including 1) the small sample size, 2) early 
timing of the intervention, 3) inclusion of patients independently of cognitive complaints/
disorders, and/or 4) limited follow-up period. Still, lessons learned from the current study 
can guide future research on (eHealth) cognitive rehabilitation in brain tumor patients.
Compared to our current RCT in 49 brain tumor patients, many more patients were 
enrolled in our previous study (n=140), resulting in differences in statistical power for 
the analyses. Initially, we aimed to include 100 patients (50 per group), but recruitment 
of patients, and also the retention of patients, was difficult. Unfortunately, recruitment 
problems are common in psycho-oncological studies, especially in RCTs.31,32 Many patients 
were not eligible for randomization according to the in/exclusion criteria (i.e. 170/330; 52%). 
In addition, a substantial part of patients declined participation. Reasons for decline varied, 
7
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but many patients (n=47) mentioned that they would expect it to be too burdensome for 
them. Of course, the targeted patients face a complex period of time after surgery, in which 
they need time for recovery, adjuvant treatment, coping with their diagnosis and symptoms, 
and want to devote their time to family, home, work resumption, and social and leisure 
activities. This seems particularly the case in this group, since patients are relatively young 
and carry many responsibilities.
Given that a very large proportion of brain tumor patients experience cognitive deficits 
at a certain point during the disease trajectory, we chose to adopt a preventive and inclusive 
approach in this study. We included patients based on their willingness to participate at an 
early stage of the disease, and not based on the presence of cognitive deficits or complaints, 
which was the case in our previous RCT.12 Also, both meningioma and low-grade glioma 
were included in the study, who may respond to cognitive rehabilitation in different ways. 
Unfortunately, the size of our sample did not allow for subgroup analyses on differences in 
outcomes for meningioma vs glioma, adherent vs non-adherent patients and patients who 
involved an informal caregiver vs patients who did not. Furthermore, it is possible that any 
positive preventative effects of the intervention may occur at a later stage (>6-months 
post-intervention), which would have required a longer follow-up period.
The effectiveness of our face-to-face program12 implies that certain ingredients of 
the program can lead to improvements in cognitive functioning in brain tumor patients. 
However, in the current study use was made of eHealth instead of the face-to-face cognitive 
rehabilitation. To our knowledge, this is the first study on eHealth cognitive rehabilitation 
in brain tumor patients. eHealth is a relatively new and rapidly evolving field of research, 
and it is also promising, since it has the potential to deliver intervention programs to many 
patients in a cost-efficient way. Studies have demonstrated that psychological eHealth 
interventions can be as effective as face-to-face programs.34,35 However, accumulating 
evidence also suggests that with an increasing amount of support, moving towards a more 
blended care approach, psychological eHealth interventions yield better results.36,37 
Although patients appreciated the two-weekly telephone assistance and could receive 
help from their informal caregiver, it is possible that our intensive cognitive rehabilitation 
program requires more intensive guidance of a professional, to achieve beneficial effects 
for brain tumor patients.
Intervention studies make use of strict protocols, in order to be able to demonstrate 
potential beneficial effects of the intervention. In clinical practice, neuropsychological 
interventions are often more tailored to the needs and situations of patients and family 
members. Given the heterogeneity of brain tumors and existing individual variability, it 
would had been interesting to identify characteristics of patients who may benefit from 
cognitive rehabilitation, and patients who do not.33 Although, despite the current findings, 
we believe that early intervention can still be beneficial for some patients, recruitment 
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of patients for participation in research was very time-consuming at this early stage. For 
follow-up research on (eHealth) cognitive rehabilitation, we would suggest a later timing 
of the intervention (e.g., in patients with stable disease), based on our findings with respect 
to the recruitment of patients.12. In this way, larger samples may be recruited allowing for 
firmer conclusions with respect to effectiveness of the intervention.
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Chapter 8
OVERVIEW OF THE FINDINGS
In the studies of the first part of the dissertation, different aspects of neuropsychological 
assessment of cognitive function and fatigue were investigated in patients with brain 
tumors, followed by the second part of the thesis which focused on cognitive rehabilitation 
via the ReMind-app.
In chapter 2, we evaluated test-retest reliability and potential practice effects of the 
computerized neuropsychological test battery CNS Vital Signs in a sample of Dutch healthy 
adults. At baseline, 158 participants were included and at 3- and 12-months follow-up, 131 
and 77 participants were reassessed. Test-retest correlations coefficients varied widely 
across cognitive domains (ICCs ranging between .40 and .88). Regarding practice effects, 
it was shown that participants scored significantly better on the Stroop Test, Shifting 
Attention Test and Symbol Digit Coding Test at the 3-month retest, resulting in significantly 
higher scores on the domains of Cognitive Flexibility, Processing Speed, and Reaction Time. 
No significant changes in performance were demonstrated between the second and third 
assessment. RCI-formulae were formulated to correct for imperfect test-retest reliability 
and practice effects and can be used in clinical care, to facilitate proper interpretation of 
individual change in cognitive performance on the CNS VS.
In chapter 3, a closer look was taken at executive functioning of patients with low-grade 
glioma and meningioma, using self-report, proxy-report and test performance measures. 
Agreement on patients’ executive functioning (EF) was examined in 47 brain tumor patients 
and their proxies. Self-report of patients was compared with proxy-report three months 
post-surgery. Furthermore, associations of reported measures of EF with performance-
based measures of EF were evaluated, as well as the influences of these performance-based 
measures on the level of patient-proxy agreement. Patients reported significantly more 
problems on the Metacognition index of the BRIEF-A in comparison with norms, and also 
in comparison with proxies. Overall, patient-proxy agreement was found to be moderate, 
and no clear associations were found between reported measures of EF and executive test 
performance. The mismatch between patient reports and cognitive test performance can 
be further investigated, as well as potential innovative methods to assess everyday EF in 
brain tumor patients.
In chapter 4, prevalence, severity and correlates of fatigue were investigated in patients 
with grade I meningioma using a validated multidimensional questionnaire. Before surgery 
(n = 65) and one year after surgery (n = 53), meningioma patients scored significantly higher 
on all subscales of the MFI compared to normative values. In a subgroup of patients who 
underwent both assessments (n = 34), mean scores for General Fatigue, Physical Fatigue and 
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Mental Fatigue remained stable over time and improvements were observed for Reduced 
Motivation and Reduced Activity. At the individual level, 68% of the patients scored high 
(Z score ≥ 1.3) on one or more subscales of the MFI before surgery. Postoperatively, 57% 
still scored high on one or more subscales. Furthermore, fatigue was associated with self-
reported cognitive complaints, anxiety and depression. From this study, it became clear 
that fatigue is a serious, common and persistent symptom in patients with meningioma 
who underwent neurosurgery, that needs more attention of clinicians and researchers in 
the field of neuro-oncology.
Then, moving towards rehabilitation of cognitive functioning, in chapter 5, our pilot study 
on the iPad-based cognitive rehabilitation program ReMind was presented. Feasibility of, 
and potential barriers to, the use of program in the clinical (research) setting were evaluated 
in 15 patients with meningioma and glioma. The cognitive rehabilitation program, based 
on the previously evaluated face-to-face program of Gehring and colleagues (Gehring et 
al., 2009), consists of psychoeducation, compensation training and retraining of attention. 
Recruitment of participants prior to surgery was challenging, as 57% of the patients who 
were scheduled for neurosurgery were not eligible, and of the patients who were invited to 
participate, 46% declined participation. Furthermore, participants completed on average 
71% of the compensation training and 76% of the retraining. Overall, participants were 
satisfied with the program and dropout was low (13%). Participants reported that an iPad-
app was an appropriate mode of delivery of the program. Some patients evaluated the 
retraining part of the program as too easy, and therefore, the it was expanded with more 
difficult exercises.
Subsequently, a larger randomized trial (RCT) was started to evaluate the efficacy of the 
iPad-based cognitive rehabilitation program ReMind with respect to cognitive outcomes 
and patient-reported outcomes (PROs). In chapter 6, the study protocol of our RCT was 
described in detail. We aimed to include 150 patients with meningioma and low-grade 
glioma prior to surgery. With a maximum attrition rate of 33%, 100 patients (50 per group) 
were expected. Neuropsychological assessments were carried out before surgery (T0) and 
three months thereafter (T3). At T3, patients were randomly assigned to the intervention 
group or waiting-list control group, and patients in the intervention group again followed the 
cognitive rehabilitation program ReMind for 10 weeks. Patients were neuropsychologically 
retested six months (T6) and twelve months (T12) after surgery.
In chapter 7, we presented the results of this RCT. Similar to the pilot study, recruitment 
of patients was difficult, which led to the inclusion of a relatively small sample of patients 
for the analyses (intervention group n  =  23, controls n  =  26 at T6). Adherence to the 
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program was higher than in the pilot study, with patients completing on average 86% of 
the compensation training and 91% of the retraining. Dropout rate on the other hand, 
was higher in the RCT than in the pilot study. Comparing mean scores of patients in the 
intervention group and control group on performance-based outcomes and PROs using 
repeated measures ANOVAs did not indicate statistically significant differences. Also, no 
significant differences between the intervention group and control group were observed 
in proportions of patients who improved or declined reliably. Percentages of patients with 
cognitive impairment were comparable at T3 and T6 (percentages around 70%), but one year 
after surgery 35% of the patients in the intervention group vs 68% of the controls showed 
impaired scores on one or more cognitive domains, which was a significant difference. For 
follow-up research on (eHealth) cognitive rehabilitation, we would suggest a later timing 
of the intervention (e.g., in patients with stable disease), based on our findings with respect 
to the recruitment of patients.
ROUTINE ASSESSMENT OF COGNITIVE FUNCTION: WHY, WHAT AND 
HOW?
Brain tumor diagnosis and its treatment have major impact on patients’ lives. Many patients 
suffer from various symptoms including cognitive deficits, fatigue and psychological 
distress. In turn, these symptoms can lead to impairments in daily functioning and 
lowered quality of life of patients.1,2 For clinicians, it is important to pay attention to these 
symptoms during the disease process, in order to be able to provide appropriate care timely. 
In addition, lower cognitive performance on preoperative neuropsychological tests can 
be predictive for worse late cognitive outcomes.3 Accurate prediction of postoperative 
cognitive performance can aid both the patient and clinician in medical decision-making 
and determine best treatment option for the individual patient.
A necessary first step is that cognitive symptoms should be detected and therefore, 
systematic assessment is crucial. However, cognitive performance on neuropsychological 
tests is not strongly correlated with self-perceived cognitive functioning as reported on 
questionnaires (see chapter 3 and 4,5). Previous research has shown that self-reported 
cognitive functioning seems more strongly associated with symptoms of anxiety, depression 
and fatigue4,6, which was also demonstrated in our fatigue study in meningioma (chapter 4). 
Possible explanations for the mismatch between cognitive performance and self-reported 
cognitive functioning are, for example, that ecological validity of neuropsychological tests 
is limited and/or that self-report of cognitive functioning is be hampered by self-report 
biases. Still, patients’ report on their cognitive functioning does not allow conclusions 
about their objective cognitive function and vice versa. For routine assessment in brain 
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tumor patients, we recommend the use of a short and efficient neuropsychological test 
battery, together with a concise screening questionnaire assessing cognitive functioning, 
psychosocial functioning and fatigue. For instance, the Distress Thermometer and Problem 
List7 can be used as a screening questionnaire, which could also be administered digitally. In 
addition, the inclusion of long-term follow-up assessment is very important, since cognitive 
symptoms or fatigue may manifest or aggravate later (for example, due to late effects of 
radiotherapy). It can also be that some patients become aware of these symptoms at a later 
stage, because of increasing demands (e.g., return to work and social obligations).6
Lastly, informal caregivers should be actively involved in the disease trajectory of patients. 
They can provide valuable information on functioning of the patient, when the patient 
is not able to provide the information him/herself. In our study on patients’ executive 
functioning (EF) it was demonstrated that proxy-report is a reasonable estimate of patient-
report of EF, which was in line with other studies on patient-proxy agreement on, amongst 
others, quality of life in brain tumor patients.8,9 Moreover, it is important to have insight in 
caregiver burden and caregiver’s quality of life, since caregivers are often confronted with 
multiple challenges, among which are dealing with a variety of symptoms, financial issues, 
changing roles and difficulties in communication.10 Appropriate care should be provided 
in time. Psychoeducation timely in the disease process, as for example incorporated in the 
ReMind-app, may be an important first step for both patients and caregivers. Furthermore, 
caregivers can benefit from information and concrete advice on coping with everyday 
difficulties10 and sometimes, referral to a clinical psychologist for psychological treatment 
can be necessary.
COGNITIVE REHABILITATION: HELPFUL OR NOT?
In different patient populations, positive effects of cognitive rehabilitation have been 
demonstrated.11-13 Also, in brain tumor patients, promising effects of cognitive rehabilitation 
have been reported.14 In the evaluation of our eHealth cognitive rehabilitation program 
ReMind, we found that post-surgical cognitive telerehabilition was feasible in brain tumor 
patients and that patients were satisfied with the program in our pilot study (chapter 5). 
However, no significant effects were found on mean scores and RCIs of cognitive outcomes 
and PROs between the intervention and control group in our RCT (chapter 7). The finding 
of our RCT were in contrast with the previous study of our group, which demonstrated 
beneficial effects of the original face-to-face-cognitive rehabilitation program.15 Besides 
differing sample sizes (49 vs 135 patients), thus, statistical power, differences in selection 
criteria (no preselection vs selection based on cognitive symptoms), and/or timing of the 
intervention (semi-acute phase vs stable disease) are possible explanations for the different 
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findings. Another important difference with our previous RCT is that in the recent study 
use was made of eHealth instead of the face-to-face cognitive rehabilitation. The proven 
effectiveness of our face-to-face program implies that certain ingredients of the program 
can lead to improvements in cognitive functioning in brain tumor patients. Potentially, the 
eHealth intervention could be further optimized, to achieve beneficial effects for brain 
tumor patients. For example, maybe the program can be offered with more support of 
a professional, moving towards a more blended care approach. Furthermore, research 
generally focuses primarily on groups, whereas in clinical practice, a more patient-centered 
approach is used, taking into account individual differences and preferences. For example, 
in our cognitive rehabilitation studies, the intervention started three months after surgery. 
From patients’ feedback it became clear that this was too early for some and too late for a 
few. Based on our findings with respect to the recruitment of patients, we would suggest 
a later timing of the intervention for future research, when patients have recovered from 
surgery and have resumed their daily activities. In this way, larger samples may be recruited 
allowing for firmer conclusions with respect to effectiveness of the intervention. When the 
cognitive rehabilitation program would be used in clinical care, the timing of the intervention 
could be adjusted to the needs of patients. Still, it is important to realize that eHealth 
interventions do not suit everyone, and that (referral to) psychological interventions are 
in line with the needs of individual patients.
OPPORTUNITIES AND CHALLENGES OF EHEALTH
Globally, there is a large shortage of healthcare personnel.16 Due to, amongst others, 
the aging population, the shortage of health care workers is likely to grow. Efficient use 
of eHealth technologies may offer a partial solution to this problem. It can increase the 
accessibility of interventions to patients and enables patients to follow an intervention 
in their own environment. In recent decades, many eHealth-apps have been developed, 
however, only a small proportion have been evidence-based or scientifically researched. In 
addition, eHealth programs are often not yet embedded in clinical care and/or reimbursed 
by health care insurers, which reduces accessibility to these programs for patients. 
Currently, the Dutch government strongly encourages the use of eHealth in health care 
and will provide financial support for this in the coming years.17
One of the concerns of eHealth is ensuring adherence to eHealth programs. While 
increasing accessibility of psychological interventions, low adherence can be a significant 
problem, through limited exposure to the whole program/not receiving the “full dosage”.18 
Fortunately, adherence in our RCT was sufficient and was higher compared to adherence 
rates of our pilot study, with average completion of 86% of the compensation training and 
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91% of the retraining. There is a lack of agreement on how best to measure adherence, 
with the number of logins and the number of completed modules as most commonly used 
methods. In a review of psychological eHealth interventions, module completion (which we 
also used in our intervention studies as a measure of adherence) was significantly correlated 
with psychological outcomes.19 However, due to the relatively small sample size of our 
intervention group (n = 23), adherence could not be taken into account. In larger trials, it is 
recommended to do so, for example by looking at dose-response relationships.
In recent years, privacy protection has received much attention within healthcare. 
International and national laws have been further tightened, for example with the 
introduction of the General Data Protection Regulation (“Algemene Verordering 
Gegevensbescherming”) in May 2018. To properly protect the privacy of patients in 
research, there are understandably strict requirements. Within the current research 
project, however, this has led to several restrictions, which, moreover, were not always 
advantageous for patients. One example was that patients and informal caregivers were not 
allowed to use their own email addresses in the remind app, which hindered sending emails 
from the program. Also, data could not be sent to a database at the university because of 
stricter regulations. As a result, we as researchers did not have access to certain data (e.g., 
answers given by patients, number of logins and performance on the retraining game) and 
also, could not provide remote real-time supervision. Of course, privacy protection is very 
important, but one has to be careful that it does not stand in the way of development and 
conducting proper research in health care.
METHODOLOGICAL CONSIDERATIONS
First and foremost, the sample sizes of some of the studies included in this dissertation 
were relatively small, which has led to reduced power and limitations in the statistical 
analyses. Recruitment difficulties were present: many patients were not eligible (according 
to the in-/exclusion criteria) and additionally, a substantial part of eligible patients declined 
participation. Declining participation is a known issue in oncological studies.20 Also, studies 
into the use of support services demonstrated that many brain tumor patients tend not to 
use support services, despite unmet needs.21 Examples of reasons given by patients are that 
they were doing well compared to other brain tumor patients or that they had prioritized 
other issues over their supportive care needs.21 Furthermore, participants in our studies 
were often highly educated. It is therefore possible that participation bias had been present, 
potentially comprising generalizability of the results.20 Taken together, future studies should 
take potential recruitment difficulties into account. For example, longer inclusion periods 
can be incorporated, and multiple participating centers can be involved in an early stage.
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In our studies, use was made of the computerized neuropsychological test battery CNS VS 
to measure different aspect of patients’ cognitive functioning and a few limitations related 
to the CNS VS should be mentioned. First, a test of free memory recall is not included in the 
CNS VS test battery. In the verbal memory test and visual memory test of CNS VS patients 
were asked to remember 15 words and figures respectively (randomly selected from a larger 
database of stimuli) and afterwards, they had to pick the 15 (to be) remembered words/
figures from a list of 30. Clearly, this involves recognition in response to a cue rather than 
recall of information actively retrieved from one’s memory without a cue. This makes the 
tasks easier and also, problems in memory retrieval are being overlooked. Furthermore, 
CNS VS does not cover all cognitive domains, for example, language, visuo-spatial function 
and social cognition are not assessed. Despite the limitations, CNS VS proved to be time-
efficient and sensitive in the detection of (mild) cognitive deficits and change in cognitive 
function in patients with brain tumors.3,22 Also, we established comprehensive Dutch 
normative data23, and developed formulae for the determination of reliable change in 
individuals (chapter 2) which makes the battery very suitable for repeated testing in our 
patient samples. Alternatively, future studies may consider the use of tests recommended 
by the International Cancer and Cognition Task Force (i.e. Hopkins Verbal Learning Test, 
Controlled Oral Word Association, Trial Making Test A/B).24 If those recommended tests 
are used, studies can be compared more easily.
In our research, we did not assess sleep-and-wake disturbances among brain tumor patients, 
although these problems often co-exist and interact with symptoms of fatigue, depression 
and cognitive deficits.25 Also, personality traits and coping style were not assessed, but may 
be important predictors of cognitive concerns and fatigue. Additionally, over the past years, 
researchers found a link between multiple molecular makers and cognitive functioning26 
and in the future, this link could be further explored. Ultimately, knowledge from genetic 
profiling might be used to identify patients who are most vulnerable for cognitive decline 
at an early stage. It is important to mention that a large number of studies in brain tumor 
patients (including chapter 2 and 3 of this dissertation) looked into associations between, 
amongst others, tumor characteristics, treatment modalities, epilepsy, psychological 
distress, fatigue, and cognitive functioning. Although in this way, new knowledge is 
acquired, predictions or causal relationships cannot be established. More experimental 
and prospective longitudinal studies are needed in the field of neuro-oncology, based on 
hypothesis-driven research, in addition to descriptive studies.




As described before, novel assessment techniques could also be further explored in future 
studies in brain tumor patients, to obtain a more complete picture of patients everyday 
cognitive functioning. For example, using an Experience Sampling Method (ESM)27,28 
to measure cognitive functioning at multiple times throughout the day, may provide 
a more realistic picture of patients’ daily functioning, since real-time measurement of 
cognitive functioning is actually integrated in the daily lives of patients.in addition, virtual 
environments (VE) are increasingly being used to enhance neuropsychological testing, 
so that they better reflect situations patients face in the outside world.29,30 Furthermore, 
linking information from multiple modalities, including for example neuropsychological 
tests, imaging outcomes and immunological parameters31, may also provide new insights 
into the multifactorial determinants of cognitive dysfunction in brain tumor patients and 
may reveal potential targets for treatment.
Compared to the number of studies on incidence, severity and correlates of cognitive deficits 
in brain tumor patients, little research has been conducted on different treatment options 
for these deficits. Besides cognitive rehabilitation studies, the effects of pharmacological 
treatments and exercise programs have been explored in brain tumor patients in the past 
decades. Donepezil, armodafinil and modafinil are the most studied pharmacological agents 
with respect to cognitive functioning in brain tumor patients. Findings on the effects of 
those agents on cognitive functioning are mixed, but the most evidence for benefits has 
been found for donepezil.14 However, long-term follow-up assessments are lacking in 
almost all studies on the effects of pharmacological agents on cognitive performance. 
Furthermore, not many exercise intervention studies have been carried out in patients 
with brain tumors (yet). The few studies that were conducted demonstrated feasibility 
of exercise interventions for brain tumor patients and suggest (small) positive effects on 
cognitive functioning and wellbeing.32,33 It would be interesting to study the combination of 
physical exercise and cognitive rehabilitation in brain tumor patients, since this combination 
has yielded positive results in other populations.34-36 Lastly, the overlap in symptoms of 
depression, anxiety, fatigue, insomnia and cognitive concerns can be used in advance. For 
instance, interventions that address emotional problems, can potentially have an indirect 
positive effect on cognitive functioning. Taken together, the field of interventions for 
cognitive deficits in brain tumor patients is developing, but still, a lot of work needs to be 
done in the future.
Besides interventions aimed at improving cognitive functioning during or after medical 
treatment, increased attention has been paid to cognition-sparing medical treatment 
strategies for brain tumor patients. Examples of cognitive-sparing techniques include awake 
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brain tumor surgery, stereotactic radiotherapy, proton therapy and hippocampal sparing 
during radiotherapy.36 The findings on these techniques seem promising so far, but further 
research (especially on long-term effects of those techniques) is needed to draw clear 
conclusions, in order to facilitate transfer of innovative techniques into clinical practice.
IMPLICATIONS FOR CLINICAL PRACTICE
In this dissertation, the need for routine neuropsychological assessment has been 
emphasized, amongst others, to be able to inform patients properly before surgery about 
possible cognitive outcomes, and to provide appropriate care timely. It should be noted that 
with repeated measurement in individuals in clinical practice, it is important to take into 
account practice effects and imperfect test-retest reliability, to enable proper interpretation 
of scores. In addition to cognitive function, symptoms of fatigue should be monitored during 
the disease trajectory, since this is a common and severe and persistent symptom among 
brain tumor patients. Cognitive symptoms or fatigue can also manifest or aggravate at a 
later stage, and therefore, long-term follow up after surgical resection is recommended.
Neuropsychological results of patients can be discussed in multidisciplinary consultations, 
facilitating timely signaling and well-considered referral to, amongst others, rehabilitation 
services or psychological care. Intervention studies make use of strict protocols, in order to 
be able to demonstrate potential beneficial effects of the intervention. In clinical practice, 
interventions can be more tailored to the needs and situations of patients and family 
members. For example, timing of the intervention can be adapted to patients’ needs and 
treatment goals can be set in collaboration. Psychoeducation on cognitive functioning (as 
incorporated in the ReMind-app) can be helpful for some brain tumor patients. However, 
more research has to be done on cognitive rehabilitation in larger samples of brain 
tumor patients, to be able to draw firm conclusions about possible effects of cognitive 
rehabilitation.
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Samenvatting
NEDERLANDSE SAMENVATTING | DUTCH SUMMARY
Achtergrond
Patiënten met een hersentumor worden vaak geconfronteerd met cognitieve stoornissen, 
vermoeidheid en psychische klachten ten gevolge van de ziekte en de behandeling. 
Deze symptomen kunnen het dagelijks leven van patiënten, en dat van hun naasten, 
ten negatieve beïnvloeden en uiteindelijk zorgen voor een lagere kwaliteit van leven. In 
de afgelopen jaren is er binnen de neuro-oncologie meer aandacht gekomen voor deze 
cognitieve en psychologische uitkomstmaten, naast medisch-oncologische uitkomstmaten 
zoals overleving en tumorprogressie. Hoewel er nu steeds meer bekend is over de 
prevalentie en ernst van cognitieve stoornissen bij hersentumorpatiënten, is er veel 
minder onderzoek gedaan naar mogelijke behandelingen voor deze stoornissen. In dit 
proefschrift wordt er verder gekeken naar het meten van neuropsychologische uitkomsten 
bij hersentumorpatiënten, en daarnaast ook naar het inzetten van postoperatieve cognitieve 
revalidatie, met als uiteindelijk doel de nazorg voor patiënten die geopereerd worden aan 
een hersentumor te kunnen verbeteren.
Belangrijkste bevindingen
In het eerste deel van het proefschrift zijn verschillende aspecten van het meten van 
cognitieve functies en vermoeidheid bij hersentumorpatiënten onderzocht. In het tweede 
gedeelte werd er gefocust op de haalbaarheid en effectiviteit van cognitieve revalidatie 
via de ReMind-app.
In hoofdstuk 2, werden de test-hertest betrouwbaarheid en mogelijke oefeneffecten van de 
gecomputeriseerde neuropsychologische testbatterij CNS Vital Signs geëvalueerd, binnen 
een steekproef van Nederlandse gezonde volwassenen. Er werden 158 participanten 
geïncludeerd, en bij de 3-maanden en 12-maanden vervolgmetingen, werden er 
respectievelijk 131 en 77 participanten opnieuw getest. Test-hertest correlatiecoëfficiënten 
varieerden sterk tussen de cognitieve domeinen van de testbatterij (ICCs tussen de 0.40 
en 0.88). Wat betreft oefeneffecten, zagen we dat participanten op de tweede meting (3 
maanden later) significant beter scoorden op de Stroop Test, Symbool Coderen en op de 
Shifting Attention Test, wat leidde tot significant hogere scores op de domeinen Cognitieve 
Flexibiliteit, Verwerkingssnelheid en Reactietijd. Er werden geen significante veranderingen 
in prestatie gevonden tussen de tweede en de derde meting. Er werden formules opgesteld 
(RCIs), waarbij test-hertest betrouwbaarheid en oefeneffecten in acht werden genomen, om 
individuele verandering in cognitieve prestaties op de CNS VS beter te kunnen interpreteren 
bij gebruik van de batterij in onderzoek en in de klinische praktijk.
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In hoofdstuk 3, werd het executief functioneren van hersentumorpatiënten nader 
onderzocht, waarbij er gebruik werd gemaakt van zelfrapportage vragenlijsten, informant 
vragenlijsten en testen voor het executief functioneren. Overeenstemming tussen patiënt 
en naaste, wat betreft het executief functioneren van de patiënt, werd onderzocht in 47 
paren. Patiënten rapporteerden significant meer problemen op de Metacognitie index van 
de BRIEF-A in vergelijking met normen, maar ook in vergelijking met hun naasten. Over 
het algemeen was de overeenstemming tussen patiënt en naaste voldoende. Scores op 
vragenlijsten bleken nauwelijks samen te hangen met scores op de executieve testen. 
Vervolgonderzoek zou zich kunnen richten op de mismatch tussen zelfrapportage en 
testprestaties. Tevens zouden nieuwe manieren van meten (bijvoorbeeld m.b.v. virtual 
reality) voor het in kaart brengen van alledaags executief functioneren verder onderzocht 
kunnen worden voor hersentumor patiënten.
In hoofdstuk 4, werd de prevalentie, de ernst en mogelijke correlaten van vermoeidheid 
in meningeoompatiënten (WHO-graad I) onderzocht, met behulp van een gevalideerde 
multidimensionele vragenlijst (de MVI). Zowel voor operatie (n  =  65) als één jaar na 
operatie (n = 53) scoorden meningeoom patiënten significant hoger op alle schalen van 
de MVI in vergelijking met normatieve gegevens. In een subgroep van patiënten die beide 
meetmomenten ondergaan hadden (n  =  34) zagen we dat de gemiddelde scores niet 
veranderden over tijd op de schalen Algehele Vermoeidheid, Fysieke Vermoeidheid en 
Mentale Vermoeidheid. Verbeteringen werden geobserveerd op de schalen Verminderde 
Motivatie en Verminderde Activiteit. Patiënten rapporteerden dus dat zij een jaar na 
operatie gemotiveerder en actiever waren, maar nog steeds vermoeidheid ervaarden. 
Op individueel niveau zagen we dat 68% van de patiënten verhoogd scoorden op één 
of meer schalen van de MVI voor operatie, en postoperatief was dit percentage 57%. 
Vermoeidheid was geassocieerd met zelf-gerapporteerde cognitieve klachten, angst- en 
depressie symptomen. Vanuit dit onderzoek werd het duidelijk dat vermoeidheid een erge, 
veelvoorkomende en persisterende klacht is in patiënten met een meningeoom die hieraan 
geopereerd worden, en dat het meer aandacht verdient van zowel onderzoekers als clinici 
binnen de neuro-oncologie.
In het tweede gedeelte van het proefschrift werd er gekeken naar de haalbaarheid en 
effectiviteit van het cognitieve revalidatieprogramma ReMind. De iPad-app ReMind is 
gebaseerd op het eerder effectief gebleken face-to-face cognitief revalidatieprogramma van 
onze onderzoeksgroep. Het programma bestaat uit psychoeducatie, compensatietraining 
en aandachts-training. In hoofdstuk 5 zijn de resultaten van het pilotonderzoek beschreven. 
Hierin werden de haarbaarheid van- en mogelijke barrières voor het gebruik van de 
cognitieve revalidatie-app geëvalueerd binnen een klinische setting bij 15 patiënten 
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met een meningeoom of laaggradig glioom. Het rekruteren van voldoende participanten 
bleek moeilijk: een aanzienlijk deel van de patiënten die gepland stonden voor operatie 
kwamen op voorhand al niet in aanmerking voor het onderzoek (zij voldeden niet aan de 
inclusiecriteria) en van de patiënten die wél uitgenodigd werden, weigerde ongeveer de 
helft om deel te nemen aan het onderzoek. De deelnemers volbrachten gemiddeld 71% 
van de compensatietraining en 76% van de aandachts-training. Over het algemeen werd 
het programma goed beoordeeld door de patiënten. Zij gaven aan dat een iPad-app een 
goede manier was om het cognitieve revalidatieprogramma te volgen. Sommigen vonden 
de oefeningen van de aandachts-training te makkelijk, waardoor we deze na de pilotstudie 
uitgebreid hebben met moeilijkere oefeningen.
Na de pilotstudie startte er een gerandomiseerd studie (RCT), om de mogelijke 
effecten van het cognitief revalidatieprogramma op cognitieve prestaties en patiënt-
gerapporteerde uitkomstmaten te evalueren. Het onderzoeksprotocol van de RCT werd 
uitgebreid beschreven in hoofdstuk 6. Het doel was om preoperatief 150 patiënten met 
een meningeoom of laaggradig glioom te includeren. Met een uitvalpercentage van 33%, 
zouden we verwachten om 100 patiënten op te volgen (50 in de interventiegroep en 50 
in de controlegroep). Neuropsychologische screening werd uitgevoerd voor operatie 
(T0) en drie maanden na operatie (T3). Op T3 werden patiënten toegewezen aan de 
interventiegroep of controlegroep. Patiënten in de interventiegroep volgde het cognitief-
revalidatieprogramma voor 10 weken. Zes maanden (T6) en één jaar (T12) na operatie 
werden vervolg neuropsychologische metingen verricht.
In hoofdstuk 7 werden de resultaten van de RCT gepresenteerd. Net als in de pilotstudie 
verliep het rekruteren van patiënten moeizaam, waardoor er uiteindelijk een relatief kleine 
steekproef over bleef voor de analyses (interventie groep n = 23, controles n = 26 op T6). 
Therapietrouw was hoger in de RCT dan in de pilotstudie, waarbij gemiddeld 86% van de 
compensatietraining was afgerond en 91% van de aandachts-training. Daarentegen vielen 
er meer patiënten uit het onderzoek in de RCT dan in de pilotstudie. De ReMind-app werd 
opnieuw positief beoordeeld door de patiënten. Er werden geen significante verschillen 
gevonden tussen interventiegroep en controlegroep in groepsgemiddelden of RCI’s van 
cognitieve prestaties en patiënt-gerapporteerde uitkomstmaten. Het percentage patiënten 
met cognitieve stoornissen was vergelijkbaar tussen de groepen op T3 en T6 (±70%), echter 
een jaar na operatie zagen we dat 35% van de patiënten in de interventiegroep afwijkende 
scores vertoonde versus 68% in de controlegroep, wat een significant verschil was. Voor 
vervolgstudies naar (eHealth) cognitieve revalidatieprogramma’s, zou een latere timing van 
de interventie in overweging kunnen worden genomen (bijvoorbeeld in een fase waarbij 
de ziekte stabiel is), gebaseerd op onze bevindingen m.b.t. het includeren van patiënten.
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Conclusies en aanbevelingen
In deze dissertatie werd het belang van routinematig neuropsychologisch screenen 
benadrukt, enerzijds om patiënten voor operatie beter te kunnen informeren over mogelijke 
cognitieve uitkomsten na operatie, en daarbij om passende zorg tijdig in te kunnen zetten. 
Bij herhaaldelijke neuropsychologische testafnames is het van belang om oefeneffecten 
en matige test-hertest betrouwbaarheid van instrumenten in acht te nemen, om de 
individuele testscores van patiënten accuraat te kunnen interpreteren. Naast cognitieve 
symptomen, is het belangrijk om symptomen van vermoeidheid te monitoren tijdens het 
ziekteproces, aangezien dit een veelvoorkomend en persisterend symptoom blijkt te zijn 
bij hersentumorpatiënten. Cognitieve stoornissen en vermoeidheid kunnen verergeren 
over de tijd of pas later in het ziekteproces ontstaan. Om die reden is het noodzakelijk om 
patiënten lang genoeg op te volgen na een neurochirurgische ingreep.
Resultaten van de neuropsychologische testen en vragenlijsten kunnen meegenomen 
worden in multidisciplinair overleg, om vroeg-signalering en weloverwogen tijdige 
verwijzing naar bijvoorbeeld revalidatie of psychologische behandeling te bespoedigen. Bij 
interventiestudies wordt er gebruik gemaakt van strikte protocollen, om eventuele positieve 
effecten te kunnen meten. In de klinische praktijk daarentegen, kunnen interventies veel 
meer afgestemd worden op de behoeften en situaties van patiënten en hun naasten. De 
timing van de interventie kan onder andere aangepast worden aan hun behoeften en doelen 
van de behandeling kunnen in samenspraak bepaald worden. Psychoeducatie over cognitief 
functioneren (zoals opgenomen in de ReMind-app) kan helpend zijn voor patiënten met een 
hersentumor. Er is echter nog veel meer onderzoek nodig op het gebied van cognitieve 
revalidatie in deze patiëntpopulatie, met grotere steekproeven, om duidelijke conclusies 
te kunnen trekken over de mogelijke effecten van cognitieve revalidatie.
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Als er iets is wat ik de afgelopen jaren geleerd heb, is het dat het belangrijk is om dankbaar 
te zijn voor wat er is. Een uitgebreid dankwoord mag dan ook niet ontbreken.
Op de eerste plaats wil ik alle deelnemers van de onderzoeken bedanken, want zonder hun 
waardevolle bijdragen zou dit proefschrift er nooit geweest zijn. Het blijft bijzonder dat 
mensen bereid zijn om zich in zo’n kwetsbare periode in te zetten voor wetenschappelijk 
onderzoek, met als doel de patiëntzorg te verbeteren. Ook wil ik de participanten bedanken 
die deelnamen als gezonde controle aan ons onderzoek.
Speciale dank gaat uit naar mijn promotor en copromotoren, jullie begeleiding en expertise 
waren onmisbaar voor de totstandkoming van dit proefschrift. Ontzettend bedankt voor 
de afgelopen jaren.
Dr. Gehring, Karin, als wetenschapper in hart en nieren doe je met passie, enthousiasme 
en vrolijkheid onderzoek, wat voor mij aanstekelijk werkte. Daarnaast is mijn kritische 
houding door jou nog wat verder aangescherpt. De artikelen in dit proefschrift zijn door 
jouw uitgebreide feedback en oog voor detail naar een hoger niveau getild. Samen zijn we 
inmiddels op veel plekken geweest, van Kaapstad tot New York, en ik zou het leuk vinden 
als onze paden in de toekomst op congressen elkaar nog kruisen.
Dr./dokter Rutten, Geert-Jan, ik bewonder hoe je het doen van wetenschappelijk 
onderzoek combineert met jouw werk als neurochirurg in de klinische praktijk, en hoe je 
deze werelden dichter bij elkaar brengt. Jouw klinische blik en uitgebreide kennis over 
hersentumoren hebben de manuscripten aanzienlijk verbeterd. Daarnaast heb ik je 
vriendelijkheid, intelligentie, bescheidenheid, mede-nerderigheid en humor de afgelopen 
jaren erg kunnen waarderen.
Prof. dr. Sitskoorn, Margriet, allereerst bedankt voor de kansen die je me hebt gegeven. 
Je zorgt ervoor dat ik net een stapje meer zet, en geeft me de vrijheid om te bepalen in 
welke richting. Je leerde me om afstand te nemen en wat meer te relativeren (iets meer 
een zenboeddhist te worden en we cross that bridge when we get there), waarvoor dank. Het is 
inspirerend om te zien hoe jij wetenschappelijke kennis toegankelijk maakt voor een breder 
publiek en daarmee je idealen handen en voeten geeft. Dream big, is wat ik mede dankzij 
jou altijd zal blijven doen.
Graag wil ik de leden van de promotiecommissie, prof. dr. Fasotti, prof. dr. Sanderman, dr. 
Nijboer, dr. Snijders en dr. De Witt Hamer, hartelijk bedanken voor de tijd die u nam voor 
het lezen en het beoordelen van mijn proefschrift. Daarnaast gaat mijn dank uit naar alle 
coauteurs, ik heb veel van jullie kunnen leren. Bedankt voor alle waardevolle bijdragen aan 
de manuscripten en de prettige samenwerkingen. Wilco, bedankt voor het delen van al je 
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(soms moeilijk voor mij te volgen) statistische kennis. Wijo, erg bedankt voor de inzichten 
die je me hebt gegeven over de academische wereld. Ik heb je integriteit, betrokkenheid 
en constructieve manier van feedback geven erg kunnen waarderen. Wouter, we hadden 
eerder dan in mijn laatste jaar papers samen moeten gaan schrijven. Marijke, wat ontzettend 
leuk en tevens een mooie afsluiting van mijn promotietraject om mee te mogen schrijven 
aan jouw (ons) review, dankjewel.
Mijn collega’s van het ETZ en de Universiteit van Tilburg wil ik ook graag bedanken. In 
het bijzonder de imaging-groep, Martijn, Wouter, Irena, Miek en Gülizar. Dankzij jullie 
weet ik (iets) meer van fMRI en heb ik een foto van mijn eigen hersenen (wat wil je nog 
meer), dank daarvoor. Ik kijk glimlachend terug op de vele discussies en congresbezoeken. 
Ook de researchcoördinatoren, betrokken verpleegkundigen, poliassistenten en 
onderzoeksassistenten van het ETZ wil ik bedanken voor hun onmisbare bijdragen aan 
het onderzoek. Daarbij wil ik ook de medewerkers van het Erasmus MC en Haaglanden MC 
hartelijk bedanken voor de samenwerking. Mede-uni-promovendi Elke en Linda, bedankt 
voor de gezelligheid en sarcastische humor.
Mijn collega’s van De Wever zou ik willen bedanken voor de kans om tijdens mijn 
promotietraject ook te kunnen werken als psycholoog in de geriatrische revalidatie zorg 
en verpleeghuiszorg, wat is ons werk toch mooi! Ik prijs mezelf gelukkig dat ik me bij jullie 
verder mag ontwikkelen als psycholoog.
M’n liefste collega-promovendi, Wietske, Eline en Sophie. Als jullie er niet waren geweest...
Wat was het bijzonder, fijn en gezellig om dit samen te kunnen doen de afgelopen jaren. 
We hebben veel met elkaar gedeeld, waarbij gelachen en gehuild, maar wel samen. Jullie 
maakten dat ik me nooit eenzaam heb gevoeld in dit proces en ik kan jullie niet genoeg 
bedanken voor alle steun.
Lieve Wietske, wat vind ik het leuk dat we vaak gedeelde idealen en interesses hebben. 
Ook heb ik veel je kunnen leren, waaronder van je rust en bedachtzaamheid. En dat je 
tevreden moet zijn met wat je hebt. Daarnaast natuurlijk van je opvoedingstips (die komen 
vast ooit van pas) en de uitspraken van Simon; de wijsheid heeft hij van geen vreemde. 
Bedankt voor alle opstekers; de lieve post-its/kaartjes/kadootjes/lekkere koffies/sms-
berichtjes/wandelingen.
Lieve Eline, ik bewonder je zorgzaamheid, precisie, doorzettingsvermogen en natuurlijk 
je skills bij onze spellenavonden. Daarnaast heb je me ook genoeg kunnen helpen met je 
statistische kennis, het sparren over van alles, en ontspannen gesprekken over nog meer. 
Jij bent van ons allemaal het meest gegroeid de afgelopen jaren en ik weet zeker dat dit de 
komende jaren alleen maar meer gaat worden. Wanneer gaan we weer naar een musical?
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Dankwoord
Lieve naamgenoot en paranimf Sophie. We werden met elkaar verward of werden voor 
het gemak ‘de Sophie’s’ genoemd. We lijken in veel opzichten op elkaar (denk aan werkethos, 
laptopsleeve, interesses en humor), wat zorgde voor een hele fijne samenwerking. Anderzijds 
verschillen we ook voldoende van elkaar om elkaar goed te kunnen aanvullen. Alle mooie 
herinneringen zal ik koesteren, zoals onze selfie-in-bed-op-congres-traditie. Onze dagelijkse 
whatsappgesprekken – ook als we in dezelfde kamer zitten – ga ik missen. Je bent een top-
wetenschapper, dat heeft me absoluut scherp gehouden de afgelopen jaren. Daarnaast ben 
je ontzettend slim, knap, geestig en zeker geen nobody. En mooi meegenomen dat we nu 
samen eindelijk de stomme grap kunnen maken over hoe je onze naam schrijft; met phd.
Lieve vrienden en familie, ontzettend dankbaar ben ik dat ik jullie in mijn leven mag hebben.
Anouk, Inger en Martine – MP Chicks –, ondanks dat we na onze studie allemaal een 
ander pad hebben bewandeld, bleven we elkaar zien en kon ik altijd bij jullie terecht. Bedankt 
voor jullie steun en de Brabantse gezelligheid! En straks allemaal GZ-psycholoog, ik ben 
trots op ons.
Lieke, Nienke, Liselot en Dorine (wat zeg ik, Liek, Nien, Lies & Do), wat vliegt de tijd, 
we kennen elkaar gewoon al 10 jaar. Een jubileum/lustrum, tijd voor een nieuwe vakantie 
samen? Bedankt voor alle gezellige kaasfondues, spelletjes, thee, chocola en weekendjes 
weg. Dr. Do(do) en dr. Fie dadelijk, wie had dat gedacht, ik vond het leuk dat we elkaar 
vaker zagen in de mooiste stad van Zuid-Nederland om ambitieuze plannen te smeden. 
Liek, ondanks dat we nu niet zomaar meer een midweekje naar New York of IJsland mogen 
vliegen, lijkt het me toch leuk om nog een keer samen naar Canada (of een ander bijzonder 
land) te gaan.
Mijn ‘oudste Bergse vrienden’, in het bijzonder Doortje, Renske en Joost. Door en Rens 
– mutsen –, wat fijn dat wij elkaar al zo lang kennen dat we aan een half woord genoeg 
hebben, oneindig kunnen praten en dat op het hoogste tempo mogelijk (wat ik met niemand 
anders zo kan). De jaren van vriendschap met jullie hebben me deels gemaakt tot wie ik ben, 
waar ik jullie niet dankbaar genoeg voor kan zijn. Joost, ik waardeer onze fijne gesprekken, je 
humor en het ontspannen gevoel wat ik bijna automatisch van je krijg als we koffiedrinken, 
iets sportiefs, of juist niets doen.
Lieve familie en schoonfamilie, Job, Sjoerd, Jonia, Fay, Jibbe, Joyce, Xaf, Femme, Bert, 
Helga, Nina, Ernst, Rick en Laura, bedankt voor alle steun, liefde en gezelligheid. Dit was 
altijd een welkome afwisseling in de soms drukke periodes.
Lieve Anne (An), mensen zeggen dat we meer op elkaar gaan lijken, dat is dan een groot 
geluk voor mij. Bedankt dat je er altijd bent en dat ik alles met je kan delen. Het was extra 
gezellig toen je 5 weken in het ETZ je coschap neurologie liep tijdens mijn promotietraject. 
De zusjes Van der Linden komen eraan. Het is super suf en tegelijkertijd leuk dat we toch 
mama achterna zijn gegaan en beiden binnen de psychologie/psychiatrie werken straks. 
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Misschien wel ooit bij dezelfde instelling (wel in de randstad toch?), lijkt me heel gezellig. 
Weet dat ik super trots op je ben en het maakt me gelukkig dat jij vandaag als paranimf aan 
mijn zijde staat.
Liefste papa en mama. Dankbaar ben ik jullie voor de onvoorwaardelijke steun, het 
vertrouwen en het veilige gevoel dat jullie me geven. Ook voor de kritische houding en de 
scherpe tong die jullie me meegegeven hebben. En dat alles open en eerlijk bespreekbaar 
moet zijn. Dat ik voel dat jullie trots op me zijn, wat ik ook doe. Mama, bedankt voor alle tips 
en psychologische peptalks aan de telefoon als ik er bijna doorheen zat. Papa, ik waardeer 
het dat je me soms aanzet om een versnelling terug te schakelen en even stil te staan bij wat 
is. Jullie zijn de aller- allerbeste ouders, ik hou van jullie!
Lieve Leon, je bent letterlijk het begin en het einde – bedankt voor de prachtige voorkant 
van mijn proefschrift. Dankjewel dat je mijn promotie overleefd hebt met mij, dat je er 
altijd voor me bent en dat je vaak beter dan ikzelf weet wat ik nodig heb. Dat je me anders, 
beter of minder over dingen laat nadenken. Je beseft niet half hoe fantastisch je bent, van 
o.a. jouw onbaatzuchtigheid, bescheidenheid, discipline, brede algemene kennis, nuance, 
structuur, sportiviteit, handigheid, opgeruimdheid en creativiteit kan ik nog veel leren. Je 
noemt me altijd ‘je lievelings-wervelwind’; ik draai het liefste om jou heen. De vele dansjes 
om te ontspannen, reizen die we maakten en bezoekjes aan het strand om de hoek, maakten 
de afgelopen jaren mooier. Nieuwsgierig ben ik naar wat we de komende jaren nog gaan 
beleven, maar eigenlijk maakt het ook niet zoveel uit, als het maar samen is.
Sophie
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